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SIRT2 belongs to the mammalian sirtuin or NAD-dependent lysine deacylase family. 
Growing evidence suggests that SIRT2 plays important roles in cell cycle regulation, stress 
response, metabolism and differentiation by deacetylating a wide variety of substrates. 
Targeting SIRT2 for cancer treatment has been a topic of debate due to conflicting reports and 
lack of potent and specific inhibitors.  
I began the project with the development and mechanistic study of SIRT2 inhibitors. From 
a collection of mechanism-based small molecule inhibitors mimicking different lysine acyl 
modifications, I characterized that a thiomyristoyl lysine compound (TM), a potent SIRT2-
specific inhibitor, has broad anticancer effect in various human cancer cells and mouse models 
of breast cancer. Mechanistically, I demonstrated that SIRT2 inhibition promotes c-Myc 
ubiquitination and degradation and that the anticancer effect of TM correlates with its ability to 
decrease c-Myc level. This study suggests that SIRT2 inhibition could be utilized to target c-
Myc and that potent and selective SIRT2 inhibitors are promising anticancer agents. 
SIRT2 has been reported to have lysine defatty-acylase activity in addition to the 
previously known deacetylase activity. However, whether the defatty-acylase activity is 
physiologically relevant has not been investigated. I identified the oncoprotein K-Ras4a as a 
SIRT2 defatty-acylase substrate. I further elucidated that SIRT2-mediated lysine defatty-
acylation promotes endomembrane localizaiton of K-Ras4a, enhances its interaction with A-
Raf, and thus promotes cellular transformation. This study not only highlights lysine fatty 
 acylation as a previously unknown regulatory mechanism for the Ras family of GTPases that is 
distinct from cysteine fatty acylation, but also unveils a new mechanism by which SIRT2 is 
involved in cancer by defatty-acylating K-Ras4a. This finding also provides further support that 
SIRT2 is a promising target for cancer treatment.  
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CHAPTER 1 
 
INVOLVEMENT OF SIRT2 IN CANCER: AN OVERVIEW a 
1. Introduction 
Sirtuins are a family of enzymes with nicotinamide adenine dinucleotide (NAD)-
dependent protein lysine deacylase. Yeast Sir2, the founding member of all sirtuins, was initially 
found to be important for calorie restriction-induced life span extension in yeast 1. Subsequent 
biochemical studies demonstrate that it is an NAD-dependent deacetylase that regulates histone 
acetylation 2.  This connection between aging and metabolism (the fact that it uses a metabolic 
important molecule, NAD, as a co-substrate) attracted great interest into this class of enzymes.  
 
Figure 1.1 The enzymatic function of sirtuins. (A) The enzymatic reaction mechanism of sirtuins. (B) 
The structure of a ternary sirtuin-NAD-acetyl peptide complex (PDB ID 2H4F). NAD, acetyl lysine, and 
the key catalytic His residue are shown in stick representation. The bound zinc is shown in grey sphere. 
The protein structure picture is generated using PyMol. 
The enzymatic reaction mechanism for sirtuin-catalyzed NAD-dependent protein lysine 
deacetylation has been well understood through a series of elegant biochemical and structural 
studies (Figure 1.1) 3,4. The conserved catalytic core of sirtuins consists of a zinc-binding 
domain and a Rossmann fold domain (Figure 1.1B) 5-7. The active site lies at the interface of the 
                                                
a This is a revised version of our published review articles: Hu, J., Jing, H. & Lin, H. Sirtuin inhibitors 
as anticancer agents. Future Med Chem 6, 945-66 (2014); Jing, H. & Lin, H. Sirtuins in epigenetic 
regulation. Chem Rev 115, 2350-75 (2015). 
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two domains. It was thought that the acetyl lysine peptide binds first, followed by the binding 
of NAD 8. Once the tertiary complex is formed, the carbonyl oxygen of the acetyl group attacks 
the C1’-position of the nicotinamide ribose, displacing nicotinamide and forming the 
alkylamidate intermediate (intermediate I, Figure 1.1A) 3. A conserved histidine residue then 
serves as a general base to deprotonate the ribose 2’-OH, which then attacks intermediate I at 
the carbonyl carbon, generating the 1’,2’-cyclic intermediate (intermediate II, Figure 1.1A). 
Intermediate II is then hydrolyzed to produce 2’-O-acetyl-ADP-ribose (2’-O-Ac-ADPR), which 
can be non-enzymatically isomerized to 3’-O-Ac-ADPR 3,4. 
In mammals, there are seven sirtuins (SIRT1-7) that localize in different subcellular 
compartments, such as cytoplasm (SIRT1 and SIRT2), nucleus (SIRT1, SIRT2, SIRT6, and 
SIRT7) and mitochondria (SIRT3, SIRT4 and SIRT5) 9,10. By regulating the activity of various 
substrate proteins, sirtuins are involved in many biological pathways, including transcriptional 
regulation, genome stability, metabolic regulation, and cell survival 11. Among the seven sirtuins, 
SIRT2 is the only predominantly cytosolic member 12,13. SIRT2 has thus far been characterized 
primarily as an NAD-dependent deacetylase. It was originally reported to co-localize with 
microtubules and deacetylate α-tubulin at lysine 40 13. Later SIRT2 was also found to be 
enriched on chromatin and regulate chromatin condensation by deacetyating histone H4 lysine 
16 (H4K16) during G2/M transition and mitosis 14. It was found that SIRT2 actively shuttles 
between cytoplasm and nucleus during interphase, while it accumulates on mitotic structures 
during mitosis 15. As more of SIRT2 substrate proteins (summarized in Table 1.1) have been 
identified, it has been intimately connected with multiple physiological processes, including cell 
cycle 16, oxidative stress response 17, metabolism 18,19, microtubule dynamics 13, apoptosis 20, 
differentiation 21,22 and aging 23. Therefore, there is growing research interest in exploring the 
potential of SIRT2 as a therapeutic target for treatment of cancer. Many SIRT2 inhibitors have 
been reported to have anticancer activities. Research in the past decade, however, has also 
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disclosed that SIRT2 possesses dual roles in tumorigenesis – they could have both tumor-
promoting and tumor-suppressing functions.  
 
Table 1.1 SIRT2 deacetylation substrates 
Substrate Full name Site of modifications Function of SIRT2-catalyzed deacetylation 
Histones 
H4  Histone H4 K16 
Regulates chromatin condensation during 
metaphase 14; regulates H4K20 methylation, 
promotes cell cycle progression and genome 
stability 24; suppresses transcription of certain 
genes 25. 
H3  Histone H3 
K18  L. monocytogenes InlB triggers SIRT2 nuclear localization to suppress gene transcription 26.  
K56 Involved in DNA replication and DNA damage repair 27,28. 
Chromatin modifying enzymes  
PR-Set7 
N-lysine 
methyltransferase 
KMT5A 
K90 
Promotes PR-Set7 chromatin localization and the 
establishment of H4K20me1 by PR-Set7 during 
G2/M phase 24.  
Transcription factors 
P300  Many Promotes binding of p300 to preinitiation complex 29. 
FOXO3 Forkhead box protein O3 Unknown 
Increases FOXO3 DNA binding and target gene 
transcription 17; Increases FOXO3 
ubiquitinylation and degradation 30. 
FOXO1 Forkhead box protein O1 Unknown 
Promotes FOXO1 interaction with PPARg and 
represses PPARg target genes 21; Inhibits 
FOXO1 interaction with ATG7 and autophagic 
cell death 31. 
HIF-1α Hypoxia-inducible factor 1α K709 
Promotes hydroxylation and degradation of HIF-
1α 32. 
RelA/p65 
RelA/p65 subunit 
of nuclear factor-
κB 
K310 Suppresses NF-κB dependent gene expression 33. 
PGC-1α 
Peroxisome 
proliferator-
activated receptor-
γ coactivator 1α 
Unknown Decreases expression of β-oxidation and mitochondrial genes 34. 
NRF2 
Nuclear factor 
erythroid-derived 
2-related factor 2 
K506, 508 
Destabilizes NRF2, which leads to reduced 
ferroportin 1 expression and consequently 
decreased cellular iron export 35. 
Cell cycle related 
BubR1 
Mitotic checkpoint 
serine/threonine-
protein kinase 
BUB1 β 
K668 Stabilizes BubR1 and improves cardiac function and extends lifespan in vivo 23. 
CDK9 Cyclin dependent kinase 9 K48  
Increases CDK9 kinase activity and decrease 
sensitivity to hydroxylurea-induced replication 
stress response 36. 
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CDH1/ 
CDC20 
Fizzy/cell division 
cycle 20 related 1/ 
Cell division cycle 
protein 20  
K69 and 159 
(CDH1), K66 
(CDC20) 
Activates the E3 ubiquitin ligase activity, leading 
to decreased Aurora A level 37. 
ATRIP ATR-interacting protein K32 
Promotes ATR-ATRIP binding to replication 
protein A-coated single-stranded DNA (RPA-
ssDNA) to drive ATR activation and thus 
facilitate recovery from replication stress 38. 
Metabolic enzymes 
LDH-A Lactate dehydrogenase A K5 Activates LDH-A 
39. 
PEPCK Phosphoenolpyruvate carboxykinase K70, 71 
Inhibits the ubiquitinylation and degradation of 
PEPCK 18. 
ACLY ATP-citrate lysase K540, 546, 554 Promotes ATP-citrate lyase degradation 40. 
G6PD 
Glucose-6-
phosphate 
dehydrogenase 
K403 Promotes the formation of active G6PD dimer and increase NADPH production 19,41,42. 
PGAM Phosphoglycerate mutase K100 Activates PGAM activity 
43. 
ALDH1A1 
Aldehyde 
dehydrogenase 
1A1 
K353 Activates ALDH1A1 activity and promote breast cancer stem cells 44. 
GKRP Glucokinase regulatory protein K5 
Destabilizes GFRP, which results in nuclear 
export of glucokinase and cytosolic glycolysis 45.  
PKM2 Pyruvate Kinase 2 K305 Activates PKM2 activity by promoting its tetramerization 46. 
Cell signaling related 
PRLR Prolactin receptor Many Facilitates prolactin receptor dimerization and activation of STAT5 47.  
K-Ras 
Kirsten rat 
sarcoma viral 
oncogene homolog 
K104 Promotes K-Ras activity 48. 
K147 Decreases K-Ras activity 49. 
PAR-3 
Partitioning 
defective 3 
homolog 
K831, 848, 
881, 1327 
Decreases the activity of aPKC and regulates 
myelin formation 50. 
TIAM1 
T-cell lymphoma 
invasion and 
metastasis 1 
K1420 Promotes activation of DVL/TIAM1/Rac axis and cell migration in cancer cells 51.  
MKP-1 
Mitogen-activated 
protein kinase 
phosphatase-1 
Unknown 
Inhibits MKP-1 activity and consequently 
activates mitogen-activated protein kinases, 
which aggravates postischemic liver injury 52. 
Structural proteins 
α-tubulin α-tubulin K40 Destabilizes microtubule 13. 
Keratin 8 Keratin 8 K207 Affects its phosphorylation and filament organization 53. 
ANKLE2 
Ankyrin repeat and 
LEM domain 
containing 2 
K302 
Regulates ANKLE2 acetylation and 
phosphorylation dynamics, which is essential for 
normal nuclear envelope reassembly 54. 
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I will next discuss the roles of SIRT2 in cancer obtained from genetic studies (knockout, 
knockdown, and overexpression), the development of sirtuin inhibitors with anticancer activity, 
and then I will highlight the recent progress on identifying SIRT2 as a versatile lysine deacylase. 
Finally, I will discuss the rationale behind my doctoral study, which is to establish SIRT2 
inhibition as an anticancer strategy and to understand the role of SIRT2 in cancer. 
2. Tumor-suppressing roles of SIRT2 
The tumor-suppressing role of SIRT2 may come from its ability to maintain genome 
stability. Sirt2-/- mice look grossly normal, but starting from 10 months of age, they tend to have 
more tumors than the wild type. This effect was attributed to the role of SIRT2 in regulating the 
genome integrity by deacetylating APC/C (CDH1/CDC20) 55. The hypothesis was that SIRT2 
is important for the mitosis and thus without SIRT2, abnormal cell division occurs and thus 
tumor arises. However, the increased spontaneous tumor formation in Sirt2-/- mice may be 
strain-dependent and was not seen in another study 24. Serrano and coworker reported that 
SIRT2 affects H4K20 methylation by deacetylating H4K16 and histone methyltransferase PR-
Set7. Sirt2-/- cells have increased H4K16 acetylation levels, decreased H4K20 methylation 
levels during G2/M transition and M phase. Sirt2-/- cells exhibit increased DNA damage and 
aberrant cell cycle progression compared with wildtype cells. Although no increased 
spontaneous tumorigenesis was observed in the Sirt2-/- mice up to one year of age, increase in 
tumorigenesis was observed in an induced skin tumor model 24. A latter study by Zhang et al. 
defined a function for SIRT2 in regulating replication stress response and genome integrity 
through deacetylation of CDK9 36. SIRT2 interacts with and deacetylates CDK9 in response to 
replication stress, thereby stimulating CDK9 kinase activity and promoting recovery from 
replication arrest. More recently, Naini et al. reported that SIRT2 blocks mitotic entry under 
mitotic stress. Phosphorylation of SIRT2 by cyclin A/CDK2 complex inhibits its activity and 
its binding affinity to centrosomes and mitotic spindles, promoting G2/M phase transition 56. 
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The tumor-suppressing role of SIRT2 may come from its ability to deacetylate or inactivate 
certain transcription factors, kinases, metabolic enzymes or oncoproteins involved in 
tumorigenesis. SIRT2 deacetylates Hypoxia-inducible factor-1α (HIF-1α), which leads to 
hydroxylation and degradation of HIF-1α 32. Loss of SIRT2 increases MEK acetylation and 
confers resistance to BRAF and MEK inhibitors in BRAF mutant melanoma and K-RAS mutant 
colon cancers57,58. SIRT2 has been shown to inhibit Wnt signaling in nonmalignant cells by 
directly binding to β-catenin, and thus attenuate cell mobility and invasion 59. Song et al. recently 
reported that SIRT2 deletion promotes K-RAS-induced tumorigenesis in vivo by regulating K-
RAS K147 acetylation status49. However, another study by Yang et al. showed that SIRT2 and 
HDAC6 may promote growth properties of cancer cells by deacetylating K-RAS at K10448. 
Therefore, the regulation of K-RAS by SIRT2 still remains obscure. SIRT2 has been shown to 
deacetylate and promote the degradation of ATP-citrate lyase (ACLY), which is important for 
lipid biosynthesis and thus tumor growth. Inhibition of SIRT2 promotes ATP-citrate lyase 
stability and thus may promote tumor growth 40. Deacetylation of pyruvate kinase 2 (PKM2) by 
SIRT2 alters glycolytic metabolism and inhibits malignant growth in cancer cells 46. Moreover, 
SIRT2 deacetylates and inhibits the peroxidase activity of peroxiredoxin (Prdx-1) in breast 
cancer cells, thereby sensitizing breast cancer cells to reactive oxygen species (ROS)-induced 
DNA damage and cytotoxicity 60.  
Consistent with a tumor suppressor role, SIRT2 levels decreased in glioma cells and 
overexpression of SIRT2 decreased the colony formation of glioma cells 61. SIRT2 was also 
found to be downregulated in skin cancer as compared with normal skin. Deletion of SIRT2 
increased tumor growth induced by 7,12-dimethylbenz(a)anthracene (DMBA) and 12-O-
tetradecanoylphorbol-13-acetate (TPA) 62. In addition, decreased expression of SIRT2 has also 
been observed in ovarian carcinoma63 and colorectal cancer64 compared with the adjacent non-
cancerous tissues.   
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3. Tumor-promoting roles of SIRT2 
In contrast to the tumor suppressor role of SIRT2, SIRT2 has been demonstrated to be 
tumor-promoting through various mechanisms. One mechanism is that SIRT2 helps to stabilize 
or activate oncogenes, such as MYC, FOXO and K-RAS. Thus, inhibiting SIRT2 will destabilize 
or inactivate these oncogenes and inhibit cancer. SIRT2 inhibition and knockdown have recently 
been shown to down regulate the C-MYC and N-MYC oncoproteins in neuroblastoma and 
pancreatic cancer cells 25. This is achieved by releasing the inhibition of SIRT2 (via its histone 
deacetylase activity) on the transcription of the ubiquitin ligase NEDD4. SIRT2 has also been 
reported to deacetylate and decrease the level/activity of FOXO1 65 and FOXO1 can increase 
cell death by activating autophagy 66. Thus, SIRT2 inhibition can promote cell death by 
increasing FOXO1 activity. SIRT2 can deacetylate K-RAS and promotes it activity and cancer 
cell growth 67. SIRT2 has recently been shown to be an AKT binding partner and critical for its 
activation by insulin 68. Moreover, SIRT2 deacetylates and stabilizes Slug to promote 
malignancy of basal-like breast cancer. Slug is well known to promote tumor progression 
through epithelial-mesenchymal transition (EMT). Therefore, depletion or inhibition of SIRT2 
could destabilize Slug and inhibit tumor growth69.  
SIRT2 inhibition has been shown to increase the levels of tumor suppressor genes, such as 
p53 and p21 70-72. Increased p53 level is achieved through deacetylation of p53, but the 
mechanism for increased p21 level is not clear. Additionally, Soung et al. recently indicated that 
SIRT2 suppresses the expression of the tumor suppressor Arrestin domain-containing 3 
(ARRDC3) in basal-like breast cancer cells by binding and increasing acetylation levels at 
ARRDC3 promoter 73. 
 SIRT2 may exert tumor-promoting function by regulating cancer cell metabolism. SIRT2 
can deacetylate and activate lactate dehydrogenase A (LDH-A) 74, which is over-expressed in 
many cancer cells and is responsible for the increased production of lactate in cancer cells. 
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SIRT2-mediated deacetylation and activation of glucose-6-phosphoate dehydrogenase (G6PD) 
stimulates pentose phosphate pathway (PPP) to supply cytosolic NADPH in response to 
oxidative damage19. It has been shown that activation of G6PD by SIRT2 promotes glioma cell42 
and leukaemia cell proliferation41. Oxidative stress could also activate the glycolytic enzyme 
phosphoglycerate mutase (PGAM) by SIRT2-dependent deacetylation43. Since PGAM plays an 
important role in NADPH homeostasis and inhibition of PGAM attenuates cell proliferation and 
tumor growth, SIRT2 may promote tumor growth by regulating PGAM. Moreover, Zhao et al. 
found that NOTCH signaling activates aldehyde dehydrogenase 1A1 (ALDH1A1) through the 
induction of SIRT2, leading to ALDH1A1 deacetylation and enzymatic activation to promote 
breast cancer stem cells44. 
In line with the tumor promoting role of SIRT2, elevated SIRT2 expression in human 
cancer samples compared with their non-transformed counterparts has been correlated with 
worse prognosis and poor survival in various cancer types, including acute myeloid leukemia75, 
prostate cancer76, non-small lung cancer77, breast cancer69, liver cancers78 and melanoma79. In 
many cancer cell lines, it has been demonstrated that SIRT2 knockdown or pharmacological 
inhibition can inhibit cancer cell proliferation and growth 47,71,78,80-86. For example, expression 
of SIRT2 has been shown to be crucial for the survival of rhabdomyosarcoma cells47. SIRT2 
activity has also been demonstrated to be essential for the survival of C6 glioma cells87.  
4. SIRT2 inhibitors 
As growing evidence shows that SIRT2 plays a role in many biological processes, there 
has been sustained interest in developing small molecules that target SIRT2. Below I provide a 
summary of SIRT2 inhibitors, with a focus on those that have been shown to have anticancer 
effect.  
4.1. Nicotinamide and its analogues 
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Nicotinamide (Table 1, entry 1) is one of the earliest sirtuin inhibitors discovered. 
Nicotinamide inhibits SIRT1, SIRT2, SIRT3, SIRT5 and SIRT6 with IC50 varying from 50 to 
184 µM 88-90. It has been shown that nicotinamide can block proliferation and promote apoptosis 
in leukemic cells, and inhibit the growth and viability of human prostate cancer cells 91,92.  
Analogues of nicotinamide and benzamide (a nicotinamide mimic) have been sought as 
sirtuin inhibitors. Two 3’-phenethyloxy-2-anilino benzamide analogues (Table 1.2, entries 2 
and 3) were discovered as potent and selective SIRT2 inhibitors with IC50 value of 1 µM and 
0.57 µM, respectively. Selective SIRT2 inhibition by 3’-phenethyloxy-2-anilinobenzamide 
leads to increase in α-tubulin acetylation in human colon cancer HCT116 cells 93. Fragment-
based approach led the design of the (5-benzamidonaphthalen-1/2-yloxy) nicotinamide 
derivatives, among which one compound (Table 1.2, entry 4) shows potent and selective SIRT2 
inhibition in vitro and in cells 94. But whether this compound exerts anticancer activity was not 
further pursued.  
AK-1 and AK-7 (Table 1.2, entries 5 and 6), another two benzamide-containing compounds, 
also exhibit selective SIRT2 inhibition 95. It has been shown that AK-1 induces cell cycle arrest 
by promoting degradation of the Snail transcription factor through inactivation of the NF-
κB/CSN2 pathway in HCT116 cells96. Later, AK-1 was also shown to destabilize HIF-1α under 
hypoxia in a von Hippel–Lindau tumor suppressor (VHL)-dependent manner in various cancer 
cell lines97. Interestingly, different from SIRT2 inhibition by AK-1, depletion of SIRT2 
upregulates HIF-1α97, suggesting that SIRT2 protein depletion may produce different outcome 
from activity inhibition or that AK-1 may have off-target effect. Moreover, both AK-198 and 
AK-799 have been demonstrated to exert neuroprotection effects in vitro and in vivo by 
decreasing sterol biosynthesis. Later, based on computational docking of AK-7 with SIRT2 
crystal structure, more benzamide derivatives were designed and synthesized, which led to the 
discovery of compound 17k (Table 1.2, entry 7) 100. 17k is selective for SIRT2 (IC50 = 0.60 µM) 
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over SIRT1 and SIRT3 (IC50 > 100 µM). However, its biological activity was not further 
investigated. 
 AEM1 (Table 1.2, entry 8) was recently identified as a selective SIRT2 inhibitor 101. It has 
an IC50 value of 18.5 µM against SIRT2, while showing only weak effects on SIRT1 and SIRT3. 
Addition of a 3-methyl-pridyl group to the carboxamide group of AEM1 (compound AEM2, 
Table 1.2, entry 8) resulted in an improved IC50 value of 3.8 µM against SIRT2. Both of AEM1 
and AEM2 sensitize non-small cell lung cancer cells to DNA-damaging agent etoposide-
induced apoptosis in a p53-dependent manner 101.  
 
Table 1.2 Nicotinamide and structurally similar analogs 
Entry # Structure IC50 Biology Activity 
1 
Nicotinamide 
 
 
SIRT1: 120 µM88 
SIRT2: 100 µM90 
SIRT3: 50 µM88 
SIRT5: 150 µM88 
SIRT6: 184 µM89 
Blocks proliferation and promoted 
apoptosis selectively in leukemic and oral 
squamous cell carcinoma (OSCC) 
cells91,102;  
Inhibits the growth and viability of human 
prostate cancer cells through inhibiting 
SIRT192.  
2 
 
SIRT1: >300 µM 
SIRT2: 1 µM 
SIRT3: >300 µM93 
 
3 
 
SIRT1: >300 µM 
SIRT2: 0.57 µM 
SIRT3: >300 µM93 
 
4 
 
SIRT1: 10.2 µM 
SIRT2: 0.048 µM 
SIRT3: 44.2 µM 94 
Induces hyperacetylation of α-tubulin in 
cells 94. 
5 
AK-1 
 
SIRT1: ND 
SIRT2:12.5 µM103 
SIRT3: ND 
Induces cell cycle arrest in HCT116 colon 
cancer cells96; 
Destabilizes HIF-1α under hypoxia in 
various cancer cell lines97; 
N
O NH2
HN O
O
S
N
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Neuroprotective in cellular and invertebrate 
Huntington's disease model98.  
6 
AK-7 
 
SIRT1: ND 
SIRT2: 15.5 µM103 
SIRT3: ND 
With brain-permeability but limited 
metabolic stability95 ; 
Neuroprotective in Huntington's disease 
mouse models99. 
7 
Compound 17k 
 
SIRT1: >100 µM 
SIRT2: 0.6 µM 
SIRT3: >100 µM 
 
8 
AEM1 
 
SIRT1: 118.4 µM 
SIRT2: 18.5 µM 
SIRT3: 20% inhibition 
at 50 µM 101 Sensitize non-small cell lung cancer cells 
to DNA-damaging agent etoposide-
induced apoptosis in a p53-dependent 
manner 101. 
8 
AEM2 
 
SIRT1: >100 µM 
SIRT2: 3.8 µM 
SIRT3: ND 101 
 
4.2. Mechanism-based thioacyllysine-containing compounds 
Compounds containing Nε-thioacetyllysine (Table 1.3, entries 1-7) can form a covalent 
ADP-ribose-adduct (1’-S-alkylimidate intermediate) during the first step of the sirtuin-catalyzed 
deacetylation reaction 104,105. This intermediate is relatively stable and does not readily undergo 
the normal downstream reactions. Thus, the intermediate occupies the sirtuin active site and 
inhibits the enzymatic activity of the sirtuin. Both mass spectrometry and crystal structures 
support this suicide substrate inhibition mechanism 104,105. Nε-thioacetyl-lysine was first 
incorporated into a peptide derived from the C-terminal region of the human p53 protein (amino 
acid residue 372–389) mimicking the substrate (Table 1.3, entry 1), which shows 2 µM IC50 
value towards SIRT1 106. Since then, a lot of efforts have been invested to further improve this 
type of mechanism-based inhibitors, including incorporating the Nε-thioacetyl-lysine into tri-, 
S
N
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H
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tetra-, and pentapeptides 107, using various N-acyl group 108-113, changing the lysine side chain 
114 as well as the C-terminal of the peptide 109. However, peptide-based inhibitors are generally 
not very appealing as they may be unstable and not cell permeable for cellular or in vivo studies. 
Thus, non-peptide N-thioacetyllysine analogs have been developed 115-117. All these inhibitors 
show some selectivity for SIRT1 over SIRT2 (Table 1.3, entries 2-6). Some of the non-peptide 
analogs inhibit SIRT1 and cell proliferation in cancer cells 115-117. However, it remains unclear 
whether SIRT2 inhibition also contributes their anticancer effects.  
Trifluoroacetyl lysine-containing peptides have also been developed as mechanism-based 
sirtuin inhibitors 118. Several cyclic and linear peptides containing trifluoroacetyl lysine (Table 
2, entries 7-8) can inhibit SIRT2 selectively with low nM IC50 values. However, whether these 
compounds can inhibit cancer cell proliferation and growth has not been reported. 
 
Table 1.3 Sirtuin inhibitors: N-thiocarbamoyl lysine and N-Tfa lysine 
Entry # Structure IC50 Biology Activity 
1  SIRT1: 2 µM
106  
2  
SIRT1: 0.57 µM 
SIRT2: 151 µM107 
 
3 
 
SIRT1: 2.7 µM 
SIRT2: 23 µM 
SIRT3: >100 µM115 
Causes a dose-dependent 
increase in p53 acetylation in 
human colon cancer HCT116 
cells 115. 
4 
 
SIRT2: 0.24 µM 
SIRT2: 1.8 µM 
SIRT3: 3.9 µM117 
 
5 
 
SIRT1: 0.89 µM 
SIRT2: 2.5 µM 
SIRT3: 8.4 µM117 
Antiproliferative effects on 
A549 lung carcinoma and 
MCF-7 breast carcinoma cells 
at µM concentrations; 
Causes cell cycle arrest at the 
G1 phase 117 6 
 
SIRT1: 5.98 µM 
SIRT2: 25.8 µM 
SIRT3: 29.4 µM117 
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7 
S2iL8 
 
SIRT1: 47 nM 
SIRT2: 3.2 nM 
SIRT3: 480 nM118 
 
8 
S2iD7 
 
SIRT1: 32 nM 
SIRT2: 3.7 nM 
SIRT3: 240 nM118 
 
9 
lin-S2iL8 
 
SIRT1: ND 
SIRT2: 6.1 nM 
SIRT3: ND118 
 
10 
lin-S2iD7 
 
SIRT1: ND 
SIRT2: 5.5 nM 
SIRT3: ND118 
 
11 
RIKTfaRY 
 
SIRT1: 280 nM 
SIRT2: 31 nM 
SIRT3: 1000 nM118 
 
 
4.3. β-naphthol-containing inhibitors 
Sirtinol. Sirtinol (Table 1.4, entry 1) is identified from a high throughput cell-based screen 
of more than 1000 compounds 119. It inhibits human SIRT1 and SIRT2 with IC50 values of 131 
µM 120 and 38 µM 119 in vitro, respectively, but it does not increase global acetylation levels of 
histones and tubulin in mammalian cells. Structure–activity relationship (SAR) study shows that 
the hydroxyl-napthaldehyde moiety is important for the inhibition 119.  
Sirtinol is reported to have anticancer activity. It induces senescence-like growth arrest 
with reduced activation of RAS-MAPK pathway in human breast cancer MCF7 cells and lung 
cancer H1299 cells 121. In another study, sirtinol induces cell apoptosis in MCF-7 cells in a 
process that requires p53 72. Sirtinol inhibits the growth of PC3 and Du145 cells and increases 
sensitivity of the cells to camptothecin and cisplatin 122. Sirtinol and cisplatin also showed 
synergistic effect at inhibiting Hela cell proliferation 123. More recently, it was found to impair 
cell growth and induce apoptosis in primary chronic lymphocytic leukemia (CLL)124. It 
destabilizes Slug and attenuates basal-like breast cancer (BLBC) growth by SIRT2 inhibition69. 
Salermide. Salermide (Table 1.4, entry 2), a reversed amide based on the structure of 
sirtinol has stronger in vitro inhibitory effect on SIRT1 and SIRT2 than sirtinol 125. It induces 
apoptosis in a wide range of human cancer cell lines but not in normal cells through inhibition 
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of SIRT1 in a p53-independent manner. It shows much more significant inhibition of leukemia 
cell lines (MOLT4 and KG1A)，colon cancer (SW480) and lymphoma primary tumors than 
the breast cancer cell line MDA-MB-231125. Salermide also induces apoptosis in non-small cell 
lung cancer (NSCLC) cells through up-regulation of death receptor 5 (DR5) 126. Similar to 
sirtinol, the cytotoxic effect of salermide is dependent on the presence of functional p53 in the 
breast cancer cell line MCF-7 72. Several salermide analogs have also been developed and shown 
to possess anti-proliferative effects in cancer cells (Table 1.4, entries 3 and 4) 127. 
Splitomicin and its derivatives. Splitomicin (Table 1.4, entry 5) was identified from a 
cell-based screening for inhibitors of Sir2 and Hst1 from yeast 128. About 100 splitomicin 
derivatives were screened and found to have different selectivity towards the two yeast sirtuins 
129. Splitomicin has no effect on mammalian sirtuins. However, a series of compounds based on 
β-aryl splitomicins (Table 1.4, entries 6-8) were synthesized and several SIRT2 inhibitors were 
further identified with low micromolar IC50 values 130. β-(4-Methyl) phenyl-8-bromo-
splitomicin (Table 1.4, entry 7) and the R-enantiomer of β-(4-methyl) phenyl-8-methyl-
splitomicin (Table 1.4, entry 8) inhibit SIRT2 with an IC50 of 1.5 µM and 1.0 µM, repectively. 
These compounds inhibit the proliferation of MCF-7 breast cancer cells only modestly, which 
was attributed to their high lipophilicity. These compounds induce tubulin hyperacetylation in 
cells, suggesting that they target SIRT2 in cells 130.  
Table 1.4 Sirtinol, salermide, Splitomicin and their analogues 
Entry # Structure IC50 Biology Activity 
1 
Sirtinol 
 
SIRT1: 131 µM 120 
SIRT2: 38 µM 119 
Inhibits viability of breast, lung, prostate, 
cervical, oral, basal-like breast cancer cells and 
CLL69,92,102,121-124. 
2 
Salermide 
 
SIRT1: 76.2 µM 
SIRT2: 45 µM72,125 
No apparent toxicity in mice at concentrations of 
100 µM125;  
Induces apoptosis in MOLT4, KG1A, K562, 
SW480, Raji and NSCLC cells125,126； 
Potent antiproliferative on MDA-MB-231 and 
colon RKO cancer cell lines, and colorectal 
carcinoma CSCs127.  
3 
 
SIRT1: 40.3 µM 
SIRT2: 19.2 µM127 
Antiproliferative in MOLT4, MDA-MB-231 and 
colon RKO cancer cell lines, and glioblastoma 
multiforme CSCs 127 
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4 
 
SIRT1: 40.3~67.3 
µM 
SIRT2: 24.2 µM127 
Inhibits glioblastoma multiforme CSCs127 
5 
Splitomicin 
 
60 µM for Sir2128.  
No inhibition against 
mammalian sirtuins 
131 
 
6 
 
SIRT2: 5.2 µM130  
7 
 
SIRT2: 1.5 µM130 
Weak anti-proliferative properties in MCF7 
breast cancer cells;  
Increases tubulin acetylation in MCF7 breast 
cancer cells130 
8 
 
SIRT2: 1.5 µM 
(racemic) 1.0 µM 
(R); 35.1% at 100µM 
(S)130 
 
4.4. Tenovin and its analogues 
A cell-based screen designed to detect small molecules that activate the tumor suppressor 
p53 led to the discovery of tenovin-1 (Table 1.5, entry 1) and its water-soluble analogue tenovin-
6 (Table 1.5, entry 2) 132,133. Biochemical assays suggest that the targets of the tenovins are 
SIRT1 and SIRT2. At low micromolar concentrations, tenovin-1 shows cytotoxic effects to BL2 
Burkitt’s lymphoma cells and ARN8 melanoma cells expressing wild type p53, and reduce 
tumor growth derived from those cells 132. It is likely that p53 contributes to the cytotoxicity of 
tenovin-1 but is not essential for the long-term killing effect 132. Tenovin-6 is more active than 
tenovin-1 to ARN8 melanoma cells and it delays the growth of ARN8-derived xenograft tumors 
132. Treatment with tenovin-6 eliminates leukemic stem cells in a mouse model for chronic 
myelogenous leukemia 134. Further modification of tenovins gave a SIRT2 inhibitor named 
tenovin-D3 (Table 1.5, entry 3), which promotes expression of p21 in a p53-independent manner, 
increases acetylation of α-tubulin, and reduces cell migration in MDA-MB-468 breast cancer 
cells 71.  
Table 1.5 Tenovin and its analogues 
Entry # Structure IC50 Biology Activity 
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1 
Tenovin-1 
 
Not determined 
due to lack of 
water solubility133 
Cytotoxic to the BL2 Burkitt’s lymphoma 
cells and ARN8 melanoma cells; reduced 
tumor growth in the BL2 and ARN8 
mouse xenograft model 132. 
2 
Tenovin-6 
 
SIRT1: 37.5 µM 
SIRT2: 10.4 µM133 
Cytotoxic to ARN8 melanoma cells; 
delayed the growth of xenograft tumors 
derived from ARN8 cells 132; deterred the 
disease progression of chronic 
myelogenous leukemia in mice model 134. 
3 
Tenovin-D3 
 
SIRT1: >90 µM 
SIRT2: 21.8 µM71 
Promotes expression of p21 in a p53-
independent manner, increases acetylation 
of α-tubulin, and reduces cell migration in 
MDA-MB-468 breast cancer cells 71. 
 
4.5. Other sirtuin inhibitors 
Many other types of compounds have been reported as sirtuin inhibitors (Table 9, entries 
1-10). Several of these are worth commenting. AGK2 (Table 1.6, entry 1) is discovered from a 
focused compound library as a selective SIRT2 inhibitor which rescues α-synuclein toxicity and 
protects against Parkinson’s disease in a cellular model 135. This study suggests that SIRT2 may 
be a good target for Parkinson’s disease. AGK2 has been widely used as a tool compound to 
inhibit SIRT2 in various studies. However, unlike other SIRT2 specific inhibitors above, to date 
its anticancer effect was only demonstrated in C6 glioma cells 127.  
ICL-SIRT078 (Table 1.6, entry 2) was identified as a SIRT2 selective inhibitor by 
pharmacophore screening. It acts as a substrate-competitive SIRT2 inhibitor (Ki = 0.62 µM, IC50 
= 1.45 µM) with more than 50-fold specificity against SIRT1, 3 and 5. Treating MCF-7 breast 
cancer cells with ICL-SIRT078 upregulates acetylation of α-tubulin and suppression of cell 
proliferation136. 
Table 1.6 Other sirtuin inhibitors 
Entry # Structure IC50 Biology Activity 
1 
AGK2 
 
SIRT1: >50 µM 
SIRT2: 3.5 µM 
SIRT3: >50 µM135 
Protective against Parkinson’s 
disease135,137;  
Potent against C6 glioblastoma cells 
127. 
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2 
ICL-SIRT078  
 
SIRT1: >100 µM 
SIRT2: 1.45 µM 
SIRT3: >100 µM136 
Upregulates acetylation of α-tubulin 
and suppression of cell proliferation 
in MCF-7 cells136. 
3 
SirReal2 
 
SIRT1: >100 µM 
SIRT2: 0.14 µM 
SIRT3: >100 µM135 
Causes increase in acetylation of α-
tubulin 138. 
4 
Tanikolide Dimer 
 
SIRT1: 36.4 µM 
SIRT2: 3.3 µM139 
 
5 
6,8-dibromo-2-pentylchroman-4-one
 
SIRT1: >200 µM 
SIRT2: 1.5 µM 
SIRT3: >200 µM 140 
 
6 
 
SIRT1: 15 nM 
SIRT2: 10 nM 
SIRT3: 33 nM 141 
 
7 
 
SIRT1: 4.3 nM 
SIRT2: 1.1 nM 
SIRT3: 7.2 nM 141 
 
 
From a compound library screening for discovering sirtuin inhibitors, SirReal2 (Table 1.6, 
entry 3) was found to selectively inhibit SIRT2 (IC50 = 140 nM) over SIRT1 and SIRT3 138. It 
belongs to a family of aminothiazoles that are termed sirtuin-rearranging ligands (SirReals). The 
crystal structure of SIRT2 in complex with SirReal2 revealed that the potency and selectivity 
are based on a ligand-induced structural rearrangement of the active site, exploiting an adjacent 
binding pocket. Treatment of HeLa cells with SirReal2 leads to hyperacetylation of α-tubulin, 
indicating inhibition of SIRT2 in cells.  
Tanikolide dimer (Table 1.6, entry 4) was isolated from the Madagascar marine 
cyanobacterium Lyngbya majuscule and was identified as a SIRT2 selective inhibitor. Among 
a series of substituted chromone/chroman-4-one derivatives, 6,8-dibromo-2-pentylchroman-4-
one (Table 1.6, entry 5) was found to be most potent and selective against SIRT2 in vitro. The 
N
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most potent sirtuin inhibitors reported to date are thieno[3,2-d]pyrimidine-6-carboxamides 
(Table 1.6, entries 6 and 7) that are developed using encoded library screen technology. These 
compounds inhibit SIRT1-3 with low nM IC50 values 141. In spite of the high potency and 
selectivity of these compounds above, the biological activities of these compounds have not 
been reported. It would be of great interest to see whether these compounds exhibit anticancer 
activity. 
5. Novel SIRT2 enzymatic activities 
The seven sirtuins share a conserved NAD-binding and catalytic core domain, but possess 
distinct N- or C-terminal extensions. Among them, only SIRT1, 2, and 3 exert robust 
deacetylase activity in vitro. SIRT4-7, in contrast, have very weak deacetylase activity in vitro 
142,143. It has been proposed that some of them may function as ADP-ribosyltransferases 143-145. 
However, this activity is also very weak in vitro and its physiological significance is still under 
debate 146,147. Recently, SIRT4-7 were shown to hydrolyze other acyl groups more efficiently 
than acetyl group (Table 1.7). For example, it was demonstrated that SIRT5 functions to remove 
negatively charged acyl groups, such as succinyl and malonyl, from protein lysine residues 148. 
SIRT6 has more efficient activity in removing long chain fatty acyl groups, such as myristoyl 
and palmitoyl 149. Similar to SIRT6, SIRT1-3 could hydrolyze long-chain fatty acyl groups 
efficiently 150-152. These findings demonstrate that different class of sirtuins may have different 
acyl lysine substrate specificity.  
Table 1.7 Acyl group specificity for mammalian SIRT1-7 
Sirtuins Acyl group specificity 
SIRT1 Acetyl153, Fatty-acyl150 
SIRT2 Acetyl13, Fatty-acyl150,151, 4-Oxononanoyl154,155 
SIRT3 Acetyl156, Fatty-acyl150 
SIRT4 Lipoyl
157, Biotinyl157, methylglutaryl158, hydroxymethylglutaryl158, 3-
methylglutaconyl158 
SIRT5 Acetyl159, Malonyl160, Succinyl160, Glutaryl161 
SIRT6 Acetyl162-164, Fatty-acyl165 
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SIRT7 Acetyl166, Fatty-acyl167   
 
After SIRT6 being identified as a lysine defatty-acylase, SIRT1, 2, 3 were also shown to 
have efficient lysine defatty-acylase activity 150-152. Regarding SIRT2, it was found to hydrolyze 
propionyl, butyryl, crotonyl, hexanoyl, decanoyl, dodecanoyl, myristoyl, and lipoyl lysine in 
vitro. SIRT2 exerts comparable steady-state rates of deacetylation, dedodecanoylation, and 
demyristoylation 150. Later, we further found that SIRT2 is able to remove myristoyl groups with 
catalytic efficiency comparable to that of removing acetyl groups from lysine residues (Table 
1.8) 151. We have also resolved the crystal structure of SIRT2 in complex with a thiomyristoyl 
peptide BHJH-TM1, showing that the myristoyl group is accommodated by a pocket formed by 
multiple hydrophobic amino acid residues. More recently, SIRT2 was identified to remove 
lysine 4-oxononanoylation (4-ONylation) from histones and other proteins in cells 154,155. SIRT2 
removes 4-ONylation in stimulated macrophages, which could be involved in cytoprotective 
signaling responses. These newly discovered activities suggest that SIRT2 may be involved in 
cancer through not only deacetylase but also other deacylase activities, which merits further 
investigation.   
 
Table 1.8 Kinetics data for SIRT2 on acetyl and myristoyl H3K9 peptides 
Acyl peptide kcat (s-1) Km (µM) kcat/Km (s-1M-1) 
H3K9 acetyl 0.275 ± 0.014 19.00 ± 0.85 14500 
H3K9 myristoyl 0.018 ± 0.003 0.24 ± 0.03 74000 
 
Promoted by the findings that SIRT5 is an efficient demalonylase and desuccinylase and 
that SIRT6 is an efficient defatty-acylase, mechanism-based SIRT5 168 and SIRT6 152 inhibitors 
have been developed. Taking the advantage of SIRT5’s unique acyl group preference, a 
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thiosuccinyl H3K9 peptide is synthesized and shown to be SIRT5-specific inhibitors with an 
IC50 of 5 µM. The thiosuccinyl peptide does not inhibit SIRT1-3 even at 100 µM. In contrast, 
the thioacetyl H3K9 peptide inhibits SIRT1-3 potently, but does not inhibit SIRT5 88. Likewise, 
thiomyristoyl peptides are shown to be potent and cell-permeable SIRT6 inhibitors. The 
thiomyristoyl peptides exert potent inhibition activity for SIRT1, 2 and 3 152, which agrees with 
the efficienty defatty-acylation activity for SIRT1, 2, and 3. These proof-of-principle study 
suggests that the mechanism-based inhibitors can be a simple approach to develop inhibitors 
specific for a particular sirtuin. Specifically, by changing the chain length of acyl groups in the 
thioacyl lysine compounds, we may obtain inhibitors specific for different sirtuins. 
6. Summary 
It seems that the biological data and the SIRT2 inhibitor studies described above do not 
completely agree with each other. One of the most striking differences between the biological 
data and pharmacological data is that while the former points to conflicting (both tumor-
suppressing and tumor-promoting) roles of SIRT2, the majority of SIRT2 inhibitors studies 
suggest that inhibiting SIRT2 is a promising anticancer strategy. The discrepancy suggests that 
a clear understanding of SIRT2’s function is still lacking and that more studies are needed to 
further delineate the precise roles of SIRT2 in cancer. 
Inhibiting an enzyme with a small molecule could lead to different outcome from knocking 
down or knocking out the corresponding gene. The enzyme concentration generally remains 
unchanged in cells with a small molecule inhibitor, while the concentration is lower when the 
gene is knocked out or knocked down. In one simple scenario, if the enzyme also has other roles 
(e.g. mediating protein-protein interactions) that are not dependent on its enzymatic activity, 
using small molecule inhibitors likely will not affect these other roles. Therefore, highly potent 
and selective SIRT2 inhibitors will help to directly test whether inhibiting SIRT2 is a good 
strategy for treating cancers. 
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However, several caveats exist in the previous SIRT2 inhibitor studies. First, most of the 
SIRT2 inhibitors reported are still not potent enough with IC50 values in the µM range. Although 
inhibitors with low nM IC50 values have been reported 141, their bioavailability and biological 
activity have not been demonstrated. Second, most of the SIRT2 inhibitors that show anticancer 
effects are not very selective. It is possible that the anticancer effects of the SIRT2 inhibitors 
are due to the inhibition of multiple sirtuins. Peck et al. have proposed that inhibiting both SIRT1 
and SIRT2 is important for the anticancer effect of salermide and sirtinol 72. Last, in most sirtuin 
inhibitor studies, no experiments were carried out to carefully examine whether the anticancer 
effect of sirtuin inhibitors was due to sirtuin inhibition or not. In Chapter 2, I will summarize 
my doctoral research to establish SIRT2 inhibition as a strategy to treat certain Myc-driven 
cancer by using a highly specific and potent SIRT2 inhibition in combination with genetic 
approaches.  
Although several lysine deacylase activities have been identified for SIRT2, the 
physiological substrates and significance of these activities remains largely unknown. To date, 
the known biological functions of SIRT2 have been attributed to its ability to deacetylate various 
substrate proteins. Therefore, it will be of great interest to study the physiological relevance and 
especially the cancer involvement of novel SIRT2 activities. In Chapter 3, I will summarize my 
work to identify a Ras protein as SIRT2 defatty-acylation target and to elucidate the function of 
SIRT2-dependent defatty-acylation in cancer.  
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CHAPTER 2 
 
A SIRT2-SELECTIVE INHIBITOR PROMOTES C-MYC ONCOPROTEIN 
DEGRADATION AND EXHIBITS BROAD ANTICANCER ACTIVITY b 
 
Abstract 
Targeting sirtuins for cancer treatment has been a topic of debate due to conflicting reports 
and lack of potent and specific inhibitors. We have developed a thiomyristoyl lysine compound, 
TM, as a potent SIRT2-specific inhibitor with broad anticancer effect in various human cancer 
cells and mouse models of breast cancer. Mechanistically, SIRT2 inhibition promotes c-Myc 
ubiquitination and degradation. The anticancer effect of TM correlates with its ability to 
decrease c-Myc level. TM had limited effects on non-cancerous cells and tumor-free mice, 
suggesting that cancer cells have an increased dependency on SIRT2 that can be exploited for 
therapeutic benefit. Our studies demonstrate that SIRT2-selective inhibitors are promising 
anticancer agents and may represent a general strategy to target certain c-Myc-driven cancers. 
  
                                                
b This is a revised version of our published paper: Jing, H., Hu, J., He, B., Negrón Abril, Y.L., Stupinski, 
J., Weiser, K., Carbonaro, M., Chiang, Y.L., Southard, T., Giannakakou, P., Weiss, R.S., Lin, H.. A 
SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer 
Activity. Cancer Cell 29, 297-310 (2016). 
For this paper, I (HJ) designed and performed all the biochemical studies except those noted below. I 
would like to acknowledge the great contribution made by all the authors below. BH and HL designed 
the sirtuin inhibitors. JH, BH and YLC synthesized the inhibitors and biotin-conjugated compounds. HJ, 
JH, and BH purified the sirtuin enzymes, performed in vitro inhibitor assay and determined the 
mechanism of SIRT2 inhibition. YLNA and JS performed the animal studies. KW, MC and PG carried 
out the Biotin-TM pull-down assay and immunofluorescence of acetyl-α-tubulin. PG suggested the 
NCI60 screening, which helped making the c-Myc connection. TS performed pathologic review. RSW 
directed the animal studies. HL directed the inhibitor development and biochemical studies, and wrote 
the manuscript with help from HJ, RSW, PG, JH and YLNA.  
 
  31 
1. Introduction 
Oncogenes that drive tumorigenesis have attracted extensive interest as therapeutic targets 
for treating cancers. MYC, and c-Myc in particular, is one such oncogene. MYC was discovered 
in studies of fulminant chicken tumors caused by oncogenic retroviruses, which co-opted 
cellular c-Myc to generate the oncogenic v-Myc 1. Subsequently, mouse plasmacytomas and 
human Burkitt lymphomas were found to be caused by c-Myc activation due to chromosomal 
translocations that fused c-Myc to the immunoglobin (Ig) gene loci 1. Recent genomic 
sequencing efforts identified c-Myc as one of the most highly amplified oncogenes in many 
different human cancers, further highlighting the oncogenic role of c-Myc activation 2. The 
identification of effective therapeutic strategies targeting Myc has been challenging. Recently 
it was demonstrated that bromodomain inhibitors that target BRD4 could suppress c-Myc 
transcription and lead to tumor inhibition in vivo 3. This finding underscores the therapeutic 
value of targeting Myc. 
The sirtuin family of NAD-dependent protein lysine deacylases has been shown to play 
important roles in many physiological processes, including the regulation of transcription, 
metabolism, and DNA repair 4-6. Many of these functions are achieved by their ability to 
deacylate various substrate proteins, including histones, transcription factors, and metabolic 
enzymes 4-11. Because the functionally related but structurally distinct zinc-dependent histone 
deacetylases (HDACs) are established cancer targets 12,13, there is interest in exploring whether 
sirtuins can also be important targets for cancers 14-16. However, there is evidence suggesting 
both tumor suppressor and oncogenic roles of sirtuins 14-16. In the case of SIRT2, genetic studies 
indicated that aged Sirt2 knockout (KO) mice show increased tumor incidence as compared to 
wild-type (WT) 17 controls. In contrast, SIRT2 was also observed to have tumor promoting 
activity in several studies 18-24. Moreover, several SIRT2 inhibitors have also been reported to 
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have anticancer effects 25-34. However, the moderate potency and specificity of the existing 
sirtuin inhibitors are insufficient to draw conclusions about the anticancer potential of sirtuin 
inhibition. Thus, whether sirtuin inhibitors are useful anticancer agents is still an open question. 
Here we set out to develop sirtuin inhibitors with improved potency and selectivity to explore 
the potential of targeting sirtuins for treating human cancers, especially c-Myc driven cancers.  
2. Results 
2.1 Development of a highly selective and potent SIRT2 inhibitor  
Most existing sirtuin inhibitors are either not very potent (e.g. with IC50 values in the high 
micromolar range) or not very selective (i.e. they inhibit several different sirtuins). More potent 
and more selective sirtuin inhibitors would greatly aid in evaluating the therapeutic potential of 
targeting sirtuins. To develop potent inhibitors specific for a particular sirtuin, we used 
mechanism-based thioacyl lysine compounds. Thioacyl lysine peptides can react with NAD in 
the sirtuin active site, forming a relatively stable intermediate that inhibits sirtuin (Fig. 2.1A) 35-
37. Recent studies suggested that different sirtuins may have different acyl group specificity 
7,9,10,38, which can be utilized to design inhibitors specific for different sirtuins 25,39,40. To target 
the sirtuins that can recognize aliphatic acyl groups, we synthesized four thioacyl lysine 
compounds, TA (thioacetyl) 41, TB (thiobutyryl), TH (thioheptanoyl), and TM (thiomyristoyl) 
(Fig. 2.1B), and then analyzed their ability to inhibit different sirtuins.  
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Figure 2.1 Development of mechanism-based inhibitor of sirtuins. (A) The enzymatic reaction 
mechanism of sirtuin-catalyzed NAD-dependent deacylation (upper panel). Thioacyl lysine compounds 
act as suicide substrates to inhibit sirtuins (lower panel). (B) Structures of four different thioacyl lysine 
sirtuin inhibitors, TA, TB, TH, and TM. M, which differs from TM by just one atom (highlighted by 
yellow color), is an inactive control of TM. (C) IC50 (µM) values of the TA, TB, TH, TM and M against 
SIRT1-7. IC50 values derived from Graphpad Prism are presented as mean values from three independent 
experiments. (D) Dose-responsive curve for TA, TB, TH, TM and M against SIRT1 and SIRT2. Error 
bars represent mean ± sd. 
Remarkable differences in the potency and selectivity of these compounds were observed 
by sirtuin activity assays in vitro (Fig. 2.1C & D). TA could inhibit SIRT1, SIRT2 and SIRT3, 
but not very potently. TB was a better SIRT1/SIRT2 inhibitor than TA. The IC50 of TB for 
SIRT1 (3.8 µM) and SIRT2 (0.43 µM) were about 3 fold and >10-fold, respectively, better than 
those of TA (Fig. 2.1C). Further increasing the size of the thioacyl group by three methylene 
groups lead to TH, which had even lower IC50 values for SIRT1 (1.2 µM) and SIRT2 (0.13 µM). 
Remarkably, TM, with a 14-carbon thioacyl group, could inhibit SIRT2 with an IC50 value of 
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0.028 µM, but inhibited SIRT1 with an IC50 value of 98 µM and did not inhibit SIRT3 even at 
200 µM (Fig. 2.1C). None of these compounds can efficiently inhibit SIRT5, SIRT6, or SIRT7. 
Thus, TM is a SIRT2-speific inhibitor in vitro. To facilitate later investigations of TM, we also 
synthesized the corresponding myristoyl lysine compound (M, Fig. 2.1B) as an inactive control 
for TM. M differs from TM by only one atom (the S atom in TM is changed to an O atom in 
M). As expected, M did not show sirtuin inhibition even at 200 µM (Fig. 2.1C). 
 
Figure 2.2 TM is a mechanism-based SIRT2 inhibitor. (A) Henri-Michaelie-Menten plots showing 
acH3K9 competition analyses of TM-mediated SIRT2 inhibition. (B) Double reciprocal plot with varied 
TM and acH3K9 concentrations. Data was fit to competitive inhibition using Graphpad Prism. (C) Henri-
Michaelie-Menten plots showing NAD competition analyses of TM-mediated SIRT2 inhibition. (D, E) 
Mass spectrometry detection of the stable covalent intermediate formed by TM and NAD. (D) The 
selected ion chromatogram (SIC) (m/z = 1123-1124) for the reaction containg SIRT2, NAD and TM. (E) 
The selected ion chromatogram (SIC) (m/z = 1123-1124) was shown on the left, the mass spectrum was 
shown on the right. The data from the reaction mixture containing NAD and TM or the mixture containing 
SIRT2 and TM were shown as negative controls. Error bars represent mean ± sd. 
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To further confirm that TM is a mechanism-based inhibitor of SIRT2, we performed 
substrate competition analyses for TM-mediated SIRT2 inhibition. At saturating NAD 
concentration, the apparent Km value for acetyl-H3K9 peptide (acH3K9) increased with 
increasing TM concentrations, whereas the vmax remained relatively constant (Fig. 2.2A). The 
double-reciprocal plot of 1/v versus 1/[acH3K9] revealed a series of lines that intersect at the 
1/v axis (Fig. 2.2B), suggesting that TM is competitive with acH3K9. This is consistent with 
our recent finding that SIRT2 possesses a large hydrophobic pocket that can accommodate the 
myristoyl group 42. At saturating acH3K9 concentration, both the apparent Km value for NAD 
and vmax decreased with increasing TM concentrations (Fig. 2.2C), suggesting that TM is 
uncompetitive with NAD, which is consistent with the fact that formation of the inhibitory 
covalent intermediate requires NAD. We then used liquid chromatography-mass spectrometry 
(LC-MS) to examine the formation of the stalled covalent intermediate. Ions with m/z of 1123.33 
(the protonated intermediate) and 1145.25 (the sodium adduct of the intermediate) were detected 
only when TM was incubated with both SIRT2 and NAD (Fig. 2.2D), but not without SIRT2 or 
NAD (Fig. 2.2E). Overall, these results indicate that TM acts as a mechanism-based inhibitor 
of SIRT2. 
2.2 TM exhibited potent anticancer activity 
Sirtuin inhibitors have been reported to have anticancer properties. However, most of the 
inhibitors used are not very selective and thus, inhibiting which sirtuins can provide beneficial 
effects remains unclear. Having a potent and very selective SIRT2 inhibitor provided a unique 
opportunity to investigate whether inhibiting SIRT2 can be useful as an anticancer strategy. We 
initially explored this in several breast cancer cell lines because of the substantial tumor-
promoting role of SIRT2 in breast cancer 22-24 and the previous studies showing that SIRT2 
inhibitors exert anti-proliferative effect against breast cancer cell lines 27,30,43-45. We assayed the 
ability of TA, TB, TH, and TM to inhibit three different human breast cancer cell lines, MCF-
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7, MDA-MB-468 and MDA-MB-231. The cytotoxicity effects of these compounds correlated 
with their in vitro SIRT2 inhibitory effects (Fig. 2.3A). TA, which showed modest SIRT1, 
SIRT2 and SIRT3 inhibition in vitro, did not inhibit cell viability at 50 µM. TB had greater 
inhibitory effect on cell viability than TA, but only showed inhibition at 50 µM. TH and TM 
were more potent than TA and TB. Compared with TH, the SIRT2-selective inhibitor TM 
showed greater inhibition of cell viability. The inactive inhibitor mimic M did not affect cell 
viability at 50 µM. Next we treated eight different human normal and breast cancer cell lines 
with TM. As shown in Fig. 2.3B, different malignant cells showed differential susceptibility to 
TM. And the two non-cancerous cell lines, MCF-10A and HME1, were much less sensitive to 
TM, suggesting that the cytotoxicity of TM is relatively selective toward cancer cells. We 
further evaluated the anticancer activity of TM using soft agar colony formation assay. TM 
significantly inhibited anchorage-independent growth of various cancer cells tested (Fig. 2.3C, 
D & E), while the control compound M did not (Fig. 2.3C).  
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Figure 2.3 TM inhibits human cancer cells. (A) Cell viability of MCF-7, MDA-MB-468 and MDA-
MB-231 cells treated with the indicated inhibitors for 72 hr. (B) Cell viability of the indicated human 
normal and breast cancer cells treated with TM for 72 hr. IC50 values were means from 3 independent 
experiments. (C) Soft agar colony formation of MCF-7 cells treated with ethanol, TM (25 µM in ethanol) 
or M (25 µM in ethanol). Representative images of colonies were shown on the left panel. (D, E) Soft 
agar colony formation of MDA-MB-468 (D) and MDA-MB-231 (E) cells treated with ethanol or TM (25 
µM). Quantification of the colony numbers was shown on the right panel. The y axis represents percent 
colony number relative to ethanol-treated cells. Statistics, two-tailed Student’s t-test. Error bars represent 
mean ± sd. ***p < 0.001.   
The correlation between the cytotoxic effects of TA, TB, TH, TM and M and their in vitro 
SIRT2 inhibitory activities suggests that SIRT2 inhibition could have anticancer effects. To 
further confirm this, we knocked down all seven sirtuins individually (Fig. 2.4A) in MCF-7, 
MDA-MB-468 cells, which were relatively sensitive to TM. SIRT2 knockdown (KD) produced 
the strongest cytotoxicity in both cell lines (Fig. 2.4B), which further supported SIRT2 
inhibition as a promising anticancer strategy. 
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Figure 2.4 SIRT2 KD exerts the best cytotoxic effect compared to other sirtuin KDs. (A) 
Representative results showing the knockdown efficiency of SIRT1-7 in HeLa cells. Cells were infected 
with lentivirus carrying Luciferase shRNA and shRNAs against SIRT1-7 for 72 hr before analyzed by 
Western blot for sirtuin levels. (B) Cell viability of MCF-7 and MDA-MB-468 cells infected with 
lentivirus carrying luciferase shRNA (Ctrl) or SIRT1-7 shRNAs for 72 hr. The heat map presents average 
relative cell viability compared to Ctrl shRNA-infected cells from three independent experiments.  
We then further examined the effect of SIRT2 KD in the same set of human breast cancer 
and non-tumorigenic mammary cell lines in which the cytotoxic effect of TM was tested. SIRT2 
KD (Fig. 2.5A) significantly decreased cell viability in a time-dependent manner in MCF-7, 
MDA-MB-468, and MDA-MB-231 cells, but did not show much cytotoxicity in BT-549, SK-
BR-3, and MDA-MB-453 cells or the non-transformed MCF-10A and HME1 cells (Fig. 2.5B). 
In MCF-7 and MDA-MB-468 cells, SIRT2 KD resulted in less than 1% cell viability after 10 
days of lentiviral infection (Fig. 2.5C). Moreover, colony formation in soft agar by MCF-7 cells 
was dramatically diminished by SIRT2 KD (Fig. 2.5E). The knockdown data are thus consistent 
with the small molecule data, indicating that SIRT2 inhibition can effectively suppress cancer 
cell proliferation and that the anticancer effect of TM is likely through SIRT2 inhibition. 
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Figure 2.5 SIRT2 KD decreases the viability of various cancer cell lines. (A) SIRT2 knockdown 
efficiency in various human normal and breast cancer cells was confirmed by Western blot (the first row) 
3 days after lentiviral infection. The α-tubulin level was used as internal standard of total protein amount. 
(B) Cell viability of various human normal and breast cancer cells infected with lentivirus carrying 
luciferase (Ctrl) or SIRT2 shRNAs for 3 or 5 days. (C) Cytotoxicity effects of SIRT2 knockdown in 
MCF-7, MDA-MB-468, MDA-MB-231 and BT-549 cells at day 10 after the infection. (D) Representative 
Western blots showing the knockdown efficiency of SIRT2 by siRNAs in MCF-7 cells. (E) Soft agar 
colony formation of MCF-7 cells transfected with scrambled siRNA or SIRT2 siRNA. Quantification of 
the colony numbers is shown in the right panel. The y axis represents percent colony number relative to 
scrambled siRNA-transfected cells. Statistics, two-tailed Student’s t-test. Error bars represent mean ± sd. 
***p < 0.001.  
2.3 TM inhibits SIRT2 in cells  
We next wanted to determine whether TM inhibits cancer cells by targeting SIRT2. We first 
carried out a number of experiments to validate that SIRT2 is the target of TM in cells. We 
conjugated biotin to TM and M to generate Biotin-TM and Biotin-M compounds (Fig. 2.6A). 
We then added these compounds to either total protein extract (Fig. 2.6B) or live cells (Fig. 
2.6C) to pull down sirtuins. Biotin-TM was able to pull down SIRT2 but not SIRT1 from the 
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HEK293T cell extract. In contrast, Biotin-M, the inactive control compound, did not pull out 
SIRT2 (Fig. 2.6B). When assayed using SIRT2 KD cells, the amount of SIRT2 pulled down by 
Biotin-TM was also decreased (Fig. 2.6C). These data suggest that TM targets SIRT2 but not 
SIRT1 in cells.  
 
Figure 2.6 TM specifically inhibits SIRT2 in cells. (A) Structures of Biotin-TM and Biotin-M. (B) Pull-
down assay to detect the binding of Biotin-M (10 µM) and Biotin-TM (10 µM) to SIRT1 and SIRT2 in 
HEK293T total cell lysate. (C) Pull-down assay to detect the binding of Biotin-TM (50 µM) to SIRT2 in 
MCF-7 cells. D-Biotin (50 µM) was used as a negative control. (D) Immunoblot for the acetylation of 
p53 (K382) in In MCF-7 or MDA-MB-468 cells treated with TSA (200 nM) and the indicated inhibitors 
(25 µM) for 6 hr. (E) Immunoblot for the acetyl-α-tubulin (K40) levels in SIRT2-overexpressing MCF-7 
cells treated with indicated inhibitors (25 µM) for 6 hr. (F) Immunoblot for acetyl-α-tubulin (K40) levels 
in MCF-7 cells treated with TM or M for 6 hr. (G) Immunofluorescence detection of the acetyl-α-tubulin 
(K40) level in MDA-MB-231 cells treated with ethanol, M or TM (25 µM in ethanol) for 6 hr.  
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Second, we confirmed that TM inhibits SIRT2 in cells by detecting the acetylation level of 
known SIRT2 as well as SIRT1 targets. In MCF-7 and MDA-MB-468 cells, TA, TB, and TH, 
inhibited SIRT1, based on the acetylation level of a known SIRT1 deacetylation target, p53. In 
contrast, TM showed almost no inhibition of p53 deacetylation (Fig. 2.6D). By detecting the 
acetylation of α-tubulin, a known SIRT2 target, we monitored SIRT2 inhibition. TA or M, 
which did not inhibit SIRT2 well, did not affect the acetylation of α-tubulin. TB and TH, which 
have intermediate SIRT2 inhibition potency, slightly increased the acetylation of α-tubulin. TM, 
the best SIRT2 inhibitor, led to the greatest increase in α-tubulin acetylation (Fig. 2.6E). The 
effect of TM on α-tubulin acetylation was dose-dependent, whereas M did not affect acetyl-α-
tubulin level at 50 µM (Fig. 2.6F). Similarly, TM, but not M, increased the level of α-tubulin 
acetylation in MDA-MB-231 cells based on immunofluorescence imaging (Fig. 2.6G). SIRT2 
has been reported to be not only a deacetylase, but also a defatty-acylase (He et al., 2014; Liu 
et al., 2014), so we further examined the effect of TM on the defatty-acylase activity of SIRT2 
in cells. Metabolic labeling of fatty-acylated proteins revealed that SIRT2 KD (Fig. 2.7A) but 
not TM (Fig. 2.7B) was able to elevate the fatty acylation levels of many proteins, suggesting 
that in cells TM is a potent inhibitor of SIRT2 deacetylase but not defatty-acylase.  
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Figure 2.7 TM does not inhibit SIRT2 defatty-acylase activity. (A) Global protein fatty acylation in 
HEK293T cells with Ctrl and SIRT2 knockdown. Protein fatty acylation was detected by a metabolic 
labeling method using alkyne-tagged fatty acid analogs Alk12 (50 µM) and Alk14 (50 µM). SIRT2 KD 
efficiency by western blot analyses is shown in the bottom panel. (B) Global protein fatty 
acylation in HEK293T cells treated with the ethanol, AGK2 (25 µM) or TM (25 µM) for 6 hr in the 
presence of Alk12 (50 µM) and Alk14 (50 µM). 
Finally, to confirm that the anticancer effect of TM is due to SIRT2 inhibition, we tested 
the sensitivity of cells to TM under SIRT2 overexpression or knockdown conditions. If TM 
inhibits cancer cells by targeting SIRT2, overexpression of SIRT2 would decrease the 
sensitivity of cells to TM (the increased SIRT2 level would require more TM for inhibition), 
while partial and transient knockdown of SIRT2 would increase the sensitivity. Indeed, 
overexpression of SIRT2 (Fig. 2.8A) significantly decreased the cytotoxicity of TM (Fig. 2.8B), 
while transient and partial knockdown of SIRT2 (Fig. 2.8C) sensitized cells to TM (Fig. 2.8D). 
These results support the conclusion that the anticancer effect of TM is through SIRT2 inhibition 
instead of other off-target effects.  
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Figure 2.8 TM targets SIRT2 in exert anticancer effect. (A) Confirmation of SIRT2 overexpression 
in MCF-7 cells transfected with pCMV vector or pCMV-SIRT2 for 12 hr. (B) Effect of SIRT2 
overexpression on the cytotoxicity effect of TM. MCF-7 cells were transfected with pCMV vector or 
pCMV-SIRT2 for 12 hr before being treated with 25 µM of TM for 12 or 24 hr. The y axis represents 
relative cell viability compared to ethanol-treated controls. (C) Confirmation of SIRT2 KD in MDA-MB-
231 cells infected with lentiviral Luciferase shRNA and SIRT2 shRNAs. (D) Effect of SIRT2 knockdown 
on the sensitivity of MDA-MB-231 cells to TM. MDA-MB-231 cells were infected with lentiviral 
Luciferase shRNA and SIRT2 shRNAs, respectively, for 24 hr before being treated with different 
concentrations of TM for another 72 hr. Cell viability was measured by CellTiter-Blue® assay. Stat 
lentiviral Luciferase shRNA and SIRT2 shRNAs istics, two-tailed Student’s t-test. Error bars represent 
mean ± sd. ***p < 0.001.  
2.4 TM inhibits tumor growth in mouse models of breast cancer 
To further demonstrate that SIRT2 inhibition can be useful for treating cancers, we tested 
TM in two mouse models of cancer. The first was a xenograft model in which the triple-negative 
breast cancer cell line, MDA-MB-231, was injected subcutaneously into immunocompromised 
mice. When tumor size reached ∼200 mm3, the mice were divided into two groups and treated 
by either direct intratumor (IT) (Fig. 2.9) or intraperitoneal (IP) (Fig. 2.10) injection of the 
control vehicle solvent (DMSO) or TM (1.5 mg TM in 50 µL DMSO; n = 5) daily. Tumors were 
collected after 30-days of treatment and analyzed. TM treatment significantly inhibited tumor 
growth as compared to the control (Fig. 2.9A, 2.9B, & 2.10A). Histopathological examination 
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revealed central areas of necrosis in tumors from both DMSO and TM treated mice, but the 
necrosis was more extensive and the overall tumor size was smaller in the TM treated mice (Fig. 
2.9D and 2.10C). IT TM injection showed a stronger effect in reducing tumor volume and 
increasing areas of necrosis as compared to IP TM injection. Analysis of TM content in tissue 
samples from TM-treated mice showed that IP-administered TM reached the tumors, even 
though the serum concentration of TM was low and a significant amount of TM accumulated in 
abdominal fat (Fig. 2.10D). TM did not cause significant toxicity in mice (one mouse from each 
treatment group died, likely due to infection caused by repeated IP injection but not due to TM 
toxicity) and no significant weight loss was observed in TM-treated mice (Fig. 2.9C & 2.10B). 
Immunohistochemistry staining of Ki-67 was performed to assess the effect of TM on the 
proliferation of tumor cells in vivo. As shown in Fig. 2.9F (upper panel) and 2.9G, as well as 
Fig. 2.10E (upper panel) and 2.10F, a significant decrease in Ki-67+ cells was observed with 
TM treatment relative to vehicle treatment. To determine whether TM inhibits SIRT2 in vivo, 
we performed immunofluorescence staining of acetyl-α-tubulin in the xenograft tumors. As 
shown in Fig. 2.9F (lower panel) and 2.9H and Fig. 2.10E (lower panel) and 2.10G, the acetyl-
α-tubulin level was moderately but statistically significantly increased in tumors from TM 
treated mice compared with those from vehicle-treated mice, suggesting that TM indeed inhibits 
SIRT2 in vivo.  
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Figure 2.9 Analysis of tumor growth and histopathological findings of xenografted mice treated by 
intratumor TM injection. Mice bearing MDA-MB-231 human breast cancer xenograft were divided 
into two groups and treated by direct intratumor injection with either the control vehicle solvent (DMSO) 
or TM (0.75 mg TM in 50 uL DMSO; n = 5) three times per week. Tumors were collected after 30-day 
treatment. (A) Gross findings at necropsy after 30 days of intratumor treatment with either DMSO or TM. 
(B) Tumor growth chart. Statistics, paired Student’s t-test. (C) Mouse body weight chart. (D) 
Hematoxylin and eosin staining of tumor tissues after 30 days of treatment with either DMSO or TM. (E) 
Detection of TM in mouse serum and tumor tissues by mass spectrometry. (F) Representative images of 
Ki-67 immunohistochemistry staining and acetyl-α-tubulin (K40) immunofluorescence staining of tumor 
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tissues after 30 days of treatment with either DMSO or TM. (G) Quantification of Ki-67+ cells in (F). 
The y axis represents Ki-67+ cells per high power field (10 HPFs/tumor for all the tumors analyzed, n = 
4 for DMSO, n = 6 for TM). Statistics, unpaired Student’s t-test. (H) Quantification of acetyl-α-tubulin 
fluorescence intensity in (F). The y axis represents integrated intensity per cell. (10 HPFs/tumor for all 
the tumors analyzed, n = 4 for DMSO, n = 6 for TM). Statistics, unpaired Student’s t-test. Error bars 
represent mean ± sd. *p < 0.05, **p < 0.01.   
 
Figure 2.10 Analysis of tumor growth and histopathological findings of xenografted mice treated 
by intraperitoneal TM injection. Mice bearing MDA-MB-231 human breast cancer xenograft were 
divided into two groups and treated by IP injection with either the vehicle (DMSO) or TM (1.5 mg TM 
in 50 µL DMSO; n = 5) daily. Tumors were collected after 30-day treatment. (A) Tumor growth chart. 
Arrows indicate time point when an animal was found dead (1 untreated, 1 treated). Statistics, paired 
Student’s t-test. (B) Mouse body weight chart. (C) Hematoxylin and eosin staining of tumor tissues after 
30 days of treatment with DMSO or TM. (D) Detection of TM in mouse serum, fat and tumor tissues by 
mass spectrometry. (E) Representative images of Ki-67 immunohistochemistry staining and acetyl-α-
tubulin (K40) immunofluorescence staining of tumor tissues after 30 days of treatment with DMSO or 
TM. (F) Quantification of Ki-67+ cells in (E). The y axis represents Ki-67+ cells per high power field (10 
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HPFs/tumor for all the tumors analyzed, n = 3 for DMSO, n = 4 for TM). Statistics, unpaired Student’s t-
test. (F) Quantification of acetyl-α-tubulin fluorescence intensity in (E) by ImageJ. The y axis represents 
integrated intensity per cell. (10 HPFs/tumor for all the tumors analyzed, n = 3 for DMSO, n = 4 for TM). 
Statistics, unpaired Student’s t-test. Error bars represent mean ± sd. *p < 0.05, **p < 0.01. 
The second mouse model was the mammary tumor model driven by mammary gland-
specific expression of polyoma middle T antigen under the control of mouse mammary tumor 
virus promoter/enhancer (MMTV-PyMT model) 46.  The MMTV-PyMT mice received daily IP 
injections with either the control vehicle solvent (DMSO) or TM (1.5 mg TM in 50 µL DMSO; 
n = 10). The Kaplan-Meier tumor-free survival curve showed that TM treatment significantly 
prolonged the tumor-free survival of mice compared with vehicle-treated mice (Fig. 2.11A). 
While the average time to tumor onset in the control group was 48 days, the mean latency for 
TM-treated mice was 54 days. Histopathological examination revealed more extensive areas of 
necrosis in the neoplasms from TM-treated mice as compared to the control group (Fig. 2.11B). 
A significant decrease in proliferation of tumor cells was observed with TM treatment relative 
to vehicle treatment as measured by Ki-67 staining (Fig. 2.11C, upper panel, and 2.11D). A 
modest but statistically significant increase in the acetyl-α-tubulin level was observed in tumors 
from TM-treated mice compared to those from vehicle-treated mice (Fig. 2.11C, lower panel, 
and 2.11E), indicating that SIRT2 was inhibited by TM in vivo. The data demonstrate that SIRT2 
inhibition with TM delays tumor onset in the MMTV-PyMT model and reduces tumor growth 
in vivo. 
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Figure 2.11 Mammary tumorigenesis in MMTV-PyMT female mice following intraperitoneal TM 
injection. (A) Kaplan-Meier tumor-free survival curve of MMTV-PyMT mice treated by IP injection 
with either the vehicle (DMSO) or TM (1.5 mg TM in 50 µL DMSO; n = 10) daily. The x-axis shows 
mice age; the y-axis shows proportion of mice remaining tumor-free. Statistics, log-rank test. (B) 
Hematoxylin and eosin staining of mammary tumors after 30 days of treatment with either DMSO or TM. 
(C) Representative images of Ki-67 immunohistochemistry staining and acetyl-α-tubulin (K40) 
immunofluorescence staining of tumor tissues after 30 days of treatment with either DMSO or TM. (D) 
Quantification of Ki-67+ cells in (C). The y axis shows Ki-67+ cells per high power field (10 HPFs/tumor 
for all the tumors analyzed, n = 4 for DMSO, n = 4 for TM). Statistics, unpaired Student’s t-test. (E) 
Quantification of acetyl-α-tubulin fluorescence intensity in (C) by ImageJ. The y axis shows integrated 
intensity per cell. (10 HPFs/tumor for all the tumors analyzed, n = 8 for DMSO, n = 8 for TM). Statistics, 
unpaired Student’s t-test. Error bars represent mean ± sd. *p < 0.05, **p < 0.01.   
2.5 COMPARE analysis with the NCI-60 cancer cell panel points to possible mechanism of 
action for the SIRT2 inhibitor TM 
To further investigate the anticancer effects of TM, we first examined whether the level of 
SIRT2 in different cell lines could be used to predict which cell lines would be more sensitive 
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to SIRT2 inhibitors. We checked the SIRT2 protein level in all the eight human normal and 
breast cancer cell lines above (Fig. 2.3B & 2.5B) to see if the sensitivity to TM correlated with 
SIRT2 level in these cell lines. Compared to MCF-10A and HME1 cells, the cancer cell lines 
showed relatively high SIRT2 expression. However, we did not see an obvious correlation 
between SIRT2 level and TM sensitivity (Fig. 2.12A & B) among the cancer cell lines, 
suggesting that other factors account for the SIRT2 inhibitor sensitivity.  
 
Figure 2.12 SIRT2 levels in different human normal and breast cancer cell lines. Western blot 
analysis of SIRT2 level (A) and semi-quantification of SIRT2 level relative to GAPDH level (B). 
To examine the anticancer activity of TM against other malignancies and the molecular 
mechanisms underlying its activity, we submitted the TM compound to the Developmental 
Therapeutics Program of the National Cancer Institute (NCI) at the National Institutes of Health 
for screening against the NCI-60 panel of human cancer cell lines 47.  The screening result 
showed that TM inhibited 36/56 of the NCI-60 cell lines by >50% at 10 µM (Fig. 2.13A). In 
particular, all the leukemia cell lines were very sensitive to TM and most of colon cancer cell 
lines were sensitive to TM. In contrast, melanoma and ovarian cancer cells were less sensitive 
to TM. Consistent with our earlier findings (Fig. 2.3), MCF-7 and MDA-MB-468 cells were 
very sensitive to TM.  
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Figure 2.13 COMPARE analysis with the NCI-60 cancer cell panel suggests possible mechanism of 
action for TM (A) NCI-60 cell line screening of TM. NCI-60 cell lines were cultured with and without 
10 µM TM for 24 hr. The percent growth of TM-treated cells compared to the controls is shown. The 
horizontal dotted red line shows 50% growth. (B) Top four correlated genes from molecular target 
Compare analysis of the NCI-60 assay data of TM. The data set used is the MT series. 
To investigate how SIRT2 inhibition halts cancer cell proliferation, we took advantage of 
NCI molecular target COMPARE analysis 48. NCI has accumulated many data sets regarding 
the properties of the NCI-60 cell lines, including gene expression, DNA methylation, protein 
expression, and post-translational modifications. The molecular target COMPARE analysis 
serves to correlate the response of the NCI-60 panel to a small molecule (TM in this case) to 
known molecular patterns. From this analysis, we found that the sensitivity of NCI-60 cell lines 
to TM correlated best with c-Myc phosphorylation/protein levels. In other words, cell lines with 
higher c-Myc phosphorylation/protein levels were more sensitive to TM (Fig. 2.13B). The 
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correlation between TM sensitivity and c-Myc is intriguing as c-Myc is an oncoprotein that is 
up-regulated in many cancers.  
2.6 TM decreases c-Myc oncoprotein level in cancer cells 
The correlation between TM efficacy and c-Myc was informative, but the small correlation 
value (~0.5) was not sufficient to establish a mechanistic relationship. To further understand the 
connection, we measured c-Myc levels in the cells treated with and without TM or M. TM 
decreased c-Myc protein levels in a time-dependent manner in MCF-7 cells, whereas M 
treatment had no effect on the c-Myc protein level (Fig. 2.14A). Similar effects of TM on c-
Myc were also observed in K562 (Fig. 2.18C) and MDA-MB-468 cells (Fig. 2.18D). Consistent 
with the effect of TM, c-Myc abundance was also reduced by SIRT2 KD (Fig. 2.14C), 
suggesting that TM works through SIRT2 inhibition to decrease c-Myc. To further establish that 
the reduction in c-Myc protein is important for the anticancer effect of TM, we examined 
whether the sensitivity of cancer cell lines to TM correlated with the decrease in c-Myc level 
induced by TM treatment. Among the six breast cancer cell lines in the NCI-60 panel, BT-549 
did not respond to treatment with 10 µM TM (Fig. 2.13A). This result was in line with our own 
findings (Fig. 2.3B). Although higher concentrations of TM did decrease the viability of BT-
549, the sensitivity was much lower than that of MCF-7 cells. Consistent with the reduced 
sensitivity to TM, SIRT2 KD in BT-549 cells did not decrease cell viability (Fig. 2.3B & 2.5B). 
We therefore examined whether TM could affect c-Myc protein levels in BT-549 cells. 
Consistent with the decreased TM sensitivity, TM treatment did not have a significant effect on 
c-Myc protein abundance in BT-549 cells (Fig. 2.14B). SIRT2 KD also failed to decrease c-
Myc levels in BT-549 cells (Fig. 2.14C). These data collectively suggest that the sensitivity of 
cancer cell lines to TM correlates with the ability of TM to decrease c-Myc levels via SIRT2 
inhibition in these cell lines. We further measured the IC50 values of TM in six different cancer 
cell lines and the corresponding decrease in c-Mycs level in these cell lines upon TM treatment. 
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Plotting the IC50 values against the decreases in c-Myc levels indicates that there was an 
excellent correlation between them (Fig. 2.14D), supporting that the ability of TM to decrease 
c-Myc is important for its anticancer effect in the cell lines that are very sensitive to TM.  
 
Figure 2.14 TM decreases c-Myc protein level. (A) c-Myc protein levels in MCF-7 cells treated with 
TM (25 µM) or M (25 µM). (B) c-Myc protein levels in BT-549 cells treated with TM (25 µM). (C) The 
levels of c-Myc, SIRT2 and α-tubulin in MCF-7 or BT-549 cells infected with luciferase or SIRT2 
shRNAs for 72 hr. (D) The correlation between the ability of TM to inhibit cancer cell lines and its ability 
to decrease c-Myc level. The x axis shows IC50 values of TM in different cell lines. The y axis shows the 
TM-induced decreases in c-Myc level. Relative c-Myc level was obtained by comparing the c-Myc 
protein level in cells treated with TM for 24 hr to that in vehicle-treated control cells. Error bars represent 
mean ± sd. 
Then to test the effect of TM or SIRT2 KD on c-Myc transcriptional activity, we did RNA-
sequencing to compare gene expression in vehicle-treated versus TM-treated, or Ctrl KD versus 
SIRT2 KD MCF-7 cells. We then used Geneset enrichment analysis (GSEA)49 to test whether 
a previously defined set of c-Myc target genes was affected by TM or SIRT2 KD. The analysis 
result showed that c-Myc target gene sets were enriched in both TM- and SIRT2 KD-decreased 
genes (Fig. 2.15), indicating that both TM and SIRT2 KD downregulate c-Myc transcriptional 
activity.  
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Figure 2.15 TM and SIRT2 KD inhibit c-Myc transcriptional activity. (A) Table of c-Myc target gene 
sets enriched among genes downregulated by TM (25 µM, 12 hr) or SIRT2 KD (72 hr) in MCF-7 cells. 
The normalized enrichment score (NES), and test of statistical significance (FDR q value) are shown. (B, 
C) Enrichment of a representative set of c-Myc target genes in TM-treated (B) and SIRT2 KD (C) MCF-
7 cells.  
 MCF-7 cells were then further analyzed for Myc-specific biological effects. Flow 
cytometry of TM-treated cells revealed a pronounced increase in cells arrested in G0/G1 phase, 
with a concomitant decrease of cells in S phase (Fig. 2.16A). Treatment of TM resulted in 
significant cellular senescence by β-galactosidase staining (Fig. 2.16B). Similar effects of TM 
on cell cycle progression and cellular senescence were also observed in K562 cells (Fig. 2.16C 
& D), suggesting that the effect of TM-induced c-Myc decrease is not restricted to breast cancer 
cells. Overall, the phenotypes of G0/G1 cell cycle arrest and cellular senescence are consistent 
with the anticipated effects of inhibiting cellular c-Myc function 50.  
To further establish that decreasing c-Myc is important for the anticancer effect of TM, we 
examined whether forced overexpression of c-Myc in MCF-7 cells is able to reduce TM-
mediated cytotoxicity. Cells were transfected with c-Myc for 12 hr before being treated with 
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TM. Overexpression of c-Myc significantly reduced the cytotoxicity effect of TM (Fig. 2.16E, 
F & G). Together, these results demonstrate TM decreases c-Myc, which is important for the 
cytotoxicity of TM in tumor cell, although it is likely not the only mechanism that underlies the 
cytotoxicity.  
 
Figure 2.16 Decreasing c-Myc protein abundance contributes to the anticancer effect of TM. (A, C) 
Cell cycle distribution (assessed by propidium iodide staining-coupled flow cytometry) of MCF-7 (B) 
and K562 (C) cells treated with TM (25 µM) for 0, 24, 48 or 72 hr. (B, D) Acidic β-gal (β-gal) staining 
in MCF-7 (B) and K562 (D) cells treated with TM (25 µM) for 5 days. Representative images were shown 
in the upper panel, quantification was shown as percentage of β-gal+ cells in the lower panel. (E, F, G) 
Effect of c-Myc overexpression (E) on the cytotoxicity effect of TM. MCF-7 cells were transfected with 
pCDH vector or pCDH-c-Myc for 12 hr before being treated with TM at indicated concentrations for 72 
hr (F) or with TM (25 µM) for another 0, 24, 48 or 72 hr (G). Cell viability was assessed by CellTiter-
Blue® assay. Statistics, two-tailed Student’s t-test. Error bars represent mean ± sd. **p < 0.01, ***p < 
0.001. 
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The c-Myc mRNA level was not affected by TM treatment, suggesting that TM does not 
affect c-Myc transcription (Fig. 2.17A & 2.17E). Therefore, the effect of TM on c-Myc protein 
turnover was tested. The half-life of c-Myc was shortened by TM treatment, suggesting that TM 
promoted c-Myc degradation (Fig. 2.17B). Treatment with a proteasome inhibitor, MG132, 
prevented the TM-induced down-regulation of c-Myc, suggesting that TM promoted the 
proteasomal degradation of c-Myc (Fig. 2.17C). Increased proteasomal degradation was 
associated with increased c-Myc ubiquitination (Fig. 2.17D).  
 
Figure 2.17 TM promotes ubiquitin-proteosomal degradation of c-Myc. (A) The mRNA levels of c-
Myc in MCF-7 cells treated with TM (25 µM) or M (25 µM) analyzed by RT-PCR. (B) Effect of TM on 
c-Myc degradation in MCF-7 cells. Cells were incubated ethanol or TM (25 µM in ethanol) for 4 hr and 
then with CHX (10 µg/mL) for 0, 0.5, 1, or 2 hr. Loading was normalized based on the level of the internal 
control, actin. The relative c-Myc protein levels at different time point of CHX treatment were calculated 
by normalizing to the corresponding level without CHX treatment. The relative c-Myc levels were plotted 
against the time of treatment with CHX. (C) Effect of MG132 on TM-mediated decrease in c-Myc protein 
level in MCF-7 cells. Cells were treated with ethanol or TM (25 µM in ethanol) for 4 hr and then MG132 
(10 µM) for 2 hr. (D) Effect of TM (25 µM) on the polyubiquitination of c-Myc in MCF-7. Error bars 
represent mean ± sd. 
It was previously reported that SIRT2 can suppress the expression of NEDD4, an E3 
ubiquitin ligase for c-Myc 18, which could explain why SIRT2 inhibition promotes c-Myc 
degradation. Indeed, NEDD4 was up-regulated by TM at the transcriptional level (Fig. 2.18A 
& E) and also modestly at the protein level (Fig. 2.18B & C) in both MCF-7 and K562 cells. 
However, this is not a universal mechanism as alteration of NEDD4 level was not detected in 
TM-treated MDA-MB-468 cells despite the observed reduction in c-Myc protein abundance 
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(Fig. 2.18D & E). As TM regulates the protein stability of c-Myc in all three cell lines, we 
checked the effect of TM on the transcription levels of several additional known E3 ligases that 
destabilize c-Myc 18,51-54. As shown in Fig. 2.18E, NEDD4 and TRPC4AP were increased in 
MCF-7 and K562 cells, but not in MDA-MB-468 cells; FBXW7 and STUB1 were up-regulated 
in only in MDA-MB-468 cells; FBXO32 was increased in all the three cell lines. However, none 
of the E3 ligase genes was obviously up-regulated by TM in BT-549 cells in which neither cell 
viability nor c-Myc level was affected by TM. These results suggested that SIRT2 inhibition led 
to up-regulation of several c-Myc E3 enzymes, which may result in the destabilization of c-Myc 
by TM.  
 
Figure 2.18 TM upregulates transcriptional levels of c-Myc E3 ubiquitin ligases. (A) The mRNA 
level of NEDD4 in MCF-7 cells treated with TM (25 µM) for 12 hr. (B) Western blot analysis of NEDD4 
protein level in MCF-7 cells treated with TM (25 µM). (C, D) Effects of TM on c-Myc and NEDD4 
protein levels in K562 (C) and MDA-MB-468 (D) cells. Cells were treated as indicated. (E) Effect of TM 
on the transcript levels of various E3 ligases of c-Myc. MCF-7, K562, MDA-MB-468 or BT-549 cells 
were treated with TM (25 µM) for the indicated time. PCR was performed for the assessment of transcript 
levels of E3 ligases (NEDD4, FBXW7, STUB1, TRPC4AP, FBXO32, SKP2), c-Myc and Actin. 
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3. Discussion  
Previous reports have suggested that SIRT1 or SIRT2 inhibitors can have anticancer activity. 
However, the potency of most of these inhibitors is modest, with IC50 values in the micromolar 
range at inhibiting purified sirtuins. Most of the sirtuin inhibitors tested for anticancer activity 
are also not very selective and can inhibit several sirtuins. The modest potency and selectivity 
make it hard to rule out off-target effects and pinpoint which sirtuin should be targeted for 
treating cancers. Our SIRT2 inhibitor TM described here has an excellent combination of 
potency and selectivity that allowed us to conclude that inhibiting SIRT2 produces anticancer 
effects in a variety of human cancer cell lines. Knocking down of all seven sirtuins also 
confirmed that SIRT2 is important for the viability of various cancer cell lines while knocking 
down other sirtuins either had no significant effect or much less effect on cancer cell viability.  
C-Myc is an important oncoprotein and is up-regulated in many human tumors. Thus, it has 
been considered as a promising cancer target. So far, no small molecules can directly target c-
Myc in vivo. Recent studies showed that bromodomain inhibitors targeting BRD4 can suppress 
c-Myc transcription and inhibit tumorigenesis 3. Our studies demonstrate that inhibiting SIRT2 
offers a different way to target c-Myc. We show here that our SIRT2 inhibitor TM can 
effectively decrease the level of c-Myc in various cancer cell lines. Our data suggest that the 
ability of TM to decrease c-Myc abundance in different cell lines correlates with the sensitivity 
of the cell lines to TM. We further demonstrate here that decreasing c-Myc protein level is an 
important mechanism that accounts for hypersensitivity of certain cancer cell lines to TM. 
However, it should be pointed out that effects on other SIRT2-regulated pathways may also 
contribute to the activity of TM in cancer cells. This is especially true given that even cells 
without TM-induced c-Myc decrease (e.g. MDA-MB-231 and BT-549 cells) can still be 
inhibited by TM at higher concentrations. This also likely explains why c-Myc overexpression 
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confers some but not complete resistance to TM (Fig. 2.16 F & G). We found that TM promotes 
the proteolytic degradation of c-Myc without affecting its transcription, which serves as an 
important but perhaps not the only mechanism by which TM destabilizes c-Myc. Aberrant 
translational control of the Myc oncoprotein has been implicated in many cancers 55,56 and might 
also be involved in TM-induced reduction in c-Myc level. Our work establishes SIRT2 
inhibition as a strategy to target the oncoprotein c-Myc, which is effective in many human 
cancer cell lines. Future detailed mechanistic investigations of the SIRT2/c-Myc regulatory 
pathway could potentially lead to the identification of additional therapeutic targets. 
The roles of sirtuins in cancer have been a topic of debate. Both tumor-promoting and 
tumor-suppressing roles of SIRT1 have been reported. For SIRT2, Kim et al. reported that 
SIRT2 is a tumor suppressor because Sirt2 KO mice develop tumors earlier than WT mice 17. 
Serrano and co-workers did not find a cancer-prone phenotype in unchallenged Sirt2 KO mice 
that they generated, although they did observe that Sirt2 KO mice had increased tumorigenesis 
when challenged with carcinogens (Serrano et al., 2013).57. Contradictory to these genetic 
studies that pointed to a weak tumor suppressor role of SIRT2, we found that inhibiting SIRT2 
with TM has broad anticancer activity in many cancer cell lines.  
Different outcomes for mouse genetic studies and pharmacological studies in cancer cells 
are not without precedent. Similar cases have been well documented in the literature 58. There 
are several possible explanations. First, there are several examples of factors that have tumor 
suppressor activity in normal cells but nevertheless are required for the growth and survival of 
transformed cells. For example, loss of function for the DNA damage checkpoint kinase ATR 
causes modest tumor predisposition, but greatly impairs the growth of established tumors 59. 
SIRT2 has been identified as a regulator of mitotic chromosome segregation 17, a function that 
could account for the weak tumor predisposition phenotype in Sirt2-deficient mice given the 
oncogenic consequences of genomic instability. Nevertheless, a greater dependency of 
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transformed cells on SIRT2 due to increased mitotic and other stresses, or because of the 
regulation of other targets such as c-Myc by SIRT2, result in heightened sensitivity to SIRT2 
inhibition in cancer cells. It also should be noted that small molecules may have off target effects, 
which could contribute to observed pharmacological effects. While it is difficult to completely 
rule out this possibility for the anticancer effect of TM, our studies using the inactive control 
compound (M) and the SIRT2 KD studies suggest that the anticancer effect is largely through 
SIRT2 inhibition.  
An alternative explanation relates to the fact that in a genetic knockout, the protein is gone 
and thus all the enzymatic activities and protein-protein interactions involving the enzyme also 
are gone. In contrast, when using a small molecule to inhibit the enzyme, the protein is intact 
and so are the protein-protein interactions that involve the protein. In the case of SIRT2, another 
layer of complexity is that SIRT2 has multiple enzymatic functions. We and others recently 
found that sirtuins are not only deacetylases. Some sirtuins, such as SIRT5 7 and SIRT6 11, prefer 
to hydrolyze other acyl lysine modifications. Perhaps more surprising is the fact that even the 
well-studied deacetylases (SIRT1, SIRT2, and SIRT3) can remove long chain fatty acyl groups 
efficiently 25,60.  Although the exact substrate proteins for the defatty-acylase activity of SIRT2 
remain to be identified, our preliminary studies showed that the fatty acylation levels of many 
proteins were elevated when SIRT2 was knocked down (Fig. 2.7A), but not when SIRT2 
inhibitor TM was used (Fig. 2.7 B). Thus, the small molecule inhibitor may selectively target 
one of the enzymatic functions of SIRT2, thus contributing to the fact that small molecule 
inhibitors may produce beneficial pharmacological effects that are different from genetic 
knockout.  
4. Methods 
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Reagents, antibodies and plasmids. All chemicals were obtained in the highest purity 
available. MG132 was from Cayman Chemical Co. (Ann Arbor, MI). Cycloheximide was 
purchased from Amresco (Euclid, OH). Trichostatin A (TSA) and AGK2 (2-Cyano-3-[5-(2,5-
dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide) were obtained from Sigma-Aldrich 
(St. Louis, MO).  
The anti-human SIRT1 antibody (3H10.2) was from EMD Chemicals Inc. (San Diego, CA). 
The anti-human SIRT2 (EPR1667), SIRT6 antibodies were from Abcam (Cambridge, MA). The 
anti-human SIRT3 (C73E3), acetyl-p53 (Lys382) antibodies were obtained from Cell Signaling 
Technology (Danvers, MA). The anti-SIRT7 (C-3), c-Myc (9E10), NEDD4 (H-135), ubiquitin 
(P4D1), β-actin (C4) and the goat anti-mouse/rabbit IgG-horseradish peroxidase-conjugated 
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-SIRT4 
(LS-C100490) antibody was purchased from LSBio, Inc. (Seattle, WA). The anti-SIRT5 
antibody (Center) was from Abgent (San Diego, CA). The anti-acetyl-α-tubulin (6-11B-1), α-
tubulin (B-5-1-2) antibodies, the anti-Flag M2 antibody conjugated with horseradish peroxidase 
and the anti-Flag M2 affinity gel were from Sigma-Aldrich.  
The pLKO.1-puro lentiviral shRNAs constructs toward Luciferase and SIRT1-7 were 
purchased from Sigma-Aldrich. Luciferase shRNA (SHC007), SIRT1 shRNA1 
(TRCN0000018980), SIRT1 shRNA2 (TRCN0000018981), SIRT2 shRNA1 
(TRCN0000040221), SIRT2 shRNA2 (TRCN0000310335), SIRT3 shRNA1 
(TRCN0000038890), SIRT3 shRNA2 (TRCN0000038893), SIRT4 shRNA1 
(TRCN0000018948), SIRT4 shRNA2 (TRCN0000232894), SIRT5 shRNA1 
(TRCN0000018544), SIRT5 shRNA2 (TRCN0000018545), SIRT6 shRNA 1 
(TRCN0000378253) and shRNA 2 (TRCN0000232528), SIRT7 shRNA1 (TRCN0000359663), 
and SIRT7 shRNA2 (TRCN0000020254) were used. The scrambled siRNA and Stealth Select 
RNAi™ siRNA targeting SIRT2 (HSS117928 and HSS177042) were purchased from 
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Invitrogen (Carlsbad, CA). To generate human SIRT2 with C-terminal Flag-tag expression 
vector, full-length human SIRT2 cDNA was amplified by PCR and inserted into pCMV-tag-4a 
vector between BamHI and XhoI sites. A human c-Myc expression vector with N-terminal Flag-
tag was obtained by PCR amplification of Flag-c-Myc and subcloning via BamHI and XhoI 
sites into pCMV-tag-4a vector.  
Cloning, expression and purification of human sirtuins. Human SIRT1, SIRT3, SIRT5 
and SIRT6 were expressed as previously described 11,61. Human SIRT2 (aa38-356) was cloned 
and inserted into pET28a vector for the expression of N-terminal His6-SUMO fusion protein. 
Then SIRT2 expression vector was introduced into an E. coli BL21. Successful transformation 
were selected by plating the cells on kanamycin (50 µg mL−1) and chloramphenicol (20 µg mL−1) 
luria broth (LB) plates. Single colonies were selected and grown in LB with kanamycin (50 µg 
mL−1) and chloramphenicol (20 µg mL−1) overnight at 37 °C. On the following day the cells 
were subcultured (1:1000 dilution) into 2 L of LB with kanamycin (50 µg mL−1) and 
chloramphenicol (20 µg mL−1). The cells were induced with 20 µM of isopropyl β-D-1-
thiogalactopyranoside (IPTG) at an OD600 of 0.6 and grown overnight at 15 °C, 200 rpm. The 
cells were harvested by centrifugation at 8000 rpm for 5 min at 4 °C (Beckman Coulter 
refrigerated floor centrifuge) and passed through an EmulsiFlex-C3 cell disruptor (AVESTIN, 
Inc.) 3 times. Cellular debris was removed by centrifuging at 20,000 rpm for 30 min at 4 °C 
(Beckman Coulter). The supernatant was loaded onto a nickel column (Histrap, Ge Healthcare) 
pre-equilibrated with 20 mM Tris-HCl pH 8.0 with 500 mM NaCl. The protein was eluted with 
a linear gradient of imidazole (0-500 mM). The desired fractions were pooled, concentrated and 
buffer exchanged. The His6-SUMO tag was removed by overnight incubation at 4 °C with 
ULP1, followed by Ni-affinity column purification to remove any undigested SIRT2. The tag-
free SIRT2 was further purified on a Superdex 75 column (Bio-Rad, Hercules, CA). The protein 
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was eluted with 20 mM Tris-HCl, pH 8.0, 500 mM NaCl. After concentration, the target protein 
was frozen at -80 °C.  
Inhibition assay for SIRT1, SIRT2, SIRT3, SIRT5. Different concentrations (0.0064, 
0.032, 0.16, 0.8, 4.0, 20, 100 and 200 µM) of TA~TM, and M were pre-incubated with 0.1 µM 
of SIRT1, 0.2 µM of SIRT2, 1 µM of SIRT3 or 1 µM of SIRT5, respectively, and 1 mM NAD 
in 20 mM Tris-HCl buffer (pH 8.0) with 1 mM dithiothreitol (DTT) at 37 °C for 15 min. Then 
10 µM of acyl peptide (acetyl-H3K9 for SIRT1, SIRT2 and SIRT3; succinyl-H3K9 for SIRT5) 
was added to initiate the reactions. Then reactions were incubated at 37°C in a total volume of 
60 µL (5 min for SIRT1, 5 min for SIRT2, 20 min for SIRT3, and 10 min for SIRT5). The 
reactions were stopped by adding 60 µL of an aqueous solution of 50% methanol containing 
200 mM HCl and 320 mM acetic acid.  
After quenching the sirtuin reactions, centrifugation was used to remove precipitated 
proteins and the supernatant was analyzed by HPLC with a reverse phase C18 column (Kinetex 
XB-C18 100A, 100 mm × 4.60 mm, 2.6 µm, Phenomenex) with a gradient of 0 % in 2 min, 0% 
to 20% in 2min, 20% to 40% B in 13 min and then 40% to 100% for 2 min at 0.5 mL/min. 
Product quantification was based on the area of absorbance monitored at 280 nm. The peak 
areas were integrated and the conversion rate was calculated from the peak areas as the fraction 
of the free H3K9 peptide from the total peptide. All reactions were done in duplicate.  
Determination of kinetic parameters for TM. For SIRT2 inhibition kinetics of TM, a 
mixture of acetyl-H3K9 (acH3K9) peptide substrate (2.5, 5, 10, 25, 50, 100, 187.5 µM), NAD 
(25, 50, 100, 250, 500, 1000, 1500 µM), TM (0, 0.01, 0.03, 0.1, and 0.3 µM), 20 mM Tris-HCl 
(pH 8.0) and 1 mM DTT was incubated at 37 °C. 1 mM NAD was used for determining the 
kinetic parameters for acH3K9 peptide, 100 µM of acH3K9 peptide was used for the 
determination of kinetic parameters for NAD. The reaction was started by adding 0.2 µM of 
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SIRT2, and stopped after 5 min by adding 60 µL of an aqueous solution of 50% methanol 
containing 200 mM HCl and 320 mM acetic acid. The samples were analyzed by HPLC as 
described above and the initial velocity was calculated. The Km and vmax were obtained from 
Michaelie-Menten plots using Graphpad Prism software.  
Mass spectrometry detection of the stalled intermediate formed by TM and NAD. 
Reactions containing 50 µM SIRT2, 100 µM NAD, 100 µM TM, 1 mM DTT, and 20 mM 
pyridinium formate (pH 7.0) was reacted for 5 min at 37 °C. Controls were run in which NAD 
or SIRT2 was removed from the reaction mixture. Reactions were quenched with 1 volume of 
acetonitrile and the mixture was centrifuged to remove the precipitated protein. The supernatant 
was then analyzed by LC-MS using water and acetonitrile as solvents.   
Inhibition assay for SIRT6. Different concentrations (0.0125, 0.05, 0.2, 0.8, 3.2, 12.8, 51.2, 
204.8 µM) of TA~TM were pre-incubated with 1 µM of SIRT6 and 1 mM NAD in 20 mM Tris-
HCl buffer (pH 8.0) with 1 mM DTT at 37°C for 20 min. Then 50 µM of myristoyl-H3K9 
peptide (myrH3K9) was added to initiate the reactions. The reactions were incubated at 37 °C 
in a total volume of 60 µL for 1 hr. The reactions were stopped by adding 60 µL of an aqueous 
solution of 50% methanol containing 200 mM HCl and 320 mM acetic acid. 
Inhibition assay for SIRT7. Different concentrations (0.0125, 0.05, 0.2, 0.8, 3.2, 12.8, 51.2, 
204.8 µM) of TA~TM were pre-incubated with 1 µM of SIRT7 and 1 mM NAD in 150mM 
NaCl and 50 mM KH2PO4 buffer (pH 8.0) with 1 mM DTT at 37°C for 20 min. Then 10 
µM myrH3K9 peptide and 0.083mg/mL tRNA were added to initiate the reactions. Then 
reactions were incubated at 37 °C in a total volume of 60 µL for 110 min. The reactions were 
stopped by adding 60 µL of an aqueous solution of 50% methanol containing 200 mM HCl and 
320 mM acetic acid. 
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Cell viability assay. Cells were seeded into 96-well plates at 3000-4000 cells per well. 
After 24 hr, test compounds were added to cells to final concentrations ranging from 1–50 µM. 
Cells were then incubated for 72 hr and cell viability was measured using the CellTiter-Blue 
viability assay (Promega) following the manufacturer’s instruction. Relative cell viability in the 
presence of test compounds was normalized to the vehicle-treated controls after background 
subtraction. Graphpad Prism software was used to determine the IC50 values. 
Knockdown of SIRT1-7 in various cell lines was achieved by lentiviral infection. Lentiviral 
supernatants were generated as described previously (Jiang et al., 2013). Cell viability was 
assessed after 3, 5 or 10 days of infection by using CellTiter-Blue.  
Cell culture and transfection. All cell culture media contained 10% (vol/vol) heat-
inactivated fetal bovine serum (FBS; Invitrogen, Carlsbad, CA) and 1% penicillin-streptomycin 
(Invitrogen) unless otherwise specified. Human MCF-7, MDA-MB-231, MDA-MB-468, HeLa, 
HME1 cells were grown in DMEM media (Invitrogen). Human BT-549, SK-BR-3, MDA-MB-
453 and K562 cells were grown in RPMI-1640 media (Invitrogen). The MCF-10A cells were 
cultured in mammary epithelial cell growth medium (MEGM; Lonza, Walkersville, MD) with 
supplements according to manufacturer’s instruction.  
To overexpress SIRT2 or c-Myc in cells, the pCMV-tag-4a vector containing SIRT2 or c-
Myc, or pCDH vector containing c-Myc were transfected into cells using FuGene 6 (Promega, 
Madison, WI) according to manufacturer’s protocol. Empty vector was transfected as negative 
control.  
Soft agar colony formation assay. For colony formation in semisolid medium, 1.0 × 104 
cells were plated in 0.3% low-melting point agarose (LMP, Invitrogen) onto 6-well plate coated 
with 1.2% LMP mixed with 2 × complete medium. For treatments, 2 × inhibitor was added to 
cells at the time of plating. The medium and inhibitor were replaced with fresh ones every 3 
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days. For colony formation of the SIRT2 KD cells, cells were transfected with the scrambled 
siRNA or SIRT2 siRNAs for 48 hr before plating in 6-well plate. Similarly, cell media was 
replaced every 3 days. After 14 days of incubation, colonies were photographed and counted 
with ImageJ.  
Western blot analysis. Western blot analysis was performed as described previously (Jiang 
et al., 2013). The proteins of interest were detected using enzyme-linked chemiluminescence 
(ECL; Pierce Biotechnology Inc.) and visualized using the Storm Imager (GE Healthcare, 
Piscataway, NJ). Quantification of Western blots was done using the Quantity One software 
(Bio-Rad).  
Biotin-TM/M pull-down assay. HEK293T cells were collected and lysed in lysis buffer 
containing 25 mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol, 1% Nonidet P-40 and 1 × protease 
inhibitor cocktail (Sigma-Aldrich). The cell extract supernatant was collected after 
centrifugation at 14,000 g for 20 min at 4 °C. Cell lysates were incubated with 10 µM Biotin-
TM or Biotin-M in the absence or presence of 1 mM NAD at 4 °C for 1 hr. The high capacity 
streptavidin resin (Pierce Biotechnology, Rockford, IL) was added to the mixture and incubated 
at 4 °C for another 1 hr. After centrifugation at 500 g for 2 min at 4 °C, the streptavidin resin 
was washed 3 times with 1 mL washing buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 10% 
glycerol, 0.2% Nonidet P-40). The resin-bound proteins were then separated with SDS-PAGE 
and immunoblotted with anti-SIRT1 or anti-SIRT2 antibodies.  
To assess the binding of TM to SIRT2 in cells, MCF-7 parental cells, Luciferase KD and 
SIRT2 KD cells were treated with 50 µM D-Biotin or Biotin-TM as indicated for 6 hr and then 
lysed in lysis buffer containing 1 mM NAD. Cell extract was collected, streptavidin pull-down 
and western blot analysis was performed as described above.  
  66 
SIRT1 inhibition in cells. MCF-7 or MDA-MB-468 cells were treated with indicated test 
compounds in the presence of 200 nM TSA for 6 hr. The acetylation level of p53 protein was 
determined by western blot using anti-acetyl-p53 (K382) antibody. β-actin served as a loading 
control. 
SIRT2 inhibition in cells. MCF-7 cells were treated with indicated inhibitors at for 6 hr 
after being transfected with pCMV-tag-4a-SIRT2 for 18 hr. Cells were collected and lysed in 
lysis buffer containing 25 mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol, 4 mM MgCl2, 0.2 
mM DTT, 100 mM NAD, 1% Nonidet P-40 and 1 × protease inhibitor cocktail. And the cell 
lysates were subjected to western blot for the analysis of acetyl-α-tubulin (K40) and α-tubulin 
levels.  
TM treatment of mice bearing human breast cancer xenotransplants. Two million 
MDA-MB-231 cells suspended in 100 µL 1 × PBS and 100 µL Matrigel were injected 
subcutaneously on the flanks of female Ncr Nu/Nu mice. Following the injections, mice were 
permitted to recover and monitored biweekly, including tumor measurement using calipers. 
Once the majority of tumors reached a threshold size of 200 mm3, mice with intraperitoneal (IP) 
or intra-tumor (IT) injections of vehicle alone (DMSO) or inhibitor (TM in DMSO) over one 
month. IP injections of 1.5 mg TM in 50 µL DMSO were given daily. IT injections of 0.75 mg 
TM in 50 µL DMSO per tumor were given 3 days per week. After one month of treatment or if 
mice met humane endpoint criteria, mice were euthanized by CO2 asphyxiation. Tissues were 
collected, fixed with 10% neutral-buffered formalin, embedded in paraffin, sectioned, and 
stained with hematoxylin and eosin (H&E). H&E-stained sections were scanned using an 
Aperio ScanScope and analyzed by a veterinarian certified in anatomic pathology by the 
American College of Veterinary Pathologists blinded to treatment group. Serum, tumor tissues 
and organs were snap frozen in liquid N2 and stored at -80 °C for subsequent analyses.  
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TM treatment of MMTV-PyMT mice. MMTV-PyMT transgenic female mice on a pure 
FVB/N background were obtained from the Jackson Laboratory and treated beginning at 6 
weeks of age with daily IP injections of vehicle (DMSO) or 1.5 mg TM in 50 µL DMSO over 
one month. Mice were monitored daily for tumor development and health status, and tumor size 
was measured twice per week. After one month of treatment or if mice met humane endpoint 
criteria, mice were euthanized by CO2 asphyxiation and necropsied. Tissues were collected and 
analyzed as described above. 
Ubiquitination assay. MCF-7 cells were transfected with pCMV-tag-4a or pCMV-tag-4a-
c-Myc, respectively. 18 hours after transfection, cells were treated with 25 µM TM for 6 hr in 
the presence of proteasome inhibitor MG132 (10 µM). Immunoprecipitation was performed 
with the cell lysates by anti-Flag M2 affinity gel as described previously 25. The gel-bound 
proteins were resolved on SDS-PAGE and detected with anti-ubiquitin antibody. The c-Myc 
level in total cell lysates was used as input control. 
Reverse transcription (RT)-PCR analysis of mRNA levels. Total RNA was extracted 
from vehicle-, TM- or M-treated cells using RNeasy Mini Kit (Qiagen, CA, USA) according to 
the manufacturer's instructions. The concentration and purity of total RNA were determined by 
using the NanoDrop (Thermo Fisher Scientific Inc, Wilmington, DE). cDNA was synthesized 
using SuperScript III reverse transcriptase (Invitrogen). Amplification of genes of interest was 
performed using Herculase II Fusion DNA Polymerase (Agilent Technologies, Santa Clara, CA) 
with the gene-specific primers shown below. 10 µl of each PCR product were analyzed by gel 
electrophoresis on a 2% agarose gel.  
Primer target Direction Sequence 
c-Myc Forward GGCTCCTGGCAAAAGGTCAGAGT 
c-Myc Reverse CTGCGTAGTTGTGCTGATGTGT 
NEDD4 Forward TCAGGACAACCTAACAGATGCT 
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NEDD4 Reverse TTCTGCAAGATGAGTTGGAACAT 
Actin Forward CATGTACGTTGCTATCCAGGC 
Actin Reverse CTCCTTAATGTCACGCACGAT 
STUB1 Forward AGCAGGGCAATCGTCTGTTC 
STUB1 Reverse CAAGGCCCGGTTGGTGTAATA 
SKP2 Forward ATGCCCCAATCTTGTCCATCT 
SKP2 Reverse CACCGACTGAGTGATAGGTGT 
TRPC4AP Forward ACAAGCACACGCTTCTTGC 
TRPC4AP Reverse CTGACACCTTTCGAGTCGCC 
FBXW7 Forward CGACGCCGAATTACATCTGTC 
FBXW7 Reverse CGTTGAAACTGGGGTTCTATCA 
FBXO32 Forward GCCTTTGTGCCTACAACTG 
FBXO32 Reverse CTGCCCTTTGTCTGACAGAAT 
Immunofluorescence of cultured cells. MDA-MB-231 cells were treated with ethanol, 
M (25 µM) or TM (25 µM) for 6 hr. Immunostaining was performed and images were 
acquired by confocal microscopy as previously described 62. 
Flow cytometry. For cell cycle analyses, MCF-7 or K562 cells were treated with 25 µM 
for 0, 24, 48 and 72 hr. Cells were spun down, washed with PBS, fixed with 70% ethanol 
overnight, and then washed with PBS. RNA was degraded with RNAse A and DNA was stained 
with propidium iodide (Invitrogen). Samples were analyzed on a BD LSR-II. Cell cycle analysis 
was performed with FlowJo flow cytometry analysis software (Tree Star, Inc., Ashland, OR).  
Cellular senescence staining. MCF-7 or K562 cells were treated with ethanol or 25 µM 
TM. After 5 days of treatment, cells were stained for senescence as previously described 63.  
Immunofluorescence and Immunohistochemistry of tumor sections. Formalin-fixed, 
paraffin-embedded (FFPE) tumors were sectioned, dewaxed and submitted to heat mediated 
antigen retrieval in 0.01 M citrate buffer for 50 min. For immunofluorescence, sections were 
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incubated with anti-acetyl-α-tubulin, followed by Alexa Fluro-488 conjugated secondary 
antibodies from Invitrogen and cell nuclei counterstaining with DAPI Fluoromount-G® from 
SouthernBiotech. Fluorescent images were taken using Zeiss LSM880 inverted confocal 
microscopy (Carl Zeiss Inc., Thornwood, NY). For immunohistochemistry, sections were 
incubated with anti-Ki67 Clone MM1 (Vector Laboratories) antibody followed by biotinylated 
polyclonal rabbit anti-mouse (DAKO). Color was developed using 3,3'-Diaminobenzidine 
tetrahydrochloride substrate from Invitrogen and counterstained with hematoxilin. Images were 
scanned using an Aperio ScanScope.  
Whole-Transcriptome Sequencing (RNA-seq) and Gene Set Enrichment Analysis 
(GSEA). MCF-7 cells were treated with ethanol or TM (25 µM) for 12 hr, or infected by shCtrl- 
or shSIRT2-carring lentivirus for 72 hr. Total RNA was isolated using the RNeasy Kit (Qiagen) 
and digested with DNase (Qiagen). mRNA was then purified with oligo-dT DynaBeads, the 
cDNA and sequencing library was constructed as described previously 64. Sequencing, reads 
mapping and transcription quantification were then performed as described previously 65. The 
read numbers of the transcripts in each sample were used for GSEA (Broad Institute). And the 
analysis parameters were selected following the instruction at the GSEA website 
(http://software.broadinstitute.org/gsea/index.jsp). 
Statistical analysis. Quantitative data were expressed as mean ± sd (standard deviation, 
shown as error bar) from at least three independent experiments. Differences between two 
groups were examined statistically as indicated (*p < 0.05, **p < 0.01, and ***p < 0.001). 
Synthesis of compounds used in the study 
General methods. Reagents were obtained from Aldrich or Acros in the highest purity 
available and used as supplied. 1HNMR was performed on INOVA 400/500 spectrometer. 
LCMS was carried out on a SHIMADZU LC and Thermo LCQ FLEET MS with a Sprite 
TARGA C18 column (40 × 2.1 mm, 5 µm, Higgins Analytical, Inc.) monitoring at 215 and 260 
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nm. Solvents used in LCMS were water with 0.1% acetic acid and acetonitrile with 0.1% acetic 
acid.  
1. Synthetic Route for TA 
 
Synthesis of compound 2. To a solution of Z-Lys-OH (2.8 g, 10 mmol) in ethanol (100 
mL) was added 20 mL of 10% (w/v) Na2CO3 aqueous solution at 0°C. The reaction mixture was 
allowed to warm to room temperature (rt) while stirred extensively. Ethyl dithioacetate (1.32 g, 
11 mmol) was added and the reaction mixture was stirred overnight at rt. Solvent was evaporated 
and then the crude product was acidified to pH＝2 with 3 M HCl on ice and extracted with 
DCM (3 x 100 mL). The organic phase was washed with brine (2 x 30 mL), dried with Na2SO4, 
and evaporated to obtain compound 2, which was directly used in the next step without further 
purification. 
Synthesis of compound TA. To a solution of compound 2 (3.38 g, 10 mmol) and N-
methylmorpholine (1.1 ml, 10 mmol) in dry dichloromethane (100 mL) at 0°C was added 
dropwisely iso-butylchloroformate (1.3 ml, 10 mmol). The reaction mixture was stirred for 30 
min at 0°C. Aniline (1.09 ml, 12 mmol) was added at 0°C and the reaction mixture was stirred 
overnight at room temperature. The solvent was removed under reduced pressure and the 
resulting residue was purified by flash chromatography on silica gel (Hexane/ethyl acetate = 
2/1) to afford the expected compound 3 (3.95 g, 95.5% yield). 1H NMR (400 MHz, CD3OD): δ 
7.53-7.51 (m, 2H), 7.34-7.22 (m, 7H), 7.08-7.04(t, J =7.2Hz, 1H), 5.06 (q, J=8.0Hz, 2H), 4.26-
4.22 (m, 1H), 3.54 (t, J=7.1Hz, 2H), 2.39 (s, 3H), 1.89-1.76(m, 1H), 1.78-1.70 (m, 1H), 1.66-
1.58 (m, 2H), 1.55-1.35 (m, 2H). 13C NMR (126 MHz, CDCl3): δ 200.88, 170.34, 156.79, 
CbzHN
O
NH2
OH
CbzHN
O
NH
S
OH
2
S
S
NaHCO3, EtOH/H2O
CbzHN
O
NH
S
NHPh
TA1
1) ClCOOiBu
    NMM/DCM
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137.34, 135.87, 129.01, 128.62, 128.35, 127.93, 124.78, 120.23, 120.13, 67.34, 55.19, 45.74, 
33.97, 32.04, 27.00, 22.70.LCMS (ESI) calcd. for C22H28N3O3S [M+H]+ 414.2, obsd. 414.3.  
2. Synthetic Route for TB, TH, and TM 
 
Synthesis of compound 4. To the solution of acid (30 mmol) in anhydrous N, N’-
dimethylformamide (DMF, 20 mL) was added N-hydroxysuccinimide (NHS, 3.45 g, 30 mmol) 
with stirring at rt. Then N, N’-dicyclohexylcarbodiimide (DCC, 6.19 g, 30 mmol) in anhydrous 
DMF (20 mL) was added to the reaction. After stirring for 2 hr, the reaction mixture was filtered. 
The filtrate was added to a solution of Z-Lys-OH (8.4 g, 30 mmol) with N, N-
diisopropylethylamine (DIEA, 5.2 mL, 30 mmol) in anhydrous DMF (50.0 mL) at room 
temperature. The resulting reaction mixture was stirred overnight. Then 44 mL water and 26 
mL 1 M HCl was added to the reaction mixture to adjust pH to 2~3. The mixture was extracted 
ethyl acetate (3 x 200 mL) and washed brine (2 x 100 mL). The organic layer was dried over 
anhydrous sodium sulfate. After removal of the solvents in vacuum, the residue was purified by 
flash chromatography on silica gel (DCM/MeOH = 20:1) to afford the expected compound 4 
(85% yield). 
Synthesis of compound 5. To a solution of compound 4 (20 mmol) in THF (100 mL) was 
added Lawesson's reagent (8.0 g, 20 mmol) at room temperature. The reaction mixture was 
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stirred overnight under nitrogen (monitored by LCMS). After removal of THF using a rotary 
evaporator, the residue was purified by silica gel column (DCM/MeOH = 20:1) to give the 
product as a white solid (76% yield). 
Synthesis of compound TB, TH and TM. To a solution of compound 5 (10 mmol) and N-
methylmorpholine (1.1 ml, 10 mmol) in dry dichloromethane (100 mL) at 0°C was added 
dropwisely iso-butylchloroformate (1.3ml, 10 mmol). The reaction mixture was stirred for 30 
min at 0°C. Aniline (1.09 ml, 12 mmol) was then added at 0°C and the reaction mixture was 
stirred overnight at room temperature. The solvent was removed under reduced pressure and the 
resulting residue was purified by flash chromatography on silica gel (Hexane/ethyl acetate= 2/1) 
to afford the expected compound TB, TH, and TM. 
TB (91% yield) 1H NMR (400 MHz, CD3OD): δ 7.57-7.45 (m, 2H), 7.39-7.12 (m, 7H), 
7.12-6.99 (m, 1H), 5.05 (q, J = 12.5 Hz, 2H), 4.27-4.23 (m, 1H), 3.55 (q, J = 12.5 Hz, 2H), 2.51 
(t, J = 7.2Hz, 2H), 1.91-1.78 (m, 1H), 1.78-1.57 (m, 5H), 1.55-1.33 (m, 2H), 0.86 (t, J = 7.2 Hz, 
3H).. 13C NMR (126 MHz, CDCl3): δ 205.60, 170.19, 156.74, 137.36, 135.88, 128.99, 128.60, 
128.33, 127.96, 124.72, 120.16, 120.06, 119.98, 67.34, 55.19, 48.93, 45.30, 31.89, 27.07, 22.78, 
22.63, 13.36. LCMS (ESI) calcd. for C24H32N3O3S [M+H]+ 442.2, obsd. 442.3; 
TH (89% yield) 1H NMR (500 MHz, CDCl3): δ 8.54 (s, 1H), 7.73 (s, 1H), 7.49 (d, J = 7.5 
Hz, 2H), 7.41-7.20 (m, 7H), 7.11 (t, J = 7.4 Hz, 1H), 5.79 (d, J = 7.5 Hz, 1H), 5.19 -5.03 (m, 
2H), 4.45-4.31 (m, 1H), 3.70-3.62 (m, 2H), 2.60(t, J = 7.5 Hz, 2H), 1.98-1.91 (m, 1H), 1.81-
1.60 (m, 5H), 1.54-1.41 (m, 2H), 1.36-1.18 (m, 6H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (126 
MHz, CDCl3): δ 205.84, 170.21, 156.75, 137.38, 135.88, 128.99, 128.60, 128.33, 127.95, 
124.71, 120.16, 67.34, 55.19, 47.16, 45.34, 31.91, 31.52, 29.47, 28.66, 27.07, 22.65, 22.53, 
14.06. LCMS (ESI) calcd. for C27H38N3O3S [M+H]+ 484.3, obsd. 484.3; 
TM (91% yield) 1H NMR (400 MHz, CD3OD): δ 7.53 (d, J = 8.0 Hz, 2H), 7.41-7.12 (m, 
7H), 7.08 (t, J = 7.4 Hz, 1H), 5.22-4.97 (m, 2H), 4.22 (dd, J = 8.8, 5.4 Hz, 1H), 3.57 (t, J = 7.1 
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Hz, 2H), 2.54 (t, J = 7.6 Hz, 2H), 1.90-1.79(m, 1H), 1.79-1.61 (m, 5H), 1.55-1.37 (m, 2H), 1.26 
(s, 20H), 0.87 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 205.84, 170.18, 156.75, 
137.37, 135.88, 128.99, 128.60, 128.33, 127.95, 124.71, 120.16, 67.35, 55.19, 47.21, 45.35, 
31.93, 29.70, 29.67, 29.65, 29.55, 29.40, 29.37, 29.06, 27.08, 22.70, 22.65, 14.15. 
 LCMS (ESI) calcd. for C34H52N3O3S [M+H]+ 582.4, obsd. 582.4; 
3. Synthesis of compound M 
 
The synthesis of compound 6 followed the method using in the synthesis of compound 4. 
To a solution of compound 6 (4.9 g, 10 mmol) and N-methylmorpholine (1.1ml, 10 mmol) in 
dry dichloromethane (100 mL) at 0°C was added dropwisely iso-butylchloroformate (1.3 ml, 10 
mmol). The reaction mixture was stirred 30 min at 0°C. Aniline (1.09 ml, 12 mmol) was added 
at 0°C and the reaction mixture was stirred overnight at rt. The solvent was removed under 
reduced pressure and the resulting residue was purified by silica gel chromatography 
(DCM/MeOH = 50:1) to afford the expected compound M (5.14 g, 91% yield). 1H NMR (400 
MHz, CD3OD): δ 7.53 (d, J = 7.9 Hz, 2H), 7.40-7.13 (m, 7H), 7.08 (t, J = 7.4 Hz, 1H), 5.13-
5.02 (m, 2H), 4.20 (dd, J = 8.5, 5.5 Hz, 1H), 3.15 (t, J = 6.7 Hz, 2H), 2.11 (t, J = 7.6 Hz, 2H), 
1.88-1.64 (m, 2H), 1.62-1.34 (m, 6H), 1.32-1.21 (s, 20H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR 
(126 MHz, DMSO-d6): δ 172.35, 171.54, 156.53, 139.43, 137.46, 129.11, 128.77, 128.22, 
128.14, 123.67, 119.66, 65.87, 55.85, 38.61, 35.92, 31.98, 31.76, 29.53, 29.50, 29.48, 29.41, 
29.35, 29.24, 29.18, 29.15, 25.77, 23.48, 22.56, 14.41.LCMS (ESI) calcd. for C34H52N3O4 
[M+H]+ 566.4, obsd. 566.5; 
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4. Synthetic Route for Biotin-TM and Biotin-M 
 
Synthesis of Compound 8. To a solution of compound 7 (14.8 g, 100 mmol) in DCM (200 
mL) was added 100 mL of di-tert-butyl dicarbonate (2.18 g, 10mmol) in DCM at 0°C. The 
reaction mixture was allowed to warm to rt and stirred extensively overnight. The organic phase 
was washed with water, until all the unreacted compound 7 was extracted. After drying over 
Na2SO4 and concentration under vacuum the Boc-protected compound 8 was quantitatively 
obtained. 
Synthesis of Compound 9. To a solution of Biotin (2.2 g, 9 mmol) and HBTU (3.41 g, 9 
mmol) in DMF (30 mL) was added DIEA (3.6 mL, 20 mmol) at room temperature with stirring 
for 30 min. Then compound 8 was added to the resulting mixture. The reaction mixture was 
stirred extensively overnight. After removal of the solvents under reduced pressure, the residue 
was purified by flash chromatography on silica gel (DCM/MeOH = 20:1 then 10:1) to afford 
the expected compound 9 (3.5 g, 81% yield). 
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Synthesis of Compound 10. To 20 mL of TFA was added the compound 9 (2 g, 4.2 mmol) 
and the resulting mixture was stirred for 30 min at room temperature. After removing the solvent 
under vacuum the deprotected compound 10 was quantitatively obtained and used in the next 
step without further purification.  
Synthesis of Compound Biotin-TM and Biotin-M. The synthesis followed the method 
using in the synthesis of TM. The solvent used to dissolve the compound 10 is DMF instead of 
DCM.  
Biotin-TM (81% yield) 1H NMR (500 MHz, CD3OD): δ 7.41-7.29 (m, 5H), 5.18-5.05 (m, 
2H), 4.49 (dd, J = 7.8, 4.8 Hz, 1H), 4.30 (dd, J = 7.9, 4.5 Hz, 1H), 4.10 (dd, J = 8.7, 5.4 Hz, 1H), 
3.66-3.52 (m, 10H), 3.44 -3.34 (m, 4H), 3.21 (dt, J = 9.9, 5.6 Hz, 1H), 2.93 (dd, J = 12.7, 5.0 
Hz, 1H), 2.71 (d, J = 12.7 Hz, 1H), 2.59 (t, J = 7.4 Hz, 2H), 2.22 (t, J = 7.4 Hz, 2H), 1.86-1.55 
(m, 10H), 1.48-1.38 (m, 4H), 1.35-1.25(m, 20H), 0.91 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
CD3OD): δ 205.01, 174.72, 173.54, 164.68, 156.99, 136.77, 128.10, 127.64, 127.42, 69.92, 
69.21, 69.09, 66.29, 61.95, 60.21, 55.61, 55.06, 45.68, 45.16, 39.66, 38.91, 35.35, 31.68, 29.44, 
29.41, 29.37, 29.33, 29.24, 29.08, 28.57, 28.37, 28.10, 26.92, 25.45, 22.95, 22.34, 13.06. LCMS 
(ESI) calcd. for C44H75N6O7S2 [M+H]+ 863.5, obsd. 863.6. 
Biotin-M (83% yield)1H NMR (400 MHz, CD3OD): δ 7.39-7.22 (m, 5H), 5.10-5.04 (m, 
2H), 4.46 (dd, J = 7.9, 4.9 Hz, 1H), 4.27 (dd, J = 7.8, 4.5 Hz, 1H), 4.05 (dd, J = 8.8, 5.3 Hz, 
1H), 3.58 (s, 4H), 3.52 (q, J = 5.2 Hz, 4H), 3.37-3.32 (m, 4H), 3.19-3.11 (m, 3H), 2.89 (dd, J = 
12.7, 5.0 Hz, 1H), 2.68 (d, J = 12.7 Hz, 1H), 2.19 (t, J = 7.5 Hz, 2H), 2.13(t, J = 7.5 Hz, 2H), 
1.80-1.34 (m, 14H), 1.26 (s, 20H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, DMSO): δ 
172.58, 172.50, 172.35, 163.15, 156.36, 137.49, 128.77, 128.21, 128.10, 69.98, 69.62, 69.42, 
65.79, 61.48, 59.64, 55.88, 55.06, 38.97, 38.88, 38.65, 35.90, 35.55, 32.14, 31.76, 29.53, 29.49, 
29.41, 29.31, 29.25, 29.18, 29.15, 28.66, 28.49, 25.78, 25.72, 23.36, 22.56, 14.43. LCMS (ESI) 
calcd. for C44H75N6O8S [M+H]+ 847.5, obsd. 847.8. 
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CHAPTER 3 
 
SIRT2 AND LYSINE FATTY ACYLATION REGULATE THE ONCOGENIC 
ACTIVITY OF K-RAS4A c 
 
Abstract 
Ras proteins play vital roles in numerous biological processes and Ras mutations are found 
in many human tumors. Understanding how Ras proteins are regulated is important for 
elucidating cell signaling pathways and identifying new targets for treating human diseases. 
Here we report that one of the K-Ras splice variants, K-Ras4a, is subject to lysine fatty acylation, 
a previously under-studied protein post-translational modification. Sirtuin 2 (SIRT2), one of the 
mammalian nicotinamide adenine dinucleotide (NAD)-dependent lysine deacylases, catalyzes 
the removal of fatty acylation from K-Ras4a. We further demonstrate that SIRT2-mediated 
lysine defatty-acylation promotes endomembrane localization of K-Ras4a, enhances its 
interaction with A-Raf, and thus promotes cellular transformation. Our study identifies lysine 
fatty acylation as a previously unknown regulatory mechanism for the Ras family of GTPases 
                                                
c  This is a revised version of our submitted paper: Jing, H., Zhang, X., Wisner, S.A., Chen, X., 
Spiegelman, N.A., Linder, M.E., Lin, H.. SIRT2 and lysine fatty acylation regulate the oncogenic activity 
of K-Ras4a. 
For this paper, I (HJ) designed and performed all the biochemical and cellular studies except those 
noted below. I would like to acknowledge the great contribution made by all the authors below. XZ 
synthesized K-Ras4a-C180myr peptide, carried out mass spectrometry analyses of H-Ras and K-Ras4a 
lysine fatty acylation, in vitro cysteine depalmitoylation assay, 32P-NAD assay, and K-Ras4a 
intereactome study. SAW purified SIRT2 protein and performed the Alk14 labeling experiment for the 
K-Ras4a single KR mutants, C186S and C180S mutants. XC validated HJ’s results on cell proliferation 
and soft agar colony formation. NAS synthesized the Alk14 probe. MEL provided pCMV5-HRAS, 
pCMV5-NRAS, pCMV5-K-RAS4B and pCMV5-RalA plasmids and consultation on Ras GTPases. HL 
directed and supervised all the studies. HJ, XZ and HL wrote the manuscript and all authors reviewed 
and approved the manuscript. 
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that is distinct from cysteine fatty acylation. These findings highlight the biological significance 
of lysine fatty acylation and sirtuin-catalyzed protein lysine defatty-acylation.  
1. Introduction 
Protein fatty acylation facilitates direct association of proteins with particular membranes 
in cells and plays a vital role in protein trafficking, cell signaling, protein-protein interactions, 
and protein activity1-3. Dysregulation of protein fatty acylation is implicated in human cancer 
and neurodegenerative diseases3. While early studies have focused on N-terminal glycine 
myristoylation and cysteine palmitoylation, little is known about lysine fatty acylation2,3. 
Although first reported over two decades ago, the biological function of protein lysine fatty 
acylation is not clear and to date only a few proteins, such as tumor necrosis factor α (TNF-α) 
and interleukin 1-α, are known to be regulated by lysine fatty acylation4-8. The enzymes that 
catalyze the addition or removal of lysine fatty acylation were not known until recently when 
we and others found that several sirtuins, the nicotinamide adenine dinucleotide (NAD)-
dependent protein lysine deacylase, could act as lysine defatty-acylase. We have previously 
reported that the TNF-α cytokine secretion9,10 and exosome secretion11 are regulated by sirtuin 
6 (SIRT6)-catalyzed removal of lysine fatty acylation, demonstrating that lysine fatty acylation 
is reversible and physiologically important. Other sirtuin family proteins, SIRT1-312-15 and 
SIRT716, have also been found to efficiently remove fatty acyl groups from lysine residues in 
vitro, suggesting that lysine fatty acylation may be more prevalent. Therefore, we sought to 
identify other proteins that may be regulated by lysine fatty acylation. 
Ras proteins are small GTPases that play important roles in numerous tumor-driving 
processes, including proliferation, differentiation, survival, cell cycle entry and cytoskeletal 
dynamics 17. They act as binary switches: they are active when GTP- bound, turning on specific 
signaling pathways by recruiting effector proteins, and inactive in the GDP- bound state 17,18. 
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Guanine nucleotide exchange factors (GEFs) activate Ras by promoting GDP-GTP exchange, 
whereas GTPase-activating proteins (GAPs) inactivate Ras by promoting intrinsic GTP 
hydrolysis17. In mammals, HRAS, NRAS, and KRAS proto-oncogenes encode four proteins: H-
Ras, N-Ras, K-Ras4a, and K-Ras4b. K-Ras4a and K-Ras4b are the two splice variants encoded 
by the KRAS gene. K-Ras4b has attracted most of the attention because it was assumed to be 
the more abundant and thus the more important K-Ras isoform mutated in human cancers. 
However, recent studies have revealed that K-Ras4a is widely expressed in many cancer cell 
lines and its level is similar to that of K-Ras4b in human colorectal tumors 19,20. A requirement 
for oncogenic K-Ras4a in lung carcinogenesis has also been demonstrated in mice 21. Thus, 
there is increasing interest in evaluating K-Ras4a as a therapeutic target and in investigating the 
regulation of K-Ras4a.  
 
Figure 3.1 Amino acid sequences of the HVRs of Ras proteins. 
Ras proteins exert their functions at cellular membranes, where they interact with distinct 
effectors and activate downstream signaling 18. Ras proteins typically have two membrane-
targeting signals at the C-terminal hypervariable regions (HVRs). All four Ras proteins are 
modified by cysteine farnesylation on their CaaX motif. H-Ras and N-Ras contain cysteine 
palmitoylation as the second membrane targeting signal, whereas K-Ras4b uses a polybasic 
region (PBR) (Fig. 3.1). K-Ras4a possesses a hybrid membrane targeting motif: multiple lysine 
residues at the C-terminus (similar to K-Ras4b) as well as cysteine palmitoylation (Fig. 3.1)19,20. 
As we set out to identify lysine fatty acylated proteins, the presence of multiple lysine residues 
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in the Ras HVRs caught our attention. If the lysine residues function simply to promote 
membrane binding by electrostatics, why are there almost invariably lysine but not arginine 
residues on the HVRs? The prevalence of lysines in Ras HVRs suggests the possibility that 
lysine residues are post-translationally modified by fatty acids. Thus, in this study, we set out 
to investigate whether Ras proteins are regulated by reversible lysine fatty acylation. 
2. Results 
2.1 H-Ras and K-Ras4a contain lysine fatty acylation  
To examine whether the lysine residues in the Ras proteins could be fatty acylated, an 
alkyne-tagged fatty acid analog, Alk14, was used to metabolically label Ras proteins9. As shown 
in Fig. 3.2A, HEK293T cells transiently expressing FLAG-tagged H-Ras, N-Ras, K-Ras4a, or 
K-Ras4b were treated with Alk14 (50 µM). We ensured that the overexpression levels of 
different Ras proteins were similar (Fig. 3.2B). FLAG-tagged Ras proteins were 
immunoprecipitated and conjugated to rhodamine-azide (Rh-N3) using click chemistry to allow 
visualization of fatty acylation by in-gel fluorescence. Hydroxylamine (NH2OH) was then used 
to remove cysteine palmitoylation. Ras-related protein Ral-A (RalA)22 and Syntaxin-6 (STX6)23 
were included as controls for the efficiency of NH2OH in removing cysteine palmitoylation. 
Quantification of the fluorescent signal revealed that NH2OH treatment removed over 95% of 
the fatty acylation from RalA or STX6. However, H-Ras, N-Ras and K-Ras4a retained 20%, 
13% and 47% relative NH2OH-resistant fatty acylation over total fatty acylation, respectively, 
whereas K-Ras4b did not show Alk14 labeling either before or after NH2OH treatment (Fig. 
3.2C). These data suggest that H-Ras, N-Ras, and K-Ras4a might possess non-cysteine fatty 
acylation.  
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Figure 3.2 Ras proteins may be lysine fatty acylated. (A) Scheme showing the Alk14 metabolic 
labeling method to study lysine fatty acylation. (B) Representative western blot analyses of FLAG-tagged 
Ras protein, RalA and STX6 in whole cell extracts. (C) In-gel fluorescence detection of the fatty acylation 
levels of Ras proteins, RalA and STX6 in HEK293T cells (top panel) and quantification of the relative 
fatty acylation levels (bottom panel). The fatty acylation level of H-Ras without NH2OH treatment was 
set to 1. (D) In-gel fluorescence showing the fatty acylation levels of H-Ras WT and 3KR mutant, N-Ras 
WT and 2KR mutant without or with NH2OH treatment. (E) Scheme showing the lysine to arginine 
mutants (4KR, 3KR, and 7KR) used to identify potential fatty acylation sites. (F) In-gel fluorescence 
showing the fatty acylation levels of K-Ras4a WT and KR mutants without or with NH2OH treatment 
(left panel) and quantification of fatty acylation levels with NH2OH treatment relative to that of K-Ras4a 
WT (right panel). FL, fluorescence; WB, western blot. Statistical evaluation was by unpaired two-tailed 
Student’s t test. Error bars represent SEM in three biological replicates. ***P < 0.001; ns, not significant. 
Representative images from three independent experiments are shown.  
To determine whether the NH2OH-resistant fatty acylation could be attributed to the lysine 
residues in the HVRs of H-Ras, N-Ras, and K-Ras4a, we mutated these lysine (K) residues to 
arginine (R) and examined the fatty acylation of the WT and KR mutants. The H-Ras 3KR 
(K167/170/185R), N-Ras 2KR (K169/170) mutant (Fig. 3.2D), and the K-Ras4a 3KR 
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(K182/184/185R) mutant but not K-Ras4a 4KR (K169/170/173/176) mutant (Fig. 3.2E & F) all 
displayed greatly reduced NH2OH-resistant fatty acylation, implying that H-Ras, N-Ras and K-
Ras might be fatty acylated on the lysine residues in their HVRs. Moreover, K-Ras4a-7KR (4KR 
& 3KR) showed comparable NH2OH-resistant fatty acylation level to the 3KR mutant, 
suggesting that K182/184/185 of K-Ras4a might be fatty acylated. We then utilized mass 
spectrometry (MS) to directly identify the lysine fatty acylation of FLAG-H-Ras, -N-Ras or -
K-Ras4a extracted from Alk14-treated HEK293T cells with tryptic digestion. This allowed us 
to identify H-Ras K170 (Fig. 3.3A) and K-Ras4a K182 (Fig. 3.3B) as being modified,  
confirming the lysine fatty acylation of H-Ras and K-Ras4a. Our attempt to identify N-Ras 
lysine fatty acylation by MS was not successful possibly because the tryptic peptide with lysine 
fatty acylation was less abundant (Fig. 1c), too short (MKacylK) or too hydrophobic 
(KacylLNSSDDGTQGCcamMGLPCprenyl, oMe)1,2,24.  
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Figure 3.3 H-Ras and K-Ras4a contain lysine fatty acylation. Tandem mass (MS/MS) spectrum of 
triply charged H-Ras (A) and K-Ras4a (B) peptides with Alk14-modification on K170 and K182, 
respectively. The b- and y-ions are shown along with the peptide sequence. The cysteine residues were 
carbamidomethylated due to iodoacetamide alkylation during sample preparation and methionine was 
oxidized.  
2.2 SIRT2 catalyzes the removal of lysine fatty acylation from K-Ras4a 
Several mammalian sirtuins, including SIRT1, SIRT2, SIRT3, and SIRT6, can efficiently 
remove fatty acyl groups from protein lysine residues in vitro (SIRT1, SIRT2, and SIRT3)25 or 
in vivo (SIRT6)9,12-14,25. So we next investigated whether any of these sirtuins could remove 
lysine fatty acylation from H-Ras or K-Ras4a and therefore regulate their function. We 
incubated H-Ras or K-Ras4a isolated from Alk14-treated HEK293T cells with purified 
recombinant sirtuins without or with NAD in vitro and examined the H-Ras or K-Ras4a fatty 
acylation level by in-gel fluorescence after click chemistry. Incubation of H-Ras or K-Ras4a 
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with Plasmodium falciparum Sir2A (PfSir2A), a sirtuin family member with robust lysine 
defatty-acylase activity26, resulted in the removal of most of the NH2OH-resistant fatty acylation 
from H-Ras and K-Ras4a in the presence of NAD (Fig. 3.4A). This result further confirmed that 
the NH2OH-resistant fatty acylation is mainly from lysine residues and indicated that lysine 
fatty acylation of H-Ras and K-Ras4a is reversible. Furthermore, SIRT2, but not SIRT1, 3, or 
6, slightly decreased the lysine fatty acylation signal of H-Ras (Fig. 3.4B); SIRT1 and SIRT2, 
but not SIRT3 and SIRT6, removed lysine fatty acylation from K-Ras4a. Notably, SIRT2 
showed better activity than SIRT1 on K-Ras4a lysine fatty acylation (Fig. 3.4C). In contrast, 
SIRT1 and SIRT2 showed little effect on the fatty acylation of K-Ras4a-3KR (Fig. 3.4D), which 
exhibited significantly lower lysine fatty acylation than K-Ras4a-WT (Fig. 1f), suggesting that 
SIRT1 and SIRT2 do not possess cysteine defatty-acylase activity. An HPLC-based in vitro 
activity assay also revealed that SIRT2 was unable to remove the cysteine myristoyl group from 
a K-Ras4a-C180myr peptide (Fig. 3.4E).  
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Figure 3.4 SIRT1 removes lysine fatty acylation from K-Ras4a, SIRT2 removes lysine fatty 
acylation from H-Ras and K-Ras4a in vitro.  (A) In-gel fluorescence detection of fatty acylation on H-
Ras and K-Ras4a treated without or with 10 µM PfSir2A and 1 mM NAD in vitro. (B, C) In-gel 
fluorescence detection of fatty acylation of H-Ras (B) and K-Ras4a (C) treated with 5 µM of SIRT1, 2, 3 
and 6 without or with 1 mM of NAD in vitro. (D) Fatty acylation of K-Ras4a-3KR treated without or 
with 5 µM SIRT2 and 1 mM NAD in vitro. (E) High-performance liquid chromatography (HPLC) traces 
showing SIRT2 hydrolyzing myristoyl group from H3K9myr peptide but not K-Ras4a-C180myr peptide. 
The reaction with H3K9myr, SIRT2 and NAD serves as a control to show that SIRT2 was active. 
Furthermore, knockdown (KD) of SIRT2 in HEK293T cells did not affect lysine fatty 
acylation of H-Ras (Fig. 3.5A & E), whereas KD of SIRT2 but not SIRT1 significantly increased 
lysine fatty acylation of K-Ras4a compared with control (Ctrl) KD (Fig. 3.5B, C & E). We also 
noted that SIRT2 KD did not affect fatty acylation of N-Ras (Fig. 3.5D & E). Taken together, 
these results illustrate that K-Ras4a is a lysine defatty-acylation substrate for SIRT2 in cells, but 
H-Ras and N-Ras are not.  
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Figure 3.5 SIRT2 KD increases lysine fatty acylation of K-Ras in cells. (A) Effect of SIRT2 KD on 
the fatty acylation level of H-Ras in HEK293T cells. (B, C) Effect of SIRT1 KD (B) and SIRT2 KD (C) 
on the fatty acylation level of K-Ras4a in HEK293T cells. (D) Effect of SIRT2 KD on the fatty acylation 
level of N-Ras in HEK293T cells. (E) Quantification of the fatty acylation levels with NH2OH treatment 
in (A-D). The fatty acylation level in the corresponding Ctrl KD was set to 1. Statistical evaluation was 
by unpaired two-tailed Student’s t test. Error bars represent SEM in three biological replicates. *P < 0.05; 
ns, not significant. Representative images from three independent experiments are shown. 
We next further validated that K-Ras4a is regulated by SIRT2-mediated defatty-acylation. 
We utilized the SIRT2-H187Y (HY) mutant, which has previously been shown to be 
catalytically dead in lysine deacetylation27, as a negative control. An HPLC-based in vitro assay 
demonstrated that the H187Y mutation dramatically decreased SIRT2 defatty-acylation activity, 
while it completely abolished its deacetylation activity (Fig. 3.6B). Co-expression of SIRT2 
with K-Ras4a in HEK293T cells substantially decreased K-Ras4a lysine fatty acylation, 
whereas co-expression of SIRT2-HY had much less effect (Fig. 3.6A), suggesting that K-Ras4a 
defatty-acylation requires SIRT2 catalytic activity. Interestingly, our finding that mutation of 
the catalytic histidine residue did not completely abolish sirtuin enzymatic activity is not without 
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precedent. For example, mutating the catalytic histidine of bacterial Sir2Tm deacetylase28, yeast 
HST2 deacetylase29, and human SIRT6 defatty-acylase11 also retained some catalytic activity.  
 
Figure 3.6 SIRT2 removes lysine fatty acylation from K-Ras4a in cells. (A) Effect of overexpressing 
SIRT2-WT and SIRT2-HY catalytic mutant on K-Ras4a fatty acylation level. (B) Comparison of the 
activities of SIRT2-WT and SIRT2-HY on H3K9ac and H3K9myr peptides by HPLC-based in vitro assay. 
The conversion rate is shown on the right.   (C) Acetylation of K-Ras4a in Ctrl or SIRT2 KD (by shSIRT2-
#2) HEK293T cells treated with ethanol or TSA (1 µM) for 1 hr. The “*” points to the light chain of the 
anti-FLAG antibody, while the arrow points to K-Ras4a. (D) Fatty acylated lysine in K-Ras4a detected 
by formation of 32P-labeled fatty acyl-ADPR using 32P-NAD. (E) MS/MS spectrum of triply charged K-
Ras4a peptide with palmitoylation on K182. The b- and y-ions are shown along with the peptide sequence. 
The cysteine residue was carbamidomethylated due to iodoacetamide treatment during sample 
preparation. (F) Lysine fatty acylation of endogenous K-Ras4a in Ctrl and SIRT2 KD (by shSIRT2-#2) 
HCT116 cells detected by Alk14 labeling and biotin pull-down. Sup, supernatant; Ac, acetyl-H3K9; Myr, 
myristoyl-H3K9.  
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To investigate whether K-Ras4a could also be regulated by SIRT2 through deacetylation, 
we examined its acetylation level using a pan-specific acetyl lysine antibody. Acetylation was 
not detected on K-Ras4a in either Ctrl KD or SIRT2 KD cells without or with histone 
deacetylases (HDAC) inhibitor Trichostatin A (TSA) (Fig. 3.6C). We also searched our K-
Ras4a MS data and did not find any peptides with lysine acetylation, indicating that SIRT2 
likely does not regulate K-Ras4a via deacetylation. 
With SIRT2 as a tool, we further confirmed the existence of lysine fatty acylation on K-
Ras4a in cells that were not treated with Alk14. We used a previously developed assay that 
relies on 32P-NAD to detect sirtuin-catalyzed deacylation reactions30. When histone H3K9 acetyl 
(Ac) and myristoyl (Myr) peptides were incubated with SIRT2-WT in the presence of 32P-NAD, 
the formation of the acyl-ADPR product could be detected by autoradiography after separation 
using thin-layer chromatography (TLC) (Fig. 3.6D, lanes 6 & 7). In contrast, the SIRT2-HY 
mutant only generated a tiny amount of the acyl-ADPR product (Fig. 3.6D, lanes 11 & 12). 
When K-Ras4a isolated from HEK293T cells was treated with SIRT2-WT in the presence of 
32P-NAD, a spot corresponding to fatty acyl-ADPR but not acetyl-ADPR was detected (Fig. 2h, 
lane 9). Control reactions without SIRT2 (Fig. 3.6D, lane 4) or with the HY mutant (Fig. 3.6D, 
lane 14) did not generate the fatty acyl-ADPR product. These results demonstrate that K-Ras4a 
contains lysine fatty acylation that can be removed by SIRT2 in the absence of Alk14 
supplementation. A peptide carrying palmitoylation, but not myristoylation, on K182 of FLAG-
tagged K-Ras4a was detected by MS (Fig. 3.6E), demonstrating that palmitoylation is the major 
native lysine acylation of K-Ras4a.  
We then investigated whether endogenous K-Ras4a is also regulated by SIRT2-catalyzed 
lysine defatty-acylation. For this purpose, we used the HCT116 human colorectal cancer cell 
line, in which K-Ras4a was shown to be expressed 19. Since the commercial antibody against 
K-Ras4a did not immunoprecipitate K-Ras4a, we enriched fatty acylated proteins labeled with 
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Alk14 as previously described31, and detected fatty acylated K-Ras4a using a K-Ras4a-specific 
antibody. HCT116 cells with Ctrl KD or SIRT2 KD were cultured in the presence of Alk14. 
Proteins were then extracted and a biotin affinity tag was attached to the Alk14-labeled proteins 
with click chemistry. The biotin-conjugated proteins were pulled down using streptavidin beads, 
and subsequently washed with 1% SDS to disrupt protein-protein interaction. Proteins that were 
only fatty acylated on cysteine residues were then released from the streptavidin beads into the 
supernatant (Sup) via NH2OH treatment, while proteins with lysine fatty acylation were retained. 
As shown in Fig. 2i, RalA (Fig. 3.2C) and transferrin receptor (TfR)32, which are predominantly 
cysteine fatty acylated, were present in the supernatant but barely detectable from the 
streptavidin beads, indicating that the NH2OH treatment was effective. In Ctrl KD cells, K-
Ras4a was mainly detected in the supernatant. However, in the SIRT2 KD cells, K-Ras4a was 
detected both on the streptavidin beads and in the supernatant, indicating that endogenous K-
Ras4a possesses lysine fatty acylation that is regulated by SIRT2. 
By immunoprecipitation of total Ras protein from Alk14-treated HCT116 cells using a pan-
Ras (Y13-259) antibody, we found that endogenous Ras proteins exhibited NH2OH-resistant 
fatty acylation (Fig. 3.7A). Moreover, SIRT2 KD increased the NH2OH-resistant fatty acylation 
of Ras proteins (Fig. 3.7B). Since SIRT2 KD did not affect lysine fatty acylation of 
overexpressed H-Ras (Fig. 3.5A & E) and N-Ras (Fig. 3.5D & E), the data suggested that the 
increase in total Ras lysine fatty acylation observed in SIRT2 KD cells can be attributed to K-
Ras4a lysine fatty acylation. This result, together with the detection of K-Ras4a lysine fatty 
acylation by Alk14 biotinylation, further supports that endogenous K-Ras4a is lysine fatty 
acylated and is regulated by SIRT2-mediated lysine defatty-acylation.  
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Figure 3.7 Endogenous K-Ras4a is lysine fatty acylated. (A) In-gel fluorescence detection of fatty 
acylation on endogenous total Ras proteins immunoprecipiated from HCT116 cells. (B)Effect of SIRT2 
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KD on fatty acylation of endogenous Ras after NH2OH treatment. (C) Comparison of the MS spectra of 
Alk14-modified K-Ras4a aa177-185 peptide from endogenous Ras and overexpressed K-Ras4a MS 
analyses. (d) Comparison of the MS spectra of K-Ras4a aa 150-161 peptide from endogenous Ras and 
overexpressed K-Ras4a MS analyses. The ion intensities for the Alk14-modified aa177-185 and the 
unmodified aa 150-161 peptides were over 200 times lower than those from overexpressed K-Ras4a. 
We also performed MS analysis of endogenous Ras immunoprecipitated from HCT116 
cells treated with SIRT2 shRNA and Alk14. We identified a peptide with a primary mass 
matching the Alk14-modified K-Ras4a aa177-185 peptide, whose exact m/z and isotope pattern 
were the same as those of overexpressed K-Ras4a (Fig. 3.7C). However, this primary mass did 
not trigger MS2, which was likely due to low peptide abundance (Fig. 3.7C &D). It has been 
shown that K-Ras has a much lower expression level than H-Ras and N-Ras because of its rare 
codon bias33,34.  
SIRT2 was reported to reside predominantly in the cytoplasm35,36. The regulation of K-
Ras4a lysine fatty acylation by SIRT2 suggested that SIRT2 might also exist at cellular 
membranes, where K-Ras4a mainly resides. Indeed, by subcellular fractionation, we found that 
SIRT2 was present in both soluble and membrane fractions (Fig. 3.8A). Co-
immunoprecipitation (co-IP) revealed K-Ras4a associated with endogenous SIRT2 (Fig. 3.8B). 
These results further support that K-Ras4a is a lysine defatty-acylase substrate for SIRT2.  
 
Figure 3.8 SIRT2 interacts with K-Ras4a. (A) Subcellular fractionation showing the localization of 
SIRT2 and FLAG-K-Ras4a. (B) Co-IP of FLAG-K-Ras4a with endogenous SIRT2 in HEK293T cells. 
Representative images from three independent experiments are shown. 
2.3 Mapping the fatty acylated lysine residues regulated by SIRT2 
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MS results suggested that K182 was the preferentially fatty acylated lysine residue on K-
Ras4a. However, the lysine 182 to arginine mutant (K182R) exhibited similar lysine fatty 
acylation levels to that of WT (Fig. 3.9A). As the 3KR (K182/184/185R) but not the 4KR 
(K169/170/173/176R) mutant significantly decreased K-Ras4a lysine fatty acylation (Fig. 3.2F), 
we also mutated K184 and K185 to arginine individually. Neither the K184R nor K185R 
mutation decreased lysine fatty acylation as the 3KR mutant did (Fig. 3.9A). These results 
suggested that K182, 184 and 185 were likely to be modified redundantly. We suspected that it 
was hard to pinpoint the exact modification site by mutagenesis because the K182R mutation 
might enhance fatty acylation on the other two nearby lysine residues. To test this hypothesis, 
we performed MS analysis of FLAG-K-Ras4a-K182A extracted from Alk14-treated HEK293T 
cells. We tested the K182A instead of K182R mutant because the K182R mutant would produce 
a tryptic peptide that is too short to be detected. As expected, the K182A mutation did not affect 
the overall level of K-Ras4a lysine fatty acylation (Fig. 3.9B). A peptide (amino acids 177-185) 
fatty acylated on K184 was detected by MS (Fig. 3.9B), which agrees with our hypothesis. It 
was likely that K185 could also be fatty acylated for the K182R mutant, because the K182/185R 
mutant slightly but significantly decreased lysine fatty acylation levels compared with the 
K182R and K185R single mutants (Fig. 3.9A). The K185 fatty acylation was not detected by 
MS most likely because the modified tryptic peptide was too short and hydrophobic (Kfatty-
acylCprenyl, oMe). Overall, these data indicate that K182/184/185 are fatty acylated redundantly and 
that the 3KR mutation is needed to abolish the lysine fatty acylation on the C-terminus of K-
Ras4a.  
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Figure 3.9 K-Ras4a is fatty acylated on lysine 182/184/185. (A) Fatty acylation levels of K-Ras4a WT, 
K182R, K184R, K185R, K182/185R, and 3KR by in-gel fluorescence (left panel) and quantification of 
fatty acylation levels after NH2OH treatment relative to that of K-Ras4a WT (right panel). (B) MS/MS 
spectrum of triply charged K-Ras4a-K182A peptide with Alk14 modification on K184. The b- and y-ions 
are shown along with the peptide sequence. The cysteine residue was carbamidomethylated due to 
iodoacetamide alkylation during sample preparation. Fatty acylation levels of K-Ras4a WT and K182A 
with NH2OH were also shown. 
K-Ras4a has been shown to be prenylated on cysteine 186 and palmitoylated on cysteine 
18019. To examine whether cysteine prenylation or palmitoylation play a role in lysine fatty 
acylation, we generated cysteine-to-serine C180S and C186S mutants. Mutation of the 
prenylcysteine (C186S) completely abolished the fatty acylation of K-Ras4a (Fig. 3.10A), 
which is consistent with the model that prenylation of the cysteine on the CaaX motif of Ras 
proteins is required for the subsequent fatty acylation37. On the other hand, mutation of the 
palmitoylated cysteine (C180S) led to a substantial but not complete loss of K-Ras4a lysine 
fatty acylation (Fig. 3.10A). The fatty acylation on the C180S mutant was NH2OH-resistant and 
was abolished by combining the C180S and 3KR mutations (Fig. 3.10B), implying that the 
C180S mutant was fatty acylated on K182/184/185. These data suggest that cysteine 
  97 
palmitoylation might play an important but nonessential role in the occurrence of lysine fatty 
acylation. It is possible that cysteine palmitoylation facilitates the lysine fatty acyl transfer 
reaction, or the delivery of K-Ras4a to where lysine fatty acylation occurs. 
We next assessed whether SIRT2 regulates fatty acylation of K-Ras4a on K182/184/185. 
SIRT2 removed lysine fatty acylation from K-Ras4a WT, the 4KR mutant and the C180S 
mutant, but not the 3KR mutant in vitro (Fig. 3.10C). SIRT2 KD in HEK293T cells increased 
lysine fatty acylation of K-Ras4a WT and the C180S mutant, but not the 3KR and C180S-3KR 
mutants (Fig. 3.10D), indicating that fatty acylation on K182/184/185 is regulated by SIRT2.  
 
Figure 3.10 SIRT2 regulates lysine fatty acylation of K-Ras4a on K182/184/185. (A) Fatty acylation 
levels of K-Ras4a WT, C180S, and C186S. (B) Fatty acylation levels of K-Ras4a WT, C180S and C180S-
3KR after NH2OH treatment. (C) In-gel fluorescence detection of fatty acylation of K-Ras4a-WT, -4KR, 
-3KR and -C180S treated without or with 5 µM SIRT2 and 1 mM NAD in vitro. (D) Fatty acylation levels 
of K-Ras4a WT, 3KR, C180S and C180S-3KR after NH2OH treatment in Ctrl and SIRT2 KD (by 
shSIRT2-#2) HEK293T cells. Quantification of the fluorescent intensity relative to K-Ras4a WT is shown 
in the bottom panel. Statistical evaluation was by unpaired two-tailed Student’s t test. Error bars represent 
SEM in three biological replicates. *P < 0.05; **P < 0.01; ***P < 0.001. Representative images from 
three independent experiments are shown. 
2.4 Lysine fatty acylation regulates subcellular localization of K-Ras4a 
We next set out to study the effect of lysine fatty acylation on K-Ras4a. A variety of PTMs 
on Ras proteins, such as cysteine palmitoylation 38,39, phosphorylation40,41 and ubiquitination42, 
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function to deliver the molecule to the right place within the cell. We hypothesized that lysine 
fatty acylation may also be critical for the correct subcellular distribution of K-Ras4a. To test 
this hypothesis, we fused Aequorea coerulescens Green Fluorescent Protein (GFP) to the N-
terminus of K-Ras4a WT and the 3KR mutant and performed live imaging with confocal 
microscopy in Ctrl and SIRT2 KD HEK293T cells to visualize K-Ras4a localization. The levels 
of over-expressed K-Ras4a WT and 3KR were equal in Ctrl and SIRT2 KD cells (Fig. 3.11A). 
We also imaged cells with similar GFP intensity under the same settings to avoid potential false 
positive observations caused by different levels of expression. In Ctrl KD cells, both K-Ras4a 
WT and the 3KR mutant displayed predominant localization to the plasma membrane (PM). 
However, the presence of 3KR on intracellular puncta was noticeably more pronounced 
compared to WT. SIRT2 KD decreased the intracellular punctate-localized K-Ras4a WT 
compared to Ctrl KD, whereas it had no effect on the punctate localization of the 3KR mutant 
(Fig. 3.11B & C), indicating that the effect of the 3KR mutation on K-Ras4a localization was 
due to lack of lysine fatty acylation. Similar effects of the 3KR mutation were obtained for K-
Ras4a in HCT116 cells and for oncogenic K-Ras4a-G12V, which exhibited comparable lysine 
fatty acylation level to K-Ras4a WT (Fig. 3.11D) in NIH3T3 cells (Fig. 3.11G & F). On the 
other hand, SIRT2 KD did not affect the intracellular punctate localization of H-Ras (Fig. 
3.11B), which is consistent with our observation that H-Ras was not regulated by SIRT2 through 
lysine defatty-acylation. Taken together, these data indicate that lysine fatty acylation inhibits 
the intracellular punctate localization of K-Ras4a and SIRT2 promotes this localization by 
defatty-acylation. In addition, the K-Ras4a-C180S mutant that lacks cysteine palmitoylation and 
the majority of lysine fatty acylation extensively localized to internal membranes, which was 
distinct from the punctate localization of the 3KR mutant that is deficient in lysine fatty 
acylation but retains cysteine palmitoylation (Fig. 3.11G & H). This implies that cysteine 
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palmitoylation might facilitate the punctate localization of K-Ras4a in the absence of lysine 
fatty acylation, while lysine fatty acylation inhibits it.  
 
Figure 3.11 Lysine fatty acylation regulates subcellular localization of K-Ras4a. (A) Western blot 
analyses showing equal overexpression of GFP-K-Ras4a WT and 3KR in HEK293T cells with Ctrl and 
SIRT2 KD. (B) Confocal images showing subcellular localization of GFP-K-Ras4a WT, 3KR, and GFP-
H-Ras in HEK293T cells with Ctrl or SIRT2 KD (by shSIRT2-#2). Insets are magnifications of the 
regions enclosed by the white dashed squares. (C) Statistical analyses of the relative cytoplasm to whole 
cell intensity of K-Ras4a WT, 3KR, and H-Ras from (a) (n = 16, 16, 16, 16, 21, 21 for each sample from 
left to right, respectively). (D) Fatty acylation levels of K-Ras4a WT and G12V in HEK293T cells. (E) 
Western blot analyses showing equal protein levels for overexpressed GFP-K-Ras4a-WT and -3KR in 
HCT116 cells, and GFP-K-Ras4a-G12V and -G12V-3KR in 3T3 cells. (F) Live cell imaging of HCT116 
cells overexpressing GFP-K-Ras4a-WT and -3KR and NIH 3T3 cells overexpressing GFP-K-Ras4a-
G12V and -G12V-3KR. Insets are magnifications of the regions enclosed by the white dashed squares. 
(G) Western blot showing equal protein levels for overexpressed GFP-K-Ras4a-WT, -3KR and -C180S 
in HEK293T cells. (H) Confocal images showing subcellular localization of GFP-K-Ras4a, -3KR, and -
C180S. The bottom panels show the magnified images of the regions enclosed by the white dashed 
squares in the top panels. Statistical evaluation was by two-way ANOVA. Centre line of the box plot 
represents the mean value, box represents the 95 % confidence interval, and whiskers represent the range 
of the values. **P < 0.01; ***P < 0.001; ns, not significant. Representative images are shown. 
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It has been shown that Ras proteins associate with and signal from endomembrane 
compartments, including the endoplasmic reticulum (ER), Golgi, endosomes and lysosome 18,42-
48. Therefore, we next set out to identify the endomembrane compartments where lysine defatty-
acylated K-Ras4a is localized. We performed colocalization analyses with a series of membrane 
compartment markers. Compared with K-Ras4a WT, the 3KR mutant exhibited more 
pronounced cytoplasmic colocalization with trans-Golgi network (TGN) marker STX6, early 
endosome marker EEA1, recycling endosome marker Rab11 and lysosome marker LAMP1 (Fig. 
3.12A & C), but not with the ER marker Sec61, trans-Golgi marker GalT and late endosome 
marker Rab7 (Fig. 3.12B & C). These results suggest that removal of lysine fatty acylation from 
K-Ras4a promotes its localization to the endomembranes in endocytic pathways, by which it 
may be routed from early endosome to the lysosome for degradation and to the TGN or recycling 
endosomes to return to the plasma membrane 49.  
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Figure 3.12 Loss of lysine fatty acylation targets K-Ras4a to endomembranes. (A) Images showing 
the colocalization of GFP-K-Ras4a WT or 3KR with STX6, EEA1, Rab11, and LAMP1 in HEK293T 
cells. Merge 2 shows the magnified white dashed squares-enclosed regions in Merge 1. (B) 
Representative images for examining the colocalization of GFP-K-Ras4a or -3KR with Sec61, GalT, and 
Rab7 in HEK293T cells. Magnifications of the white dashed squares-enclosed regions in Merge 1 are 
shown as Merge 2. (C) Statistical analyses of the cytoplasmic colocalization of K-Ras4a or -3KR with 
the indicated intracellular membrane markers from (A & B) using Pearson’s coefficient (n = 11, 11, 11, 
11, 17, 17, 10, 10, 11, 11, 11, 11, 13, 13 cells for each sample from left to right, respectively). Statistical 
evaluation was by two-way ANOVA. Centre line of the box plot represents the mean value, box 
represents the 95 % confidence interval, and whiskers represent the range of the values. *P < 0.05; **P 
< 0.01; ns, not significant. Representative images are shown. 
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2.5 Lysine fatty acylation regulates transforming activity of K-Ras4a 
We next investigated whether lysine fatty acylation also affects the function of K-Ras4a. 
We assessed the ability of constitutively active K-Ras4a-G12V and the K-Ras4a-G12V-3KR 
mutant to enable anchorage-independent growth, promote proliferation in monolayer cultures 
and stimulate migration in Ctrl and Sirt2 KD cells. In Ctrl KD cells, expression of K-Ras4a-
G12V-3KR resulted in significantly more colony formation on soft agar than did expression of 
K-Ras4a-G12V. Furthermore, Sirt2 KD caused a greater decrease in the colony formation 
induced by K-Ras4a-G12V (75% decrease) than by K-Ras4a-G12V-3KR (45% decrease) (Fig. 
3.13). Additionally, Sirt2 KD more potently inhibited K-Ras4a-G12V-mediated colony 
formation than H-Ras4a-G12V-mediated colony formation (Fig. 3.13), consistent with the fact 
that SIRT2 regulates lysine fatty acylation of K-Ras4a but not H-Ras or K-Ras4a 3KR. Thus, 
lysine fatty acylation inhibits the ability of K-Ras4a-G12V to induce anchorage-independent 
growth of cells and SIRT2 promotes it through defatty-acylation. One caveat of the result, 
however, was that Sirt2 KD still decreased the colony formation induced by K-Ras4a-G12V-
3KR or H-Ras-G12V, whose lysine fatty acylation was not regulated by SIRT2. This is not 
unexpected because SIRT2 is known to exert tumor-promoting functions by deacetylating 
various targets50-58. Thus, the effect of Sirt2 KD on K-Ras4a-G12V-3KR- and H-Ras-induced 
transformation might be attributed to other substrates for SIRT2.  
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Figure 3.13 SIRT2-dependent lysine defatty-acylation increases K-Ras4a transforming activity. (A) 
Representative western blot analyses of Sirt2, FLAG-K-Ras4a-G12V, FLAG-K-Ras4a-G12V-3KR, 
FLAG-H-Ras-G12V protein levels in NIH3T3 cells with Ctrl or Sirt2 KD used in (B and C). (B) 
Anchorage-independent growth of NIH 3T3 cells stably expressing Mock, K-Ras4a-G12V, -G12V-3KR 
or H-Ras-G12V with Ctrl or Sirt2 KD. (C) Quantification of the colony numbers in (B) relative to that of 
the cells expressing K-Ras4a-G12V-shCtrl or H-Ras-G12V-shCtrl. Statistical evaluation was by unpaired 
two-tailed Student’s t test. Error bars represent SEM in eight biological replicates or as indicated. ***P 
< 0.001. Representative images (A, B) from at least three independent experiments are shown. 
In monolayer cultures, NIH3T3 cells expressing K-Ras4a-G12V-3KR displayed a higher 
proliferation rate than those expressing K-Ras4a-G12V. Sirt2 KD inhibited the proliferation of 
the NIH3T3-K-Ras4a-G12V cells (47% inhibition) slightly more than that of the NIH3T3-K-
Ras4a-G12V-3KR (34% inhibition) cells (Fig. 3.14A). Thus, lysine fatty acylation negatively 
regulates K-Ras4a-G12V-induced cell proliferation under monolayer culture conditions, but the 
effect was smaller than that on anchorage-independent growth (Fig. 3.13). Results from 
transwell migration assays revealed that the 3KR mutation did not affect the capability of K-
Ras4a-G12V to induce cell migration. Consistent with this finding, Sirt2 KD decreased K-
Ras4a-G12V and K-Ras4a-G12V-3KR-mediated cell migration similarly (Fig. 3.14B & C). 
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Therefore, lysine fatty acylation does not affect the ability of K-Ras4a-G12V to stimulate cell 
migration. 
 
Figure 3.14 Lysine fatty acylation regulates K-Ras4a-G12V-mediated cell proliferation but not 
migration. (A) Effect of Ctrl or Sirt2 KD on proliferation of NIH3T3 cells stably overexpressing Mock, 
K-Ras4a-G12V or -G12V-3KR. Cell numbers were determined by crystal violet staining 0 or 5 days after 
the transduction with shCtrl or shSirt2-carrying lentivirus. The y axis represents cell numbers normalized 
to that of the corresponding shCtrl group on Day 0. (B) Representative images of transwell migration 
assay in NIH3T3 cells stably overexpressing Mock, K-Ras4a-G12V or -G12V-3KR with Ctrl or Sirt2 
KD. (C) Migration cell numbers in (B) relative to that of Mock with Ctrl KD. Statistical evaluation was 
done using unpaired two-tailed Student’s t test. Error bars represent SEM in four biological replicates. 
**P < 0.01; ***P < 0.001; ns, not significant. 
2.6 A-Raf is involved in the regulation of K-Ras4a by lysine fatty acylation  
The dynamic regulation of Ras localization is known to be closely coupled to its signaling 
output 43,59,60. We decided to further explore the molecular mechanism underlying the regulation 
of K-Ras4a-mediated transformation activity by lysine fatty acylation. We first sought to 
examine whether lysine fatty acylation affects K-Ras4a activation by a pull-down assay with 
the Ras-binding domain (RBD) of Raf1, which only binds to the GTP-bound form of Ras43. 
Neither the 3KR mutation nor SIRT2 KD affected EGF-stimulated GTP loading of K-Ras4a 
(Fig. 3.15A & b) or the constitutively GTP-loaded state of K-Ras4a-G12V (Fig. 3.15C & D). 
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We then determined whether K-Ras4a at endomembranes exists in its GTP-bound state using 
DsRed-RBD (DsRed fused to the N-terminus of RBD) as a probe. Notably, we observed more 
colocalization of DsRed-RBD with K-Ras4a on intracellular puncta in cells expressing the 3KR 
mutant (Fig. 3.15E, F & G) than in cells expressing K-Ras4a WT. Furthermore, SIRT2 KD 
decreased the colocalization of DsRed-RBD with K-Ras4a WT at intracellular puncta, but not 
with the 3KR mutant (Fig. 3.15E). 
 
Figure 3.15 Lysine fatty acylation regulates the subcellular localization of active K-Ras4a. (A, B) 
RBD pull-down assay in HEK293T cells expressing FLAG-K-Ras4a WT or 3KR with Ctrl or SIRT2 KD 
(by shSIRT2-#2) (A). Cells were serum-starved overnight and treated with 100 ng/mL EGF for 0, 5 and 
15 min. The relative RBD binding with respect to cells expressing K-Ras4a and shCtrl at 0 min was 
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quantified in (B). (C, D) RBD pull-down assay in HEK293T cells expressing FLAG-K-Ras4a-G12V or 
-G12V-3KR with Ctrl or SIRT2 KD (C). Cells were cultured in FBS-free or complete medium for 12 hr 
before being subjected to RBD pull-down. RBD binding relative to cells expressing K-Ras4a-G12V-
shCtrl was quantified in (D). (E) Co-localization of GFP-K-Ras4a WT or 3KR with DsRed-RBD in live 
HEK293T cells with Ctrl or SIRT2 KD. (F) Live cell imaging showing the colocalization of GFP-K-
Ras4a WT or 3KR with DsRed-RBD in HCT116 cells. (G) Live cell imaging showing the colocalization 
of GFP-K-Ras4a-G12V or -G12V-3KR with DsRed-RBD in NIH3T3 cells. Error bars represent SEM in 
three biological replicates. The images shown are representative of 80–100% of the cells examined. 
The results above suggest that SIRT2-dependent lysine defatty-acylation may promote the 
localization of activated (GTP-loaded) K-Ras4a at endomembranes, which raises the possibility 
that lysine defatty-acylation may alter the signaling specificity of K-Ras4a by recruiting 
different effector proteins to endomembranes. We therefore investigated whether lysine defatty-
acylation influenced the binding and activation of the three most well characterized Ras 
effectors: Raf1, PI3K, and RalGDS61. Co-immunoprecipitation demonstrated that neither the 
3KR mutation nor Sirt2 KD altered the binding of K-Ras4a-G12V with Raf1, PI3K, or RalGDS 
(Fig. 3.16 A). We also assessed the capacity of K-Ras4a-G12V and -G12V-3KR in Ctrl and 
Sirt2 KD cells to activate Raf1, PI3K, and RalGDS signaling pathways using phosphorylated 
Erk, phosphorylated Akt, and phosphorylated Jnk as reporters, respectively. K-Ras4a-G12V and 
-G12V-3KR induced comparable levels of Erk activation, which was not affected by Sirt2 KD. 
Sirt2 KD resulted in a reduction of Akt and Jnk activation, but the effect was similar for both 
K-Ras4a-G12V and -G12V-3KR (Fig. 3.16B), suggesting other Sirt2 targets that are important 
for Akt and Jnk activation. These results suggest that SIRT2 catalyzed lysine defatty-acylation 
of K-Ras4a does not affect the activation of Raf1, PI3K or RalGDS by K-Ras4a.  
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Figure 3.16 Lysine fatty acylation does not affect K-Ras4a signaling through Raf1, PI3K, RalGDS 
or B-Raf. (A) Co-IP of FLAG and Raf1, p110α or RalGDS in NIH3T3 cells stably expressing Mock, 
FLAG-K-Ras4a-G12V or -G12V-3KR with Ctrl or Sirt2 KD. (B) Western blot analyses of phospho-Erk, 
-Akt and -Jnk in NIH3T3 cells stably expressing Mock, FLAG-K-Ras4a-G12V or -G12V-3KR with Ctrl 
or Sirt2 KD. (C) Co-IP of FLAG and B-Raf in NIH3T3 cells stably expressing Mock, FLAG-K-Ras4a-
G12V or FLAG-K-Ras4a-G12V-3KR with Ctrl or Sirt2 KD. Representative images from three 
independent experiments are shown. 
To identify proteins whose binding to K-Ras4a is regulated by lysine fatty acylation, we 
performed a protein interactome study using stable isotope labeling by amino acids in cell 
culture (SILAC) (Fig. 3.17). We cultured NIH3T3 cells with stable K-Ras4a-G12V and K-
Ras4a-G12V-3KR overexpression in light-isotope- and heavy-isotope-labeled medium, 
respectively. We then performed FLAG IP, mixed the eluted fractions from both IPs, digested 
with trypsin and analyzed by MS to identify proteins with Heavy/Light (H/L) ratios > 1.3 or < 
0.77, which were candidates that would potentially bind to K-Ras4a-G12V and K-Ras4a-G12V-
3KR differently. The experiment was also repeated after swapping the heavy and light SILAC 
labels. Additionally, to confirm that the effect of the 3KR mutation on the K-Ras4a-G12V 
interactome was due to the lack of lysine fatty acylation, we also examined the K-Ras4a-G12V 
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interactome in Ctrl and Sirt2 KD cells with SILAC, which enabled the identification of proteins 
(H/L > 1.3 or < 0.77) whose binding to K-Ras4a-G12V was regulated by Sirt2.  
 
Figure 3.17 Interactome study identifies K-Ras4a-G12V interacting proteins that potentially 
mediate the effect of lysine fatty acylation. Schematic workflow of the K-Ras4a-G12V SILAC 
interactome study. 
Integration of the three interactome experiments resulted in 175 interacting proteins with at 
least two unique peptides and H/L ratio. Among them, nine proteins exhibited increased binding 
to K-Ras4a-G12V-3KR compared to K-Ras4a-G12V, and their interaction with K-Ras4a-G12V 
was inhibited by Sirt2 KD, suggesting that lysine defatty-acylation enhanced K-Ras4a-G12V 
interaction with these proteins. On the other hand, one protein showed decreased binding to K-
Ras4a-G12V-3KR compared to K-Ras4a-G12V, and its interaction with K-Ras4a-G12V was 
increased by Sirt2 KD, suggesting that lysine defatty-acylation repressed K-Ras4a-G12V 
interaction with it (Fig. 3.18A). 
Among these 10 proteins, the serine/threonine-protein kinase A-Raf and Apoptosis-
inducing factor 1 (Aif), whose interaction with K-Ras4a-G12V might be increased by lysine 
defatty-acylation, attracted our attention. A-Raf is a member of the Raf family of 
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serine/threonine-specific protein kinases, acts as a Ras effector and plays an important role in 
apoptosis 62,63 and tumorigenesis 64-66. In response to apoptotic stimuli, Aif is released from the 
mitochondrial intermembrane space into the cytosol and nucleus, where it functions as a 
proapoptotic factor 67. Since suppression of apoptosis is linked to Ras-induced transformation68, 
it is plausible that A-Raf and Aif are involved in the regulation of K-Ras4a transformation 
activity by lysine fatty acylation. To test this hypothesis, we first validated the interactome 
results by co-IP. Although more interaction of Aif with K-Ras4a-G12V-3KR was observed than 
with K-Ras4a-G12V, Sirt2 KD did not affect the interaction of Aif with either K-Ras4a-G12V 
or K-Ras4a-G12V-3KR (Fig. 3.18B & C) and was not investigated further. However, a greater 
interaction of A-Raf with K-Ras4a-G12V-3KR was observed than with K-Ras4a-G12V, and 
Sirt2 KD significantly decreased the interaction of A-Raf with K-Ras4a-G12V but not with K-
Ras4a-G12V-3KR (Fig. 3.18D & E). Thus, we concluded that A-Raf was an effector protein of 
K-Ras4a that was regulated by lysine fatty acylation and SIRT2. Unlike the effect of Sirt2 KD 
on K-Ras4a-G12V-A-Raf interaction, Sirt2 KD did not alter H-Ras-G12V-A-Raf interaction 
(Fig. 3.18D & E). As mentioned earlier, lysine fatty acylation did not affect the binding between 
C-Raf (Raf1) and K-Ras4a-G12V (Fig. 3.16A). We also assessed the interaction of K-Ras4a-
G12V with another Raf family member, B-Raf. Co-IP indicated that neither 3KR mutation nor 
Sirt2 KD altered the binding of B-Raf to K-Ras4a-G12V (Fig. 3.16C). These results collectively 
demonstrate that removal of lysine fatty acylation from K-Ras4a by SIRT2 results in its 
preferential association with A-Raf, but not B-Raf or C-Raf. 
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Figure 3.18 Lysine fatty acylation alters interaction between K-Ras4a and A-Raf. (A) List of proteins 
whose binding to K-Ras4a-G12V may be altered (H/L > 1.3 or < 0.77) by lysine fatty acylation. (B) Co-
IP of FLAG and Aif in NIH3T3 cells stably expressing Mock, FLAG-K-Ras4a-G12V or -G12V-3KR 
with Ctrl or Sirt2 KD. The “*” points to the heavy chain of the anti-FLAG antibody, while the arrow 
points to Aif. (C) Quantification of relative Aif binding level in (B) compared to that in cells expressing 
K-Ras4a-G12V-shCtrl. (D) Co-IP of A-Raf with an anti-FLAG antibody in NIH 3T3 cells stably 
expressing Mock, FLAG-K-Ras4a-G12V, FLAG-K-Ras4a-G12V-3KR, or FLAG-H-Ras-G12V with 
Ctrl or Sirt2 KD. (E) Quantification of relative A-Raf binding levels in (a). Statistical evaluation was by 
unpaired two-tailed Student’s t test. Error bars represent SEM in four biological replicates. *P < 0.05; 
**P < 0.01; ***P < 0.001; ns, not significant. Representative images are shown. 
Our results suggest that SIRT2-mediated lysine defatty-acylation does not affect the 
magnitude of K-Ras4a activation but promotes endomembrane localization of active K-Ras4a. 
It has been reported that the efficient activation of certain effector pathways by Ras is dependent 
on the entry of Ras to the endosomal compartment 42,69. Therefore, it is plausible that lysine 
defatty-acylation may facilitate the endomembrane recruitment of A-Raf by K-Ras4a, thereby 
increasing K-Ras4a oncogenic activity. Live cell imaging revealed that A-Raf colocalized with 
K-Ras4a-G12V at both the PM and endomembranes. K-Ras4a-G12V-3KR showed more 
colocalization with A-Raf on the endomembranes than K-Ras4a-G12V did. Sirt2 KD inhibited 
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the endomembrane recruitment of A-Raf by K-Ras4a-G12V but not that by K-Ras4a-G12V-
3KR (Fig. 3.19). These results are in line with our hypothesis. Thus, it is likely that by regulating 
endomembrane recruitment of A-Raf, K-Ras4a lysine fatty acylation may alter its signaling 
output through A-Raf, thereby modulating its transforming activity. 
 
Figure 3.19 Lysine fatty acylation regulates endomembrane recruitment of A-Raf by K-Ras4a. (A) 
Images showing the localization of GFP-K-Ras4a-G12V or -G12V-3KR and DsRed-A-Raf in live 
HEK293T cells with Ctrl or SIRT2 KD (by shSIRT2-#2). (B) Statistical analyses of the relative cytoplasm 
to whole cell intensity of K-Ras4a and A-Raf from (A) (n = 17 for all samples). Statistical evaluation was 
by two-way ANOVA. Centre line of the box plot represents the mean value, box represents the 95 % 
confidence interval, and whiskers represent the range of the values. **P < 0.01; ***P < 0.001; ns, not 
significant. Representative images are shown. 
While the functions of B-Raf and C-Raf in Ras-mediated oncogenic transformation have 
been well elucidated, the role of A-Raf in this process remains obscure70. So we next examined 
whether A-Raf plays a role in K-Ras4a-G12V mediated transformation using the soft agar 
colony formation assay. Inhibition of A-Raf expression with shRNA (Fig. 3.20A) partially 
suppressed K-Ras4a-G12V-induced colony formation, indicating that A-Raf is important for K-
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Ras4a-G12V mediated transformation. Moreover, A-Raf KD abrogated the 3KR mutation-
mediated increase and Sirt2 KD-mediated decrease in the transformation activity of K-Ras4a-
G12V (Fig.3.20B & C), suggesting that A-Raf is important for the regulation of K-Ras4a 
transforming activity by SIRT2-dependent lysine defatty-acylation. These results further 
support the model that lysine defatty-acylation by SIRT2 enhances the recruitment of A-Raf to 
K-Ras4a at endomembranes, thereby promoting oncogenic activity of K-Ras4a.  
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Figure 3.20 A-Raf mediates the regulation of K-Ras4a-G12V transforming activity by lysine fatty 
acylation. (A) Western blot analysis of A-Raf, Sirt2 and FLAG in NIH3T3 cells expressing Mock, 
FLAG-K-Ras4a-G12V or -G12V-3KR with Ctrl or SIRT2 KD, and Ctrl or A-Raf KD. (B) Images 
showing anchorage-independent growth of NIH3T3 cells stably expressing the K-Ras4a-G12V or -
G12V-3KR with Ctrl or Sirt2 KD, and Ctrl or A-Raf KDs. (C) Quantification of the relative colony 
numbers in (B) The y axis represents colony numbers relative to that of the Sirt2 or A-Raf control KD 
cells expressing K-Ras4a-G12V. Statistical evaluation was by unpaired two-tailed Student’s t test. Error 
bars represent SEM in five biological replicates. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant. 
Representative images are shown. 
3. Discussion  
Protein lysine fatty acylation was discovered over two decades ago 4-8. However, very little 
is known about its functional significance. Our current study furnishes a model where K-Ras4a 
is fatty acylated on lysine residues at its C-terminal HVR, and the removal of lysine fatty 
acylation by SIRT2 facilitates its endomembrane localization and interaction with A-Raf, thus 
enhancing its transforming activity (Fig. 3.21). These findings demonstrate that a Ras protein is 
modified and regulated by a previously under-appreciated PTM, lysine fatty acylation, which 
expands not only the regulatory scheme for Ras proteins, but also the biological significance of 
lysine fatty acylation. Moreover, our study reveals the first lysine defatty-acylation substrate for 
SIRT2 and uncovers the physiological relevance of SIRT2 as a lysine defatty-acylase12,14,15.  
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Figure 3.21 Model for the regulation of K-Ras4a by SIRT2-mediated removal of lysine fatty 
acylation. Removal of lysine fatty acylation by SIRT2 facilitates K-Ras4a to localize to endomembranes 
and interact with A-Raf, and thus enhances its activity to transform cells. 
We found that H-Ras and K-Ras4a possess lysine fatty acylation that could be hydrolyzed 
by sirtuins in vitro or in cells. Although our attempt to detect N-Ras lysine fatty acylation by 
MS was not successful, the N-Ras-K169/170R (2KR) mutant presented decreased NH2OH-
resisitant fatty acylation compared with WT, suggesting that N-Ras might be lysine fatty 
acylated (Fig. 3.2C & D). While cysteine palmitoylation of Ras proteins was discovered almost 
three decades ago71, lysine fatty acylation of Ras was not identified for several reasons. First, 
lysine fatty acylation did not emerge as a physiologically significant modification until recent 
years. Correspondingly, the possibility of lysine fatty acylation on Ras proteins had not been 
investigated previously. Second, previously people only focused on Ras cysteine palmitoylation 
because mutations of the palmitoylated cysteine to serine abolished the palmitoylation of H-
Ras72, N-Ras72 and K-Ras4a19 based on 3H-palmitic acid labeling. Therefore, lysine fatty 
acylation of Ras proteins might have been missed based on the mutagenesis results. Similar to, 
but slightly different from these previous reports, we found that mutating the plamitoylated 
cysteine of K-Ras4a decreased lysine fatty acylation by nearly 90% (Fig. 2.10A) but not 
completely. A similar effect of the palmitoylated cysteine to serine mutation was also observed 
for R-Ras225. Last, although the palmitoylation sites for Ras proteins were characterized with 
the chemoproteomic approaches based on acyl-biotin exchange (ABE)23,73 or acyl-resin-assisted 
capture (acyl-RAC)3,74, these approaches are cysteine-centric and do not allow identification of 
amide-linked fatty acylation. Direct site identification of palmitoylation has been challenging 
owing to the low abundance and high hydrophobicity of the modified peptides, which are easily 
lost during sample preparation1. Our current study highlights the regulation of Ras proteins by 
lysine fatty acylation and suggests that additional studies are required to understand the 
regulation of this important class of proteins. Many Ras superfamily small GTPases contain 
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lysine-rich sequences at their C-termini. It is therefore of great interest to us to investigate 
whether lysine fatty acylation could act as a general regulatory mechanism for many Ras-related 
small GTPases.  
The discovery of lysine fatty acylation on K-Ras4a raises the question of the relative 
abundance of lysine versus cysteine fatty acylation. Semi-quantification of the fluorescence 
intensity from Alk14 labeling results enables us to roughly estimate the stoichiometry of lysine 
fatty acylation. Based on this, K-Ras4a exhibits nearly 50% of lysine fatty acylation relative to 
total fatty acylation (Fig. 3.2C). Therefore, the ratio of cysteine palmitoylation to lysine fatty 
acylation may be close to 1:1 on K-Ras4a. The 3KR mutation decreased K-Ras4a lysine fatty 
acylation by about 50% (Fig. 3.2F & 3.9A), suggesting that the C-terminal lysine fatty acylation 
regulated by SIRT2 is around 50% of the lysine fatty acylation and 25% of the total fatty 
acylation. Regarding endogenous K-Ras4a, by quantifying the K-Ras4a western blot signal 
from the streptavidin beads and supernatant in Fig. 3.6F, we estimated that about 28% and 50% 
of the fatty acylated K-Ras4a is lysine fatty acylated in Ctrl KD and SIRT2 KD HCT116 cells, 
respectively. Unfortunately, precise quantitation of protein fatty acylation still remains a 
significant unsolved challenge and we could not determine the ratio of fatty acylated versus 
unmodified K-Ras4a. 
To study the physiological function of K-Ras4a lysine fatty acylation, we utilized the K-
Ras4a-3KR mutant in combination with SIRT2 KD. The lysine-to-arginine mutant maintains 
the positive charge of the polybasic patch, which makes it a good lysine fatty acylation-deficient 
mimic. Recently, Zhou et al. reported that lysine and arginine residues are not equivalent in 
determining the membrane lipid binding specificity of K-Ras4b C-terminus, which raises the 
possibility that the effect of 3KR mutation might not be solely due to lack of lysine fatty 
acylation75. Likewise, changes in the SIRT2 KD cells could be mediated through other 
substrates for SIRT2. Therefore, it is critical to employ both the 3KR mutant and SIRT2 KD to 
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rule out these possibilities. SIRT2 KD enhances the lysine fatty acylation of K-Ras4a WT but 
not 3KR mutant. Thus, if a biological effect is due to lysine fatty acylation, SIRT2 should have 
a great impact on the effect of K-Ras4a WT than that of the 3KR mutant. Of note, H-Ras, which 
shares similar properties with K-Ras4a, but is not a lysine defatty-acylase target for SIRT2, also 
serves as a good control for the effect of SIRT2 KD. Indeed, SIRT2 KD repressed the 
endomembrane localization, transforming activity, and A-Raf binding of K-Ras4a WT more 
than that of K-Ras4a 3KR or H-Ras, indicating that SIRT2-dependent lysine defatty-acylation 
facilitates endomembrane localization of K-Ras4a, enhances its interaction with A-Raf, and thus 
promotes cellular transformation.  
Goodwin et al. previously reported that cysteine depalmitoylated H-Ras and N-Ras traffic 
to and from the Golgi complex by a nonvesicular mechanism, and suggested a model where 
cysteine palmitoylation traps Ras on membranes, enabling Ras to undergo vesicular transport 
76. In line with this, Tsai et al. 19 and we observed that the K-Ras4a-C180S mutant, which 
possesses no cysteine palmitoylation and little lysine fatty acylation localizes to ER/Golgi-like 
internal membranes (Fig. 3.11H). Differently, we found that removal of the lysine fatty 
acylation by SIRT2, which results in K-Ras4a with only cysteine palmitoylation, promotes 
endomembrane localization of K-Ras4a (Fig. 3.11B). This evidence supports the model that 
cysteine palmitoylation enables K-Ras4a to undergo vesicular transport, whereas lysine fatty 
acylation blocks K-Ras4a translocation from the PM to endomembranes (Fig. 3.21). 
Furthermore, the C180S mutant suppressed K-Ras4a-G12V-mediated anchorage-independent 
growth and activation of MAPK signaling19,20. In contrast, the 3KR mutant increased K-Ras4a-
G12V-mediated anchorage-independent growth (Fig. 3.13), exhibited no effect on MAPK 
signaling (Fig. 3.16), but activated A-Raf instead (Fig. 3.18). Considering the possibility that 
lysine fatty acylation largely relies on cysteine palmitoylation to occur, it is likely that the 
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reversible lysine fatty acylation adds a layer of regulation for K-Ras4a above that of cysteine 
palmitoylation. 
In the GTP-bound active form, Ras proteins bind directly to the Ras binding domain (RBD) 
of Raf, then form secondary interactions with a cysteine-rich domain (CRD). Although the RBD 
and CRD are highly conserved in all Raf isozymes, there is evidence for different binding 
affinities for Ras proteins to the individual Raf proteins77,78. For example, Weber et al. reported 
that A-Raf presents significantly lower binding affinities to H-Ras-G12V as compared to C-Raf 
because the Ras-binding interface of C-Raf differs from A-Raf by a conservative arginine to 
lysine exchange at residue 59 or 22 respectively79. Furthermore, Williams et al.80 and Fischer et 
al.81 found that farnesylation of H-Ras is required for its binding to C-Raf but not B-Raf, 
implying the involvement of Ras C-terminal PTM in the regulating Ras-Raf interactions. Based 
on these previous studies, it is likely that the C-terminal PTM of K-Ras4a regulates its 
interaction with Raf isozymes and that lysine fatty acylation may inhibit the binding of K-Ras4a 
to A-Raf but not to B-Raf and C-Raf. 
Mutations that activate Ras are found in about 30% of all human tumors screened. KRAS 
mutations, which affects both K-Ras4a and K-Ras4b, occur most frequently, accounting for 86% 
of RAS-driven cancers82. Though K-Ras4a is homologous to the transforming cDNA identified 
in Kirsten rat sarcoma virus83, its function and regulation is less characterized compared to K-
Ras4b. Recent studies showed that K-Ras4a is widely expressed in human cancers, suggesting 
that K-Ras4a plays a significant role in KRAS-driven tumors19,20. Our findings reveal that K-
Ras4a is regulated by SIRT2-dependent lysine defatty-acylation. Depletion of SIRT2 increased 
lysine fatty acylation and diminished oncogenic transforming activity of K-Ras4a, suggesting 
that interference with K-Ras4a lysine fatty acylation could be an approach to anti-K-Ras therapy.  
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The seven mammalian sirtuins, SIRT1-7, are implicated in various biological pathways and 
are considered potential targets against a number of human diseases55. So far, the known 
biological functions of sirtuins have been mainly attributed to their deacetylase activities. 
Although sirtuins are increasingly recognized as lysine deacylases in addition to deacetylases, 
the biological significance of sirtuins as lysine deacylases remains largely unknown84. Our work 
here identifies the first physiological defatty-acylation substrate for SIRT2. Since protein acyl 
lysine modifications likely use acyl-CoA molecules as the acyl donors, the cellular metabolic 
state can affect acyl lysine PTMs by altering the concentration of acyl-CoA molecules. Sirtuins 
requires NAD as a co-substrate and the NAD level is regulated by cellular metabolism. Thus 
SIRT2 may provide an additional link between K-Ras4a signaling and cellular metabolism. 
Given that Ras proteins play critical roles in many human cancers, SIRT2, as a Ras regulator, 
may be an important therapeutic target for cancer, which is consistent with several recent 
reports50,53,54,57,58,85-87. The physiological and pathophysiological roles of SIRT2 thus merit 
further investigation.  
4. Methods 
Reagents, antibodies and plasmids. Chemicals from commercial sources were obtained 
in the highest purity available. Alk14, Rhodamin-N3 and Biotin-N3 were synthesized as 
previously reported88. Trichostatin A (TSA, T8552), protease inhibitor cocktail (P8340), 
phosphatase inhibitor cocktail (P0044), Azide-PEG3-biotin (762024), Tris[(1-benzyl-1H-1,2,3-
triazol-4-yl)methyl]amine (TBTA, 678937), Tris(2-carboxyethyl)phosphine (TCEP, 75259), 
hydroxylamine (NH2OH, 159417), NAD (NAD100-RO), Puromycin (P8833), Crystal Violet 
(C0775), low-melting point agarose (A0701), triple FLAG peptide (F4799), L-lysine (L9037), 
L-arginine (A8094), [13C6, 15N2]-L-lysine (608041) and [13C6, 15N4]-L-arginine (608033) were 
purchased from Sigma-Aldrich. The anti-human SIRT1 (05-1243), anti-RalA (ABS223) and 
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anti-Ras (Y13-259, OP01A) antibodies were from EMD Chemicals Inc. The anti-SIRT2 
(ab134171), Transferrin Receptor (ab84036) antibodies were from Abcam. The anti-SIRT2 
(12650), Phospho-Erk1/2 (Thr202/204) (9101), Erk1/2 (4696), Phospho-Akt (Thr308) (9275), 
Phospho-Akt (Ser473) (9271), Akt (4691), Phospho-SAPK/JNK (Thr182/Tyr185) (4668), 
SAPK/JNK (9252), Syntaxin 6 (STX6, 2869), EEA1 (3288) antibodies were purchased from 
Cell Signaling Technology. The anti-β-Actin (sc-4777), K-Ras4a (sc-522), A-Raf (sc-408), B-
Raf (sc-166), C-Raf (sc-227), Na/K-ATPase (sc-21712), GAPDH (sc-47724), the normal rat 
IgG (sc-2026) and the goat anti-mouse/rabbit/Rat IgG-horseradish peroxidase-conjugated 
antibodies were purchased from Santa Cruz Biotechnology. The anti-Acetyl Lysine antibody 
(ICP0380) was obtained from Immunechem. The anti-FLAG M2 antibody conjugated with 
horseradish peroxidase (A8592) and the anti-FLAG M2 affinity gel (A2220) were from Sigma-
Aldrich. Enzyme-linked chemiluminescence (ECL) plus (32132) western blotting detection 
reagent, Cy3-conjugated goat anti-rabbit IgG (H+L) secondary antibody (A10520) and the high 
capacity Streptavidin agarose (20357) were purchased from Thermo Fisher Scientific. FuGene 
6 (E2692) transfection reagent and sequencing grade modified trypsin (V5111) were purchased 
from Promega. 32P-NAD+ was purchased from PerkinElmer. Saponin (S0019-25G) was from 
TCI America. Sep-Pak C18 cartridge was purchased from Waters. 
The pLKO.1-puro lentiviral shRNAs constructs for luciferase and human SIRT1, SIRT2, 
and mouse SIRT2 were purchased from Sigma-Aldrich. Luciferase shRNA (SHC007), human 
SIRT1 shRNAs (#1, TRCN0000018980, #2, TRCN0000018981), human SIRT2 shRNAs (#1, 
TRCN0000040219, #2, TRCN0000310335), mouse SIRT2 shRNA (TRCN0000012118), 
mouse A-Raf shRNAs (#1, TRCN0000022612, #2, TRCN0000022610) were used. The human 
K-RAS4A expression vector with N-terminal FLAG tag was obtained by RT-PCR amplification 
of K-RAS4A and subcloning via EcoRI and SalI sites into pCMV5 vector. The human K-RAS4A 
lentiviral vector was obtained by inserting FLAG-K-RAS4A into pCDH-CMV-MCS-EF1-Puro 
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vector between the EcoRI and NotI sites. The human H-RAS lentiviral vector was obtained by 
inserting FLAG-HRAS into pCDH-CMV-MCS-EF1-Puro vector between the EcoRI and 
BamHI sites. The GFP-K-Ras4a and GFP-H-Ras expression vectors were constructed by 
inserting K-RAS4A and H-RAS cDNA into pGFP1-C1 vector between the BglII and SalI sites, 
respectively. The human STX6 expression vector with N-terminal FLAG tag was constructed 
by inserting FLAG-STX6 cDNA into pCMV-tag-4a vector between the EcoRI and XhoI sites. 
To generate the expression vector for human SIRT2 with C-terminal FLAG tag, full-length 
human SIRT2 cDNA was amplified by PCR and inserted into pCMV-tag-4a vector between the 
BamHI and XhoI sites. The expression vectors for H-Ras, N-Ras, K-RAS4A mutants and 
SIRT2-H187Y were generated by QuikChange site-directed mutagenesis89. The DsRed cDNA 
without stop codon was inserted using NotI and BamHI sites into pCMV-tag-4a to generate 
pCMV-tag-4a-DsRed-C vector that enables cloning of gene of interest with N-terminal DsRed. 
The DsRed-RBD expression vector was constructed by inserting cDNA coding the Ras-binding 
domain of human Raf1 (aa51-131) into pCMV-tag-4a-DsRed-C vector between EcoRV and 
XhoI sites. The DsRed-A-Raf expression vector was generated by inserting mouse Araf cDNA 
into pCMV-tag-4a-DsRed-C vector using BamHI and EcoRI sites. DsRed-GalT plasmid90 was 
obtained from Dr. Yuxin Mao (Cornell Univeristy, Ithaca, NY). Expression vectors for 
mCherry-Sec61 beta (Addgene plasmid #49155)91, mCherry-Rab11 (Addgene plasmid #55124), 
DsRed-Rab7 (Addgene plasmid #12661)92 and Lamp1-RFP (Addgene plasmid #1817)93 were 
gifts from Gia Voeltz, Michael Davidson, Richard Pagano and Walther Mothes, respectively.  
Cell culture, transfection and transduction. Human HEK293T cells were grown in 
DMEM media (11965-092, Gibco) with 10% heat inactivated (HI) fetal bovine serum (FBS, 
26140079, Gibco). Mouse embryonic fibroblast NIH3T3 cells were grown in DMEM media 
supplemented with non-essential amino acids (11140050, Gibco) and 15% HI FBS. Human 
HCT116 cells were grown in McCoy’s 5A media (16600082, Gibco) with 10% HI FBS. The 
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cell lines were purchased from American Type Culture Collection (ATCC). The cell lines were 
not further authenticated after purchase from ATCC. All cell lines were tested for and showed 
no mycoplasma contamination. 
For SILAC experiment, ‘light’ NIH3T3 cells were maintained in DMEM media for SILAC 
(88420, Thermo Fisher Scientific) supplemented with 100 mg/L [12C6, 14N2]-L-lysine, 100 mg/L 
[12C6, 14N4]-L-arginine and 15% dialyzed FBS (26400036, Thermo Fisher Scientific); ‘heavy’ 
NIH3T3 cells were cultured in DMEM media for SILAC supplemented with 100 mg/L [13C6, 
15N2]-L-lysine, 100 mg/L [13C6, 15N4]-L-arginine and 15% dialyzed FBS. Cells were cultured in 
SILAC media for at least six doubling times to achieve maximum incorporation of ‘labeled’ 
amino acids into proteins before the interactome study was performed. 
To transiently overexpress proteins of interest in cells, the expression vectors were 
transfected into cells using FuGene 6 according to the manufacturer’s protocol. Empty vector 
was transfected as a negative control. Lentiviral infection for overexpressing H-Ras, K-Ras4a 
WT and mutants or knocking down SIRT1, SIRT2 and A-Raf was performed as previously 
described 9,53. Puromycin (3 µg/mL for NIH3T3 cells, 1.5 µg/mL for HEK293T cells) was added 
to the cell culture media to select NIH3T3 cells with stable overexpression of Mock (pCDH 
empty vector control), K-Ras4a-G12V, K-Ras4a-G12V-3KR or H-Ras-G12V as well as 
HEK293T cells with stable luciferase KD (Ctrl KD), SIRT1 KD, or SIRT2 KD.  
Immunoprecipitation of Alk14-labeled proteins of interest. HEK293T cells (parental 
cells, luciferase KD, SIRT1 KD, or SIRT2 KD) were transiently transfected to express FLAG-
tagged protein of interest overnight. The cells were then cultured with fresh medium containing 
50 µM Alk14 for 6 h. Cells were collected and lysed in 1% NP-40 lysis buffer (25 mM Tris-HCl 
pH 8.0, 150 mM NaCl, 10% glycerol, 1% Nonidet P-40) with protease inhibitor cocktail. The 
supernatant was collected after centrifugation at 16,000g for 20 min at 4 °C. Protein 
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concentration was determined by Bradford assay (23200, Thermo Fisher Scientific). 0.5-1 mg 
cell lysate was incubated with 10 µL suspension of anti-FLAG M2 affinity gel for 2 h at 4 °C. 
The affinity gel was then centrifuged at 500 g for 2 min at 4 °C, washed three times with 1 mL 
IP washing buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.2% Nonidet P-40) and used for 
further experiments. 
Detection of fatty acylation on protein of interest by on-beads click chemistry and in-
gel fluorescence. The immunopurified protein with Alk14 labeling was suspended in 20 µL IP 
washing buffer for click chemistry. Rh-N3 (3 µL of 1 mM solution in DMF, final concentration 
150 µM) was added to the above suspension, followed by the addition of TBTA (1 µL 10 mM 
solution in DMF, final concentration 500 µM), CuSO4 (1 µL of 40 mM solution in H2O, final 
concentration 2 mM), and TCEP (1 µL of 40 mM solution in H2O, final concentration 2 mM). 
The click chemistry reaction was allowed to proceed at room temperature for 30 min. The 
reaction mixture was mixed with 10 µL of 6 × protein loading buffer and heated at 95 °C for 
10 min. After centrifugation at 16,000 g for 2 min at room temperature, 15 µL of the supernatant 
was treated with NH2OH (pH 8.0, 1 µL of 5 M solution in H2O, final concentration 300 mM) or 
equivalent volume of water (negative control) at 95 °C for 7 min. The samples were resolved by 
SDS-PAGE. Rhodamine fluorescence signal was recorded by Typhoon 9400 Variable Mode 
Imager (GE Healthcare Life Sciences, Piscataway, NJ) with setting of Green (532 nm)/580BP30 
PMT 500 V (normal sensitivity). Fiji software94 was used for quantification of the fluorescence 
intensity. Signal intensity of in-gel fluorescence was normalized with respect to that of the 
corresponding FLAG western blot. 
Defatty-acylation of K-Ras4a by sirtuins in vitro. The Plasmodium falciparum Sir2A 
(PfSir2A)26, the human SIRT195, SIRT253, SIRT395 and SIRT69 were expressed as previously 
described. The immunoprecipated Ras with Alk14 labeling on anti-FLAG affinity gel was 
suspended in 25 µl of assay buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 2 mM MgCl2, 1 
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mM DTT) with 10 µM of PfSir2A or 5 µM of SIRT1, SIRT2, SIRT3, SIRT6 or the 
corresponding amount of BSA and with or without 1 mM NAD and incubated at 37 °C for 30 
min (SIRT2) or 1 h (PfSir2A, SIRT1, 3 and 6). The reaction was stopped by washing the affinity 
gel using 1 mL of IP washing buffer for 3 times. On-bead click chemistry and in-gel 
fluorescence were carried out as described above. 
High-performance liquid chromatography (HPLC)-based SIRT2 activity assay. 
SIRT2 or SIRT2-H187Y (1 µM) was incubated in 60 µL of reaction buffer (20 mM Tris, pH 
8.0, 1 mM DTT, 1 mM NAD) with 32 µM acetyl H3K9, myristoyl H3K9, or myristoyl K-
Ras4a-C180 peptides, respectively, at 37°C for 10 min (deacetylation) or 20 min 
(demyristoylation). Reactions was quenched with 60 µL ice-cold acetonitrile and spun down at 
18,000 g for 10 min to remove the precipitated protein. The supernatant was then analyzed by 
HPLC on a Kinetex XB-C18 column (100 A, 75 mm × 4.6 mm, 2.6 µm, Phenomenex). The 
peak areas were integrated and the conversion rate was calculated from the ratio of the free 
H3K9 peptide peak area over the total peak areas of the substrate and product peptides. 
Western blot. Western blot analysis was performed as described previously9. The proteins 
of interest were detected using ECL plus and visualized using the Typhoon 9400 Variable Mode 
Imager (GE Healthcare). Quantification of signal intensity from western blots was done using 
Fiji software. To assess the effect of lysine fatty acylation on the signaling output of K-Ras4a-
G12V through Erk, Akt and Jnk, NIH3T3 cells stably expressing Mock, FLAG-K-Ras4a-G12V 
or -G12V-3KR were infected with lentivirus carrying luciferase (Ctrl) or mouse Sirt2 shRNA 
for 3 days, collected and lysed in 1% NP-40 lysis buffer with protease inhibitor cocktail and 
phosphatase inhibitor cocktail. Cell lysates were then subjected to western blot for the analyses 
of indicated proteins.  
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To detect acetyl lysine on K-Ras4a, HEK293T cells with stable Ctrl KD or SIRT2 KD were 
transfected with empty vector or pCMV5-K-RAS4A overnight. The cells were then treated with 
ethanol or trichostatin A (TSA, 1 µM) for 1 hr. The cells were collected and lysed in 1% NP-40 
lysis buffer with protease inhibitor cocktail. Cell lysates (~3 mg), with/without overexpression 
of K-Ras4a, were incubated with 10 µL of anti-FLAG M2 affinity gel suspension for 2 h at 4 °C. 
The affinity gel was washed three times with 1 mL of IP washing buffer and then heated in 15 
µL of 2 × protein loading buffer at 95 °C for 10 min. The supernatant was then resolved by SDS-
PAGE and the acetylation of K-Ras4a was examined by western blot using anti-acetyllysine 
antibody after transfer to a PVDF membrane. Total cell lysates from TSA-treated HEK293T 
cells were used as a positive control for the acetyllysine blot. After recording the acetyl-lysine 
signal, the PVDF membrane was stained with Coomassie blue to detect K-Ras4a protein. A 
western blot using anti-FLAG antibody was carried out in parallel to demonstrate equal loading 
of K-Ras4a. 
 Subcellular fractionation. HEK293T cells were transfected with pCMV5-K-RAS4a and 
cultured for overnight before being collected. Cell pellets were re-suspended in subcellular 
fraction buffer (250 mM Sucrose, 20 mM HEPES, pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 1 mM 
EDTA, 1 mM EGTA and 1 mM DTT) containing protease inhibitor cocktail and homogenized 
on ice by 10 passes through a 25-gauge syringe needle. Nuclei and intact cells were removed 
by centrifugation at 3,000 rpm for 5 min. Mitochondrial fraction was removed by centrifuging 
the postnuclear supernatant at 8,000 rpm for 5 min. The supernatant was ultracentrifuged at 
40,000 rpm for 1 hr.  The resulting supernatant (cytosol fraction) was concentrated through the 
filter. The pellet (membrane fraction) was washed with subcellular fraction buffer, re-
centrifuged for 45 min and dissolved in 4% SDS lysis buffer (4% SDS, 50 mM triethanolamine 
pH 7.4, and 150 mM NaCl). Equivalent portions of the cytosol and membrane fractions were 
then subjected to western blot analyses.  
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Co-Immunoprecipitation. To examine the interaction between FLAG-tagged K-Ras4a 
and SIRT2, HEK293T cells transfected with empty vector or pCMV5-FLAG-K-RAS4A were 
cultured overnight, collected and lysed in 1% NP-40 lysis buffer with protease inhibitor cocktail. 
To examine the interaction between FLAG-tagged K-Ras4a-G12V/K-Ras4a-G12V-3KR or H-
Ras-G12V and A-Raf/B-Raf/C-Raf (Raf1)/p110α/RalGDS, NIH3T3 cells stably expressing 
Mock, FLAG-K-Ras4a-G12V, -G12V-3KR, or FLAG-H-Ras-G12V were infected with 
lentivirus carrying luciferase (Ctrl) or mouse Sirt2 shRNA for 3 days, collected and lysed in 1% 
NP-40 lysis buffer with protease inhibitor cocktail. For both experiments, total cell lysates (2 mg 
of total protein for detecting SIRT1/2, 50 µg for A-Raf and c-Raf, 1 mg for B-Raf, p110α and 
RalGDS, determined by Bradford assay) were incubated with 10 µL suspension of anti-FLAG 
M2 affinity gel for 2 hr at 4 °C. The resulting affinity gel was washed three times with 1 mL IP 
washing buffer and heated in protein loading buffer (2 × final concentration) at 95 °C for 10 min. 
Western blot was then performed to detect levels of the indicated proteins.  
Detection of lysine fatty acylation on K-Ras4a using the 32P-NAD assay. The 32P-NAD 
assays were carried out as described previously with minor modification30. HEK293T cells were 
transfected with empty pCMV5 vector or pCMV5-K-RAS4A overnight and lysed in 1% NP-40 
lysis buffer with protease inhibitor cocktail. For each reaction, cell lysates (3 mg of total protein, 
determined by Bradford assay) were incubated with 10 µL suspension of anti-FLAG M2 affinity 
gel for 2 hr at 4 °C. The affinity gel was washed three times with 1 mL of IP washing buffer. 
The resulting anti-FLAG affinity gel or the synthetic acetyl and myristoyl H3K9 peptides30 (25 
µM, positive control) were mixed with 10 µL solutions containing 1 µCi 32P-NAD, 50 mM Tris-
HCl pH 8.0, 150 mM NaCl, 1 mM DTT. The reactions were incubated with 1 µM BSA (negative 
control), SIRT2, or SIRT2-H187Y at 37°C for 30 min. A total of 2 µL of each reaction were 
spotted onto silica gel TLC plates and developed with 7:3 ethanol:ammonium bicarbonate (1 M 
aqueous solution). After development, the plates were air-dried and exposed to a 
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PhosphorImaging screen (GE Healthcare). The signal was detected using Typhoon 9400 
Variable Mode Imager (GE Healthcare).  
Biotin pull-down of lysine fatty acylated endogenous K-Ras4a. The assay was carried 
out as previously described with some modifications 31. Briefly, HCT116 cells were infected 
with lentivirus carrying luciferase (Ctrl) or SIRT2 shRNA for 3 days and treated without or with 
Alk14 (50 µM) for 6 hrbefore being collected. Total proteins were then extracted using 1% NP-
40 lysis buffer with protease inhibitor cocktail. 10 mg of total protein extract was subjected to 
click reaction with 100 µM Biotin-N3, 500 µM TBTA, 1 mM CuSO4 and 1 mM TCEP in a final 
volume of 5 mL. The reaction was allowed to proceed at room temperature for 1 hr. Proteins 
were precipitated by adding 4 volumes of ice-cold methanol, 3 volumes of water, and 1.5 
volumes of chloroform. Precipitated proteins were pelleted by centrifugation (4,500× g, 20 min, 
4 °C), washed twice with 50 mL of ice-cold methanol and air-dried. The protein pellet was 
suspended in 4% SDS buffer (4% SDS, 50 mM triethanolamine pH 7.4, and 150 mM NaCl, 10 
mM EDTA). The solubilized protein mixture was diluted to 1% SDS with 1% Brij 97 (in 50 
mM triethanolamine pH 7.4, and 150 mM NaCl) and incubated with streptavidin agarose (0.2 
ml slurry for 1 mg of protein) for 1 hrat room temperature. The streptavidin beads were washed 
three times with 10 mL of 1% SDS in PBS buffer. The streptavidin beads were incubated with 
1 M NH2OH (pH 8.0) in 300 µL of 1% SDS PBS buffer for 1 hrat room temperature to elute 
proteins with only cysteine fatty acylation. The resulting supernatant was concentrated to 20 µL 
final volume using the Amicon Ultra-0.5 Centrifugal Filter (UFC501008, EMD Millipore). The 
resulting streptavidin beads were washed three times with 1% SDS PBS buffer. Both the 
concentrated supernatant and washed beads were heated in protein loading buffer (2 × final 
concentration) at 95 °C for 10 min and subjected to western blot analyses. 
Confocal microscopy. Cells were seeded in 35-mm glass bottom dishes (MatTek) and 
transfected with relevant constructs overnight.  
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For live cell imaging, cells were incubated in the Live Cell Imaging Solution (A14291DJ, 
Thermo Fisher Scientific) and imaged with a Zeiss 880 confocal/multiphoton inverted 
microscope (Carl Zeiss MicroImaging, Inc., Thornwood, NY) in a humidified metabolic 
chamber maintained at 37 °C and 5% CO2. For time-lapse movies, 60 single section images 
were recorded at 1 sec intervals for 1 min.  
For immunofluorescence, cells were rinsed with 1 × PBS twice and fixed with 4% 
paraformaldehyde (v/v in 1 × PBS) for 15 min. The fixed cells were washed twice with 1 × PBS, 
permeabilized and blocked with 0.1% Saponin/5% BSA/1 × PBS for 30 min. The cells were 
then incubated overnight at 4 °C in dark with indicated primary antibody at 1/50 - 1/100 dilution 
(in 0.1% Saponin/5% BSA/1 × PBS). Cells were washed with 0.1% Saponin/1 × PBS three 
times and incubated with Cy3-conjugated goat anti-rabbit IgG (H+L) secondary antibody at 
1/1000 dilution (in 0.1% Saponin/5% BSA/1 × PBS) at room temperature in dark for 1 hr. 
Samples were washed with 0.1% Saponin/1 × PBS three times and mounted with Fluoromount-
G® (0100-01) from SouthernBiotech before imaging with Zeiss LSM880 inverted confocal 
microscopy. Images were processed with Fiji software. 
For colocalization analyses of GFP-K-Ras4a WT or -3KR with various intracellular 
membrane markers, live cell imaging was performed for colocalization with mCherry-Sec61, 
DsRed-GalT, mCherry-Rab11, DsRed-Rab7 and Lamp1-RFP; immunofluorescence was 
performed for colocalization with STX6 (1/50 dilution for anti-STX6 antibody) and EEA1 
(1/100 dilution for anti-EEA1 antibody).  
Quantitative analyses of colocalization and fluorescence intensity. Fiji software was 
used for quantification. To quantify the degree of cytoplasmic colocalization, background was 
subtracted, then the cytoplasm area was selected and quantified for each cell examined. 
Pearson’s correlation coefficient96 was calculated using Fiji plug-in Coloc2 program 
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(http://fiji.sc/Coloc_2) on a single plane between the two indicated fluorescent signals. To 
quantify fluorescence intensity, background was subtracted and the cytoplasm area or the whole 
cell was selected for integrated signal intensity quantification. Relative cytoplasm with respect 
to whole cell fluorescence intensity was presented. 
Soft agar colony formation assay. To assess the effect of Ctrl or Sirt2 KD on K-Ras4a-
G12V, -G12V-3KR or H-Ras-G12V-mediated anchorage-independent growth, NIH3T3 cells 
with stable overexpression of Mock, K-Ras4a-G12V or -G12V-3KR were infected with Ctrl 
shRNA- or Sirt2 shRNA-carrying lentivirus for 6 hrand cultured in complete medium for 
another 72 hrbefore being seeded for soft agar colony formation assay.  
To determine the effect of Ctrl or A-Raf KD, NIH3T3 cells with stable overexpression of 
Mock (pCDH empty vector control), K-Ras4a-G12V or -G12V-3KR were first infected with 
Ctrl shRNA- or Sirt2 shRNA-carrying lentivirus for 6 hr and then with Ctrl shRNA- or A-Raf 
shRNAs for another 6 hr. The infected cells were then cultured in complete medium for another 
72 hr before being seeded for soft agar colony formation assay. 
0.6% base low-melting point agarose (LMP) and 0.3% top LMP were prepared by mixing 
1.2% LMP in H2O and 0.6% LMP in H2O, respectively, with 2 × complete medium in 1:1 (v/v) 
ratio. 1.5 mL of 0.6% base LMP was added to each well of 6-well plate and allowed to solidify 
for 30 min at room temperature. Then 5.0 × 103 cells were resuspended in 0.3% LMP top LMP 
and plated onto 6-well plate pre-coated with the base LMP. 150 µL of complete medium was 
added on top of the 0.3% LMP and refreshed every 3 days. After 14 days of culture, colonies 
were stained with 0.1% crystal violet (m/v in 25% methanol) for 30 min, rinsed with 50% 
methanol, and counted. 
Cell proliferation assay. NIH3T3 cells with stable overexpression of Mock, K-Ras4a-
G12V, or -G12V-3KR were seeded in 12-well plate at a density of 1.5 × 104 cells/well 24 hr 
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before being infected with luciferase (Ctrl) shRNA- or Sirt2 shRNA-carrying lentivirus for 0 or 
5 days. After knocking down Sirt2 for the indicated time, cells were washed with 1 × PBS, fixed 
with ice-cold methanol for 10 min and then stained with 0.25% crystal violet (m/v, in 25% 
methanol) for 10 min. The stained cells were washed with running distilled water, air-dried and 
solubilized in 200-800 µL of 0.5% SDS in 50% ethanol. Absorbance of the resulting solution 
was measured at 550 nm. 
Transwell migration assay. NIH3T3 cells with stable overexpression of Mock, K-Ras4a-
G12V or -G12V-3KR were infected with Ctrl shRNA- or Sirt2 shRNA-carrying lentivirus for 
6 hr and cultured in complete medium for another 72 hr. Cells were cultured in serum-free 
medium for 12 hr before the assay. The assay was performed in 24-well Transwell plate with 8 
mm polycarbonate sterile membrane (Corning Incorporated). Cells were plated in the upper 
chamber (20,000 cells/insert) in 200 µL of serum-free medium. Inserts were then placed in wells 
containing 600 µL of medium supplemented with 10% FBS. 12 hr later, cells on the upper 
surface of the filter were detached with a cotton swab and cells on the lower surface of the filters 
were fixed with ice-cold methanol for 10 min and stained with 0.1% crystal violet for 15 min. 
The cells were then rinsed with distilled water, photographed and counted. Migration was 
quantified by counting the migrated cells in ten random microscopic fields. 
Active Ras pull-down and detection. Ras activity was determined using a Ras binding 
domain of Raf1 (RBD) pull-down assay kit (16117, Thermo Fisher Scientific) by following the 
manufacturer’s instructions. Briefly, to determine RBD binding of K-Ras4a WT and -3KR in 
Ctrl or SIRT2 KD cells, HEK293T cells expressing FLAG-K-Ras4a WT or 3KR were infected 
with luciferase (Ctrl) shRNA- or human SIRT2 shRNA-carrying lentivirus for 6 hr and cultured 
in complete medium for another 72 hr. Cells were then serum-starved overnight and treated with 
100 ng/mL EGF for 0, 5 and 15 min. At the end of treatment, cells were rinsed with ice-cold 1 
× PBS and scraped on ice in lysis buffer containing 25mM Tris pH 7.2, 150 mM NaCl, 5 mM 
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MgCl2, 1% NP-40 and 5% glycerol and 1 × protease inhibitor cocktail. The samples were 
collected, vortexed, incubated on ice for 5 min and centrifuged at 16,000 g at 4 °C for 15 min 
to remove cellular debris. Protein concentration was measured by Bradford assay. Equal 
amounts of lysate (500 µg) were incubated with RBD-coated agarose beads at 4 °C for 1 hr. The 
beads were then washed three times with ice-cold lysis buffer, boiled for 5 min at 95 °C, and 
active Ras was analysed by western blot using Ras-specific antibodies (16117, Thermo 
Scientific). For comparison to total Ras protein, 1% of total lysates used for pull-down was 
analysed by immunoblot. 
To determine RBD binding of K-Ras4a-G12V and -G12V-3KR in Ctrl or SIRT2 KD cells, 
HEK293T cells were transfected with pCMV5-FLAG-K-Ras4a-G12V or -G12V-3KR and 
infected with luciferase (Ctrl) shRNA- or human SIRT2 shRNA-carrying lentivirus 12 hr after 
the transfection. 72 hr later, cells were cultured in FBS-free or complete medium for another 12 
hr before being subjected to RBD pull-down as described above.  
K-Ras4a interactome by SILAC. Three SILAC experiments were performed to determine 
K-Ras4a-G12V or -G12V-3KR interacting proteins: (1) NIH3T3 cells stably overexpressing 
FLAG-K-Ras4a-G12V cultured in DMEM with [12C6, 14N2]-L-lysine and [12C6, 14N4]-L-arginine 
as “light” cells, and NIH3T3 cells stably overexpressing FLAG-K-Ras4a-G12V-3KR cultured 
in DMEM with [13C6, 15N2]-L-lysine and [13C6, 15N4]-L-arginine as “heavy” cells. (2) NIH3T3 
cells stably overexpressing FLAG-K-Ras4a-G12V-3KR cultured in DMEM with [12C6, 14N2]-
L-lysine and [12C6, 14N4]-L-arginine as “light” cells, and NIH3T3 cells stably overexpressing 
FLAG-K-Ras4a-G12V cultured in DMEM with [13C6, 15N2]-L-lysine and [13C6, 15N4]-L-arginine 
as “heavy” cells. The second group served as the reverse SILAC of the first group. (3) NIH3T3 
cells stably overexpressing FLAG-K-Ras4a-G12V and transiently transduced with luciferase 
(Ctrl) shRNA cultured in DMEM with [13C6, 15N2]-L-lysine and [13C6, 15N4]-L-arginine as 
“heavy” cells, and NIH3T3 cells stably overexpressing FLAG-K-Ras4a-G12V and transiently 
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transduced with mouse Sirt2 shRNA cultured in DMEM with [12C6, 14N2]-L-lysine and [12C6, 
14N4]-L-arginine as “light” cells. 
Cells were collected and lysed in 1% NP-40 lysis buffer containing protease inhibitor 
cocktail. Protein concentration was quantified by Bradford assay, and 8 mg of total protein from 
each sample was subjected to FLAG IP to enrich FLAG-K-Ras4a-G12V or -G12V-3KR with 
its interacting proteins. After washing the FLAG resin five times with IP washing buffer, the 
resins from ‘heavy’ and ‘light’ cells were mixed. Enriched proteins on the resin were eluted 
with triple FLAG peptide following the manufacturer’s protocol. Eluted proteins were 
precipitated with methanol/chloroform/water (4/1.5/3 volume ratio with the sample volume set 
as 1), and the protein pellets were washed twice with 1 mL ice-cold methanol. The protein 
pellets were air dried for 10-15 min, and subjected to disulfide reduction and protein 
denaturation in 100 µL of buffer containing 6 M urea, 10 mM DTT and 50 mM Tris-HCl pH 
8.0 at room temperature for 1 hr. Then iodoacetamide (final concentration 40 mM) was added 
to alkylate the proteins at room temperature for 1 hr. Subsequently, DTT (final concentration 
40 mM) was added to stop alkylation at room temperature for 1 hr. The samples were then 
diluted 7 times with buffer containing 1 mM CaCl2 and 50 mM Tris-HCl pH 8.0 and digested 
with 2 µg trypsin at 37˚C for 12 hr. Trypsin digestion was quenched with 0.2 % trifluoroacetic 
acid. Then the mixture was desalted using Sep-Pak C18 cartridge following the manufacturer’s 
protocol and subjected to liquid chromatography (LC)-MS/MS analysis.  
The lyophilized peptides were reconstituted in 2% acetonitrile (ACN) with 0.5% formic 
acid (FA) and analyzed by LTQ-Orbitrap Elite mass spectrometer coupled with nanoLC. 
Reconstituted peptides were injected onto Acclaim PepMap nano Viper C18 trap column (5 µm, 
100 µm ´ 2 cm, Thermo Dionex) for online desalting and then separated on C18 RP nano 
column (5 µm, 75 µm ´ 50 cm, Magic C18, Bruker). The flow rate was 0.3 µL/min, and the 
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gradient was 5-38% ACN with 0.1% FA from 0-120 min, 38-95% ACN with 0.1% FA from 
120-127 min, and 95% ACN with 0.1% FA from 127-135 min. The Orbitrap Elite was operated 
in positive ion mode with spray voltage 1.6 kV and source temperature 275 ˚C. Data-dependent 
acquisition (DDA) mode was used by one precursor ions MS survey scan from m/z 375 to 1800 
at resolution 120,000 using FT mass analyzer, followed by up to 10 MS/MS scans at resolution 
15,000 on 10 most intensive peaks. Collision-induced dissociation (CID) parameters were set 
with isolation width 2.0 m/z and normalized collision energy at 35%. All data were acquired in 
Xcalibur 2.2 operation software. MS1 and MS2 data were processed using Sequest HT software 
within the Proteome Discoverer 1.4.1.14 (PD 1.4, Thermo Scientific). 
Detection of lysine fatty acylation on Ras by mass spectrometry. To detect H-Ras lysine 
fatty acylation, HEK293T cells were transfected with pCMV5-H-Ras for 24 hr and treated with 
50 µM Alk14 for another 6 hr. To detect K-Ras4a lysine fatty acylation, HEK293T cells with 
stable SIRT2 KD were transfected with pCMV5-FLAG-K-Ras4a for 24 hr and treated with or 
without 50 µM Alk14 for another 6 hr. Cells were collected and lysed in 1% NP-40 lysis buffer 
with protease inhibitor cocktail. FLAG IP was then performed with 50 mg of total protein lysate 
to purify FLAG-K-Ras4a or Flag-H-Ras. After washing the FLAG resin three times with IP 
washing buffer, H-Ras or K-Ras4a was eluted by heating at 95 ºC for 10 min in buffer containing 
1% SDS and 50 mM Tris-HCl pH 8.0. After centrifuging at 15,000 g for 2 min, the supernatant 
was transferred to a new tube and was treated with 300 mM NH2OH pH 7.4 at 95 ºC for 10 min. 
The Ras protein was then precipitated by methanol/chloroform and processed (disulfide 
reduction, denaturing, alkylation and neutralization) as described above. The resultant Ras 
protein was digested with 2 µg of trypsin at 37˚C for 2 hr in a glass vial (to avoid absorption of 
the fatty acylated peptide by plastics). Then desalting was done using Sep-Pak C18 cartridge 
following the manufacturer’s protocol. 
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For the LC-MS/MS analysis of the digested peptides, the same settings described for the 
SILAC experiment were applied except the LC gradient was 5-95% ACN with 0.1% FA from 
0-140 min. The settings for identifying Alk14 modification in Sequest were: two miscleavages 
for full trypsin with fixed carbamidomethyl modification of cysteine residue, dynamic 
modifications of 234.198 Da (Alk14) on lysine residue, N-terminal acetylation, methionine 
oxidation and deamidation of asparagine and glutamine residues. The peptide mass tolerance 
and fragment mass tolerance values were 15 p.p.m. and 0.8 Da, respectively. 
Detection of lysine fatty acylation on endogenous Ras in HCT116 cells. HCT116 cells 
(parental cells, or cells infected with shCtrl/shSIRT2-carrying lentivirus for 3 days) were 
cultured with fresh medium containing 50 µM Alk14 for 6 h. Cells were collected and lysed 
using the same method described above. Pan-Ras immunoprecipitation was performed using 
pan-Ras (Y13-259) antibody by following manufacturer's protocol. The lysine fatty acylation 
on endogenous Ras was detected by on-beads click chemistry and in-gel fluorescence using the 
same method described above. To directly detect lysine fatty acylation on endogenous Ras by 
mass spectrometry, 200 mg of total lysates from HCT116 cells with SIRT2 KD was used for 
pan-RAS immunoprecipitation, followed by denaturation, alkylation, neutralization, trypsin 
digestion and LC-MS/MS analysis using the same method described above. 
Statistical analysis. Quantitative imaging data were expressed in box plot as indicated in 
figure legends. Statistical evaluation of imaging data was done using two-way ANOVA. Other 
quantitative data were expressed as mean ± SEM (standard error of the mean, shown as error 
bar). Differences between two groups were examined using unpaired two-tailed Student’s t test. 
The P values were indicated (*P < 0.05, ** P < 0.01, and *** P < 0.001). P values < 0.05 were 
considered statistically significant. No statistical tool was used to pre-determine sample size. 
No blinding was done, no randomization was used, and no sample was excluded from analysis.  
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CHAPTER 4 
 
SUMMARY AND FUTURE PERSPECTIVES  
 
SIRT2 has been closely implicated in cell cycle regulation, stress response, metabolism and 
differentiation by deacetylating a wide variety of substrates. Targeting SIRT2 for cancer 
treatment, however, was a topic of debate due to conflicting reports and lack of potent and 
specific inhibitors. My work in Chapter 2 demonstrated that TM is as a highly potent and 
selective mechanism-based SIRT2 inhibitor and exhibits broad anticancer activity in part by 
decreasing the protein level of c-Myc. SIRT2 has been reported by several groups to have lysine 
defatty-acylase activities in addition to the deacetylase activity, but the substrates and 
physiological function for its defatty-acylase activity were unknown. In Chapter 3, I identified 
a Ras protein, K-Ras4a, as a SIRT2 lysine defatty-acylase target and elucidated that the SIRT2-
dependent defatty-acylation promotes the oncogenic activity of K-Ras4a. Here I summarize the 
lessons I learned from these studies and the questions to be addressed in the future.  
1. Lessons learned 
Phenotype of genetic knockout (KO) mice may not predict the effect of small molecule 
inhibitors.  
A previous study showed that Sirt2 KO mice tend to develop tumors earlier than wildtype 
mice 1. Another study reported that although the spontaneous tumor development phenotype 
was not observed, tumor development upon DNA damage did increase in Sirt2 KO mice 2. So, 
it was surprising that the SIRT2-selective inhibitor, TM, can inhibit the proliferation of many 
cancer cell lines tested. I further confirmed with several experiments that SIRT2 inhibition 
produces the anticancer effects. This suggests the phenotype of genetic knockout mice may not 
predict the effect of small molecule inhibitors. Sometimes depletion of a protein genetically and 
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small molecule inhibition may produce different effect. Therefore, getting potent and selective 
inhibitors is the ultimate way to demonstrate whether a protein is a good anticancer target or 
not.  
Removal of palmitoylation could promote Ras function. 
Palmitoylation has been shown to be essential for the plasma membrane association and 
function of H-Ras and N-Ras. Studies with nonpalmitoylated variants of H-Ras and N-Ras also 
supports the importance of palmitoylation in RAS-driven tumorigenesis3,4. However, my study 
in Chapter 3 reveals that lysine fatty acylation (palmitoylation) impedes the transforming 
activity of K-Ras4a, which seemed counter-intuitive. Actually, it has been demonstrated that 
the dynamic de/reacylation cycle promotes Ras redistribution to cellular membranes where it is 
active and that depalmitoylation inhibitors inhibit Ras function. Therefore, it is possible that 
lysine fatty acylation blocks the dynamic acylation cycle of K-Ras4a. Removal of lysine fatty 
acylation by SIRT2 may facilitate the distribution of K-Ras4a to endomembranes where it 
recruits A-Raf to promote oncogenic transformation.  
Targeting the vulnerabilities of cancer. 
Myc hyperactivation or overexpression and K-Ras mutations are among the most common 
drivers of human cancer. Thus, both Myc and K-Ras are highly pursued cancer drug targets. 
Despite intensive studies, it remains challenging to target Myc or K-Ras directly. One possible 
approach to treat Myc- or K-Ras-driven cancers is to identify the ‘Achilles’ heel’ target that is 
not inherently tumorigenic but essential for the cancer cells to survive. My studies in Chapter 2 
suggest that SIRT2 inhibition is a way to target c-Myc indirectly. SIRT2 inhibitor up-regulates 
the transcription of several c-Myc E3 ubiquitin ligases that promote c-Myc degradation, and 
thus inhibits cancer cell proliferation. In other word, the survival of certain c-Myc-driven cancer 
cells relies on SIRT2. In Chapter 3, I demonstrated that SIRT2 promotes K-Ras4a-induced 
oncogenic transformation, suggesting that SIRT2 inhibition may produce therapeutic benefit in 
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K-Ras-driven cancers. Therefore, the dependence on SIRT2 may be a vulnerability of Myc- or 
K-Ras-driven cancer cells, and thus offer an attractive approach for the development of novel 
anticancer therapeutics.  
2. Questions to be addressed and future directions 
How does SIRT2 regulate expression of E3 ligases of c-Myc? 
In Chapter 2, I showed that TM upregulates several E3 ligases of c-Myc in MCF-7 cells 
(sensitive to TM) but not in BT-549 cells (resistant to TM). It is unclear how SIRT2 regulates 
the expression of these E3 ligases and why such regulation was not observed in BT-549 cells. 
Understanding the mechanism may point out new ways to target c-Myc and also help to predict 
what tumors may be sensitive to SIRT2 inhibition. Since SIRT2 inhibition by TM affects 
transcriptional levels of the E3 ligases and SIRT2 is known to act as a histone deacetylase to 
repress gene expression2,5, it is possible that SIRT2 could be recruited to the promoter regions 
of the genes for the E3 ligases to inhibit their expression through histone deacetylation in MCF-
7 but not in BT-549 cells. To test this hypothesis in the future, chromatin immunoprecipitation 
(ChIP) coupled to quantitative real-time PCR and interactome study could be performed to 
compare chromatin localization and interacting proteins of SIRT2 in the two cell lines. 
Presumably, the different mechanisms for the chromatin recruitment of SIRT2 could be ascribed 
to the susceptibility of cells to SIRT2 inhibitor.  
What is the stoichiometry of K-Ras4a lysine fatty acylation? 
Determining the stoichiometry of lysine fatty acylation would be crucial for us to better 
understand its functional consequences. Semi-quantification of the fluorescence intensity from 
Alk14 metabolic labeling results enabled us to roughly estimate the stoichiometries for cysteine 
palmitoylation and lysine fatty acylation. However, this estimation may not be accurate due to 
our limited knowledge on the site occupancy of fatty acylation and possible palmitoylation loss 
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during sample preparation. In the future, development of mass spectrometry analysis that allows 
precise quantitation of protein lysine fatty acylation will help to address this question and thus 
will greatly advance our understanding of the complex regulation of Ras proteins by lysine fatty 
acylation. 
How does recruitment of A-Raf to endomembranes promote K-Ras4a-induced 
transformation? 
In Chapter 3, my results indicated that A-Raf is required for the regulation of K-Ras4a by 
SIRT2-mediated lysine defatty-acylation. I also demonstrated that lysine defatty-acylation 
promotes the association between K-Ras4a and A-Raf at endomembranes. However, it is 
unclear how binding of A-Raf to K-Ras4a at endomembranes promote K-Ras4a function. 
Unlike B-Raf and C-Raf, which are the other two members of the Raf serine/threonine kinase 
family and promote cellular transformation by activating MEK/ERK MAPK pathway, A-Raf 
has weak MEK kinase activity and is a less understood Ras effector protein6. In line with this, 
lysine fatty acylation did not affect the activation of ERK, which is downstream of MEK. 
Therefore, there may be other mechanisms involved in the effect of A-Raf. To elucidate the 
mechanism, quantitative phosphoproteomics can be conducted to identify A-Raf kinase 
substrates and compare the phosphorylation status of A-Raf substrates when K-Ras4a WT or 
the 3KR mutant is expressed. Alternatively, interactome study can be employed to search for 
A-Raf interacting partners that are regulated by K-Ras4a lysine fatty acylation.  
Proteome-wide identification of defatty-acylation substrates for SIRT2. 
To better understand the physiological relevance of the defatty-acylase activity of SIRT2, 
more substrates need to be identified and the corresponding function of lysine fatty acylation 
need to be investigated. SILAC-based quantitative proteomics coupled with Alk14 metabolic 
labeling can be conducted to discover SIRT2 targets. Briefly, SIRT2 WT and KO (or KD) cells 
are cultured in light and heavy medium, respectively, in the presence of Alk14. Proteins are then 
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extracted and a biotin affinity tag is attached to the Alk14-labeled proteins with click chemistry. 
The biotin-conjugated proteins are pulled down using streptavidin beads. The proteins with only 
cysteine fatty acylation can be removed by on-beads hydroxylamine. Samples are then on-beads 
digested with trypsin and submitted for mass spectrometry analysis. My previous attempts using 
this method did not lead to successful identification of SIRT2 substrates. The top hits were 
found to have either no fatty acylation or only cysteine palmitoylation. High background and 
lack of modification site information are the two major problems of the previous methodology.  
In the future, optimization could be done in the following ways. Firstly, one SILAC sample 
with SIRT2 KO (or KD) cells treated without Alk14 and with Alk14 should be included to rule 
out proteins that bind to streptavidin beads. Secondly, stringent hydroxylamine treatment and 
washes could help to remove more proteins with only cysteine fatty acylation and the interacting 
proteins of the real SIRT2 substrates. Thirdly, RNA-sequencing of the SIRT2 WT and KO (or 
KD) cells can be performed in parallel to rule out proteins that are regulated by SIRT2 in the 
transcriptional level. Lastly, biotin-N3 with a cleavable liner, which allows cleavage to release 
the captured proteins or peptides on streptavidin beads, could be used. Thus, all the peptides 
labeled with Alk14 will contain a tag that can be treated as a modification with a unique mass 
shift for precise location of the modified lysine residue.  
Functional contribution of the defatty-acylase activity of SIRT2. 
As I have demonstrated with my doctoral studies, SIRT2 possesses not only deacetylase 
activity, but also defatty-acylase activity. Previous studies have highlighted the functional 
significance of the SIRT2 deacetylase. My study in Chapter 3 underscores the functional 
significance of SIRT2 defatty-acylase. However, the multiple enzymatic functions of SIRT2 
make it very difficult to dissect the contribution of any certain enzymatic activity by genetically 
manipulating SIRT2 level in cells. Identification of SIRT2 mutants that have either deacetylase 
activity or defatty-acylase activity will greatly help us to study the specific function of 
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deacetylase or defatty-acylase activity of SIRT2. Previous studies in our laboratory have shown 
that mutating a glycine residue that is conserved in SIRT1-6 to alanine in SIRT6 results in a 
SIRT6 mutant that has only defatty-acylation activity and lacks deacetylation activity in cells7. 
Moreover, the crystal structure of SIRT2 in complex with a thiomyristoyl peptide BHJH-TM18 
(PDB 4R8M) revealed that the myristoyl group is accommodated by a hydrophobic pocket. 
Based on these previous studies, mutating the conserved glycine residue or the key residues in 
the acyl-binding pocket may provide the best chance to differentiate SIRT2 defatty-acylase 
activity from deacetylase activity. 
Development of inhibitors that target the defatty-acylase activity of SIRT2. 
The emerging biological functions, especially cancer relevance, of SIRT2 as a lysine 
defatty-acylase suggests that inhibitors targeting the defatty-acylase activity of SIRT2 merit 
further investigation. My studies in Chapter 2 showed that the fatty acylation levels of many 
proteins were elevated when SIRT2 was knocked down, but not when SIRT2 inhibitor TM was 
used (Fig. 2.7). Furthermore, TM exerted little effect on the lysine fatty acylation of K-Ras4a, 
suggesting that TM may selectively target the deacetylase activity of SIRT2. Considering that 
low Km value of SIRT2 for fatty acyl substrate, SIRT2 may preferentially bind to fatty acyl 
substrate rather than TM. Therefore, increasing binding affinity to SIRT2 could be an approach 
to obtain defatty-acylase inhibitors. Alternatively, as TM binds to SIRT2 in cells, targeted 
degradation of SIRT2 protein could be achieved by coupling TM to proteolysis-targeting 
chimera (PROTAC) technology. 
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